Document:

EX-10.2

 Exhibit 10.2 

EXECUTION VERSION 
 MAPLE
HOLDINGS II B.V. 
 AND 

MONDELĒZ INTERNATIONAL HOLDINGS LLC 

AND 
 MAPLE PARENT HOLDINGS CORP.

  
  

SHAREHOLDERS’ AGREEMENT 

RELATING TO MAPLE PARENT HOLDINGS CORP. 
  

 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

 CONTENTS 
  

							
	Clause	  	 	  	Page	 
			
	1.	  	Intepretation	  	 	3	  
	2.	  	The Business of the Group	  	 	4	  
	3.	  	Board of Directors	  	 	8	  
	4.	  	Proceedings of Directors	  	 	11	  
	5.	  	The Executive Team	  	 	14	  
	6.	  	Reserved Matters and Board Authority Matters	  	 	15	  
	7.	  	Deadlock	  	 	16	  
	8.	  	Shareholder Meetings	  	 	17	  
	9.	  	Strategic Plan and Annual Contract	  	 	17	  
	10.	  	Accounting and Reporting	  	 	17	  
	11.	  	Group Funding	  	 	17	  
	12.	  	Dividend Policy	  	 	18	  
	13.	  	Other Policies	  	 	19	  
	14.	  	Covenants - non-compete and non-solicitation	  	 	19	  
	15.	  	Transfers of Shares	  	 	23	  
	16.	  	Exit Events	  	 	30	  
	17.	  	Completion of Share Transfers	  	 	33	  
	18.	  	Regulatory Consents for Transfers	  	 	35	  
	19.	  	New Issues of Shares	  	 	36	  
	20.	  	Duration and Termination	  	 	37	  
	21.	  	Warranties	  	 	38	  
	22.	  	Confidentiality	  	 	38	  
	23.	  	Announcements	  	 	39	  
	24.	  	Further Assurances and Undertakings	  	 	40	  
	25.	  	Supremacy of this Agreement	  	 	40	  
	26.	  	Entire Agreement and Non-Reliance	  	 	41	  
	27.	  	Costs	  	 	41	  
	28.	  	General	  	 	41	  
	29.	  	Assignment	  	 	42	  
	30.	  	Notices	  	 	43	  
	31.	  	Governing Law	  	 	44	  
	32.	  	Arbitration	  	 	44	  
	33.	  	Jurisdiction	  	 	45	  
	34.	  	Counterparts	  	 	45	  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - i - 

							
	 Schedule 1 Reserved Matters
	  	 	46	  
	 Schedule 2 Board Authority Matters
	  	 	50	  
	 Schedule 3 Board Composition at Closing
	  	 	51	  
	 Schedule 4 Committees
	  	 	52	  
	 Part A: Audit Committee Terms of Reference
	  	 	52	  
	 Part B: Compensation Committee Terms of Reference
	  	 	57	  
	 Part C: Compliance Officer Duties and Responsibilities
	  	 	60	  
	 Schedule 5 Reserved
	  	 	61	  
	 Schedule 6 Accounting and Information Rights
	  	 	62	  
	 Schedule 7 Governance Policies
	  	 	64	  
	 Schedule 8 Deed of Adherence
	  	 	65	  
	 Schedule 9 Agreed Form Documents
	  	 	67	  
	 Schedule 10 Transfer Value
	  	 	68	  
	 Schedule 11 Strategic Plan and Annual Contract
	  	 	70	  
	 Schedule 12 Non-Business Activities
	  	 	73	  
	 Schedule 13 Amendments following Step Down Rights
	  	 	74	  
	 Schedule 14 Interpretation
	  	 	80	  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - ii - 

 THIS AGREEMENT is made on March 7, 2016  

AMONG: 
  

	(1)	MAPLE HOLDINGS II B.V., a private company with limited liability company incorporated under the laws of the Netherlands, with its registered office at Oosterdoksstraat 80, 1011 DK Amsterdam, the Netherlands and
with registered number 65317610 (“Maple Holdings”);  

  

	(2)	MONDELĒZ INTERNATIONAL HOLDINGS LLC, a Delaware limited liability company (“MDLZ”); and 

  

	(3)	MAPLE PARENT HOLDINGS CORP., a Delaware corporation (the “Company”). 

INTRODUCTION: 
  

	(A)	On 6 December 2015, Acorn Holdings B.V. (the parent entity of Maple Holdings), Maple Holdings Acquisition Corp., Keurig Green Mountain, Inc., and JAB Holdings B.V. entered into a merger agreement pursuant to which
Maple Holdings Acquisition Corp. was to be merged with and into Keurig Green Mountain, Inc., with Keurig Green Mountain, Inc. surviving the merger as a wholly-owned indirect subsidiary of Maple Holdings (the “Merger”).

  

	(B)	In connection with the closing of the Merger, Maple Holdings has made a loan to the Company in the aggregate principal amount of $1.815 billion pursuant to the Term Loan Agreement (the “Loan”), dated as
of February 25, 2016.  

  

	(C)	On the date of this Agreement, pursuant to the Share Exchange Agreement, dated as of the date hereof (the “Exchange Agreement”), among Maple Holdings, JDE Holdings Minority B.V., Acorn Holdings B.V.,
Delta Charger Holdco B.V., MDLZ, Mondelēz Coffee Holdco B.V., the Company and Jacobs Douwe Egberts B.V., MDLZ acquired the B Shares and $440,000,330 in principal amount of the Loan. 

 

	(D)	From the date of this Agreement, Maple Holdings will hold all of the A Shares and MDLZ will hold all of the B Shares which represent approximately 75.76% and 24.24% respectively of the entire issued share capital of the
Company and Maple Holdings and MDLZ will each hold $1,374,999,670 and $440,000,330 of the principal amount of the Loan, respectively. 

  

	(E)	Maple Holdings and MDLZ have agreed to enter into this Agreement for the purpose of regulating the management of the Company and their relationship with each other as shareholders in the Company. 

IT IS AGREED as follows: 
  

	1.	INTERPRETATION 

 Words and expressions defined in this Agreement shall have the meanings
given to them in schedule 14. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -3- 

	2.	THE BUSINESS OF THE GROUP 

  

	2.1	Scope and conduct of the Business 

  

	 	2.1.1	The business of the Group (the “Business”) shall be: 

  

	 	(a)	trading green coffee and tea; 

  

	 	(b)	the development, manufacturing, marketing and sales of: 

  

	 	(i)	roast and ground coffee, whole bean coffee, soluble (instant) coffee, liquid coffee concentrate and combinations of those products (“Coffee Products”) for preparation and consumption of water based
coffee drinks (“Coffee”) and, when combined with other liquids (e.g. milk) for preparation and consumption of other beverages that contain Coffee Products as main and/or predominant ingredient and/or flavour (“Coffee
Beverages”);  

  

	 	(ii)	loose leaf and sachet tea and combinations of those products (“Tea Products”) for preparation and consumption of water-based tea drinks (“Tea”) and when combined with other liquids
(e.g. milk) for the preparation of other beverages that contain Tea Products as the main and/or predominant ingredient and/or flavour (“Tea Beverages”);  

 

	 	(iii)	Coffee Products and Tea Products and chocolate which, in combination with so-called on-demand brewing systems provide for the preparation of on-demand Coffee and Coffee Beverages or Tea and Tea Beverages or Chocolate
Beverages; and 

  

	 	(iv)	Coffee and Coffee Beverages and Tea or Tea Beverages for ready-to-drink consumption where Coffee Products or Tea Products are the main and/or dominant ingredient and/or flavour component, either carbonated or
non-carbonated, 

 in all distribution channels, including retail/fast moving consumer goods, wholesale, out- of- home, coffee
shops, instant consumption, modern trade, traditional trade, e-commerce and whether distributed directly or indirectly through distributors or wholesalers; 
  

	 	(c)	 the marketing and sales of (x) Chocolate Beverages, chocolate ingredients for Coffee Beverages
and ingredients for a limited portfolio of non coffee beverages (milk powders or milk concentrates, and juice powders or juice concentrates whether or not sold simultaneously with coffee) offered in conjunction with Coffee Beverages as an
ancillary offering to the main coffee portfolio, in each case only intended for use in out of home coffee machines and (y) other non coffee products which complement the coffee out of home coffee portfolio (sugar, milk and chocolate powder in
single portioned sticks/containers, single wrapped cookies, single wrapped chocolate and stir sticks) as an ancillary offering to Coffee Beverages dispensed through coffee machines (which include machines that

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -4- 

	 	
dispense other beverages as long as coffee is in the main offering) in the out of home distribution channel only. For the avoidance of doubt, it is not intended that chocolate, Chocolate
Beverages or such other non coffee products will form part of the Business other than in the limited circumstances set out in paragraph (b)(iii) and this paragraph (c); 

 

	 	(d)	the marketing and sales of on-demand brewing systems for Coffee Beverages and Tea Beverages including brewers and accessories through direct consumer, online or out-of-home distribution channels and the development
and/or manufacturing of the same through third party cooperation; and 

  

	 	(e)	the development, manufacturing, marketing and sale of (i) on-demand brewing systems (whether done directly or indirectly, or through third parties) for the delivery of hot beverages of all kinds and cold beverages
dispensed through the KOLD beverage system, (ii) products that are used in combination with such on-demand brewing systems under owned brands or brands licensed from third parties, in each case in all distribution channels anywhere in the
world, and (iii) related accessories, in each case, except for any activities which would cause a breach of any contract with a third party. 

  

	 	2.1.2	The scope of the Business shall be worldwide. 

  

	 	2.1.3	The Business shall be conducted in accordance with: 

  

	 	(a)	this Agreement and the Articles; 

  

	 	(b)	the Strategic Plan and the Annual Contract; and 

  

	 	(c)	applicable Law. 

  

	 	2.1.4	The Business shall trade under the name to be agreed between the Shareholders before Closing. 

  

	2.2	Development of the Business 

  

	 	2.2.1	Each Shareholder and the Company agrees that the business of the Group shall be confined to the Business, unless a change in the Business is approved as a Reserved Matter. 

 

	 	2.2.2	Each Shareholder shall use all reasonable endeavours to promote and develop the Business to the best advantage of the Group and agrees that, save as set out in clause 14, any expansion or development of the Business
shall only be carried out through the Group. 

  

	 	2.2.3	For as long as Maple Holdings and its Affiliates and MDLZ and its Affiliates hold, collectively, shares representing a majority of the voting power of each of JDE and the Company (the “Joint Control
Period”), the Company shall procure that, at the request of JDE, each Group Company will license or sub-license to JDE (and any of its subsidiaries), on commercially reasonable terms (including to reflect risk and expense incurred, and
expected to be incurred, in connection with the development of) any Product Technical IP, that is: 

  

	 	(a)	Controlled by any Group Company as at the date of this Agreement; and 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -5- 

	 	(b)	Controlled by any Group Company after the date of this Agreement from time to time, 

 other
than to the extent that doing so would result in or create a material risk of (i) loss of, or inability to acquire, Technical IP rights or rights to use Technical IP rights under licence, (ii) breach of any licence under which such
Technical IP is licensed to the Group, (iii) breach of any other contract in existence at the date of this Agreement, or (iv) breach of Law. The Company will make its representatives available for a meeting with JDE representatives
periodically, at the reasonable request of JDE, to provide details of any relevant new Technical IP or Technical IP development initiatives for which partnership may be sought. For the avoidance of doubt, unless otherwise specifically provided in
the relevant license or sub-license, any licenses or sub-licenses granted during the Joint Control Period shall not terminate automatically by virtue of the expiry of the Joint Control Period and shall continue on the terms previously agreed. 

For purposes of this Clause 2.2.3, “Product Technical IP” means, with respect to any product, service, functionality or other
capability relevant to the business of JDE, the Technical IP necessary for or used in the research, development, manufacture, commercialization, use or support of such product, service, functionality or other capability, and
“Controlled” means, with respect to any Group Company, owned by, or licensed to it. 
  

	2.3	Anti-corruption compliance 

  

	 	2.3.1	Each Shareholder shall not, and shall procure that its Affiliates shall not, and shall use its reasonable endeavours to procure that their respective Agents shall not, in connection with this Agreement or the Business:

  

	 	(a)	pay, offer, promise, give or authorize, directly or indirectly, the payment of money or anything of value to a Government Official (or any other person at a Government Official’s request or with their assent or
acquiescence) intending to: 

  

	 	(i)	influence a Government Official in his official capacity in order to assist a Group Company, a Shareholder or any person in obtaining or retaining business or a business advantage, or in directing business to any third
party; 

  

	 	(ii)	secure an improper advantage; 

  

	 	(iii)	induce any such Government Official to use his influence to affect or influence any act, omission or decision of a Government Entity in order to assist a Group Company, the Shareholders or any other person in obtaining
or retaining business, or in directing business to any third party; or 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -6- 

	 	(iv)	provide an unlawful personal gain or benefit, of financial or other value, to any such Government Official; or 

  

	 	(b)	otherwise, make any bribe, payoff, influence payment, kickback or other unlawful payment to any person, regardless of the form, whether in money, property or services, to obtain or retain business or to obtain any
improper advantage for any Group Company. 

  

	 	2.3.2	The Company acknowledges that it is required to comply with applicable Anti-Bribery Laws and Sanctions Laws. The Company shall, and shall procure that each other Group Company shall, and shall use its reasonable
endeavours to procure that their respective Agents shall: 

  

	 	(a)	not take any action, directly or indirectly, which would, or might reasonably be expected to, expose any Shareholder or any of its Affiliates to an offence for violation of any applicable Anti-Bribery Laws or Sanctions
Laws; 

  

	 	(b)	in connection with this Agreement or the Business, not: 

  

	 	(i)	pay, offer, promise, give or authorize, directly or indirectly, the payment of money or anything of value to a Government Official (or any other person at a Government Official’s request or with their assent or
acquiescence) intending to: 

  

	 	(A)	influence a Government Official in his official capacity in order to assist a Group Company, a Shareholder or any person in obtaining or retaining business or a business advantage, or in directing business to any third
party; 

  

	 	(B)	secure an improper advantage; 

  

	 	(C)	induce any such Government Official to use his influence to affect or influence any act, omission or decision of a Government Entity in order to assist a Group Company, the Shareholders or any other person in obtaining
or retaining business, or in directing business to any third party; or 

  

	 	(D)	provide an unlawful personal gain or benefit, of financial or other value, to any such Government Official; or 

  

	 	(ii)	otherwise, make any bribe, payoff, influence payment, kickback or other unlawful payment to any person, regardless of the form, whether in money, property or services, to obtain or retain business or to obtain any
improper advantage for any Group Company; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -7- 

	 	(c)	adopt such accounting standards and procedures as are necessary to ensure that each Group Company makes and keeps books, records and accounts which, in reasonable detail, accurately and fairly reflect the transactions
and disposition of the assets of such Group Company; 

  

	 	(d)	adopt and maintain a system of internal accounting controls sufficient to ensure that: (i) no off-the books accounts are maintained; (ii) assets are used only in accordance with management directives;
(iii) the integrity of financial statements is maintained; (iv) transactions are recorded as necessary to permit each Group Company’s auditor to prepare or appropriately review financial statements in conformity with generally
accepted accounting principles in its jurisdiction of organization and to maintain accountability for assets; (v) access to assets is permitted only in accordance with the general or specific authorization of such Group Company’s
management, acting in their legitimate capacity as such; (vi) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(vii) there are reasonable assurances that violations of applicable Anti-Bribery Laws and Sanctions Laws will be prevented, detected and deterred; and 

  

	 	(e)	take all appropriate action to cause each Group Company to adopt and implement the Governance Policies. 

  

	3.	BOARD OF DIRECTORS 

  

	3.1	Management of the Group 

 The Board shall be responsible for the overall direction and
supervision of the business of the Group in accordance with the Strategic Plan, the Annual Contract, the Articles and this Agreement. 
  

	3.2	Board composition 

  

	 	3.2.1	The Board shall consist of up to 11 Directors. 

  

	 	3.2.2	The A Shareholder shall be entitled to appoint up to seven non-executive A Directors to the Board and to remove any A Director appointed by it from time to time. 

 

	 	3.2.3	The B Shareholder shall be entitled to appoint up to two non-executive B Directors to the Board and to remove any B Director appointed by it from time to time. 

 

	 	3.2.4	The Shareholders shall appoint the CEO to act as the Management Director. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -8- 

	 	3.2.5	The Board may nominate an independent industry expert as an additional Director (the “Board Nominee”) and, if so nominated, the Shareholders shall take such action as may be necessary to cause such
individual to be appointed to the Board. 

  

	 	3.2.6	The Directors at Closing shall be as set out in schedule 3. It is intended that the non executive directors appointed to the Board will largely comprise the same individuals as are on the JDE Board. 

 

	3.3	Appointment and removal of Directors 

  

	 	3.3.1	Any appointment or removal of an A Director or a B Director or the Board Nominee by the A Shareholder or the B Shareholder or the Board (as the case may be) shall be made by such Shareholder giving written notice to the
Company (with a copy to the other Shareholder), in the case of an A Director or a B Director, or to the A Shareholder and B Shareholder by the Company on behalf of the Board, in the case of the Board Nominee. The appointment or removal shall, to the
extent permitted by Law, take effect immediately upon receipt of the notice by the Company, or the Shareholders, as the case may be, or such later date specified by the Shareholder or the Company, as applicable, in the notice. 

 

	 	3.3.2	If an A Director or a B Director or Board Nominee dies, resigns, is removed or retires, the A Shareholder or the B Shareholder or the Board (as the case may be) may appoint another Director in accordance with this
clause 3. 

  

	 	3.3.3	If at any time the A Shareholder or the B Shareholder ceases to own a single Share or if there is a Step Down in relation to the B Shareholder, the A Shareholder or the B Shareholder (as the case may be) shall promptly
procure the resignation of each Director appointed by it or, if there is a Step Down, the relevant number of Directors appointed by it. 

  

	 	3.3.4	Any Shareholder who removes a Director appointed by it in accordance with the terms of this Agreement shall indemnify and keep indemnified the other Shareholder and any Group Company on demand against all losses,
liabilities and costs which such person may incur arising out of, or in connection with, any claim by such Director for wrongful or unfair dismissal, redundancy or otherwise arising out of such Director’s ceasing to hold office.

  

	 	3.3.5	The Shareholders (following the recommendation of the Board) may remove a Management Director at any time and must remove a Management Director if he ceases to be CEO. The Management Director may not vote on his or her
own appointment or removal. If the CEO is removed from the Board, the Shareholders (following the recommendation of the Board) shall appoint his successor (nominated in accordance with clause 5.1.2) to the Board. 

 

	3.4	Chairman 

  

	 	3.4.1	The A Shareholder shall be entitled to appoint and remove any A Director as the Chairman of the Board (the “Chairman”) by giving written notice to the Company (with a copy to the B Shareholder). 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -9- 

	 	3.4.2	The Chairman at Closing shall be as set out in schedule 3. 

  

	 	3.4.3	The Chairman shall preside at any Board meeting at which he is present and shall be responsible for administering the work of the Board so as to ensure good order without favouring any of the Directors or Shareholders
or any particular proposal and to afford all Directors an opportunity to participate fully. 

  

	 	3.4.4	If the Chairman for the time being is unable to attend any Board meeting, a majority of the A Directors attending such meeting shall be entitled to appoint one of their number to act as chairman at such meeting only.

  

	3.5	Subsidiary boards 

 Unless required by local Law or regulation or the terms of any
collective bargaining agreement, the directors of the boards of all other Group Companies shall comprise Directors, members of the Executive Team or employees of the Group, in each case who are suitably qualified and competent for the position. 

 

	3.6	Committees 

  

	 	3.6.1	Subject to applicable Law, Directors may delegate any of their powers to a committee of the Board constituted under this clause 3.6, save for the power to resolve on a Reserved Matter or a Board Authority Matter.

  

	 	3.6.2	Subject to clause 3.6.4, the Board shall determine the composition of any such committee as they see fit, save that: 

  

	 	(a)	the A Shareholder shall be entitled to appoint at least one Director to each such committee, and to remove any such appointment from time to time, by giving written notice to the Company (with a copy to the B
Shareholder); and 

  

	 	(b)	the B Shareholder shall be entitled to appoint at least one Director to each such committee, and to remove any such appointment from time to time, by giving written notice to the Company (with a copy to the A
Shareholder). 

  

	 	3.6.3	The voting and quorum requirements for meetings of any such committees shall be the same as for Board meetings. Each committee member will have one vote each. 

 

	 	3.6.4	The Audit Committee and Compensation Committee shall be comprised of Directors. The initial composition of the committees at Closing shall be as set out in parts A and B respectively of schedule 4. The Shareholders
intend no change to the composition of these committees for the first 12 months following Closing. The Audit Committee and Compensation Committee shall have the terms of reference set out in parts A and B respectively of schedule 4.

  

	 	3.6.5	The A Shareholder shall be entitled to appoint and remove any Director as the chairman of the Compensation Committee by giving written notice to the Company (with a copy to the B Shareholder). 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -10- 

	 	3.6.6	The B Shareholder shall be entitled to appoint and remove any Director as the chairman of the Audit Committee by giving written notice to the Company (with a copy to the A shareholder). 

 

	3.7	Remuneration and expenses of Directors 

 The Directors shall be entitled to receive
repayment of reasonable expenses incurred in relation to the performance of their duties as Directors and, if so determined by the Board, to reasonable fees for acting in their capacity as such and for sitting on committees in equal amounts (except
that the Chairman and the chairman of the Audit Committee and the Compensation Committee may receive a higher amount for serving as such). For the avoidance of doubt, the Board can only decide to pay director’s fees to all Directors or to no
Directors. Directors shall not otherwise be entitled to receive any remuneration by way of salary, commission, fees or otherwise in relation to the performance of their duties as Directors. 

 

	3.8	Directors’ insurance and indemnity 

  

	 	3.8.1	The Company shall maintain adequate directors’ and officers’ liability insurance for the benefit of the Directors. 

  

	 	3.8.2	The Company shall provide the Directors with the benefit of an indemnity against any liability which the Directors may incur in relation to the Group to the extent permitted by applicable Law. 

 

	3.9	Secretary 

 The Board may, in its discretion, appoint an individual to act as secretary
to the Board to assist the Chairman and the Board with such administrative matters as the Chairman or the Board, as applicable, deem appropriate. 
  

	4.	PROCEEDINGS OF DIRECTORS 

  

	4.1	Convening Board meetings 

  

	 	4.1.1	The Directors shall hold Board meetings at least four times in each Financial Year and at least once every fiscal quarter (“Quarterly Meetings”). 

 

	 	4.1.2	At any time any Director may request the Chairman to convene a Board meeting and such meeting shall be convened in accordance with clauses 4.2.2 and 4.2.3 as soon as practicable following receipt of such request.

  

	4.2	Notice of Board meetings 

  

	 	4.2.1	The dates for Quarterly Meetings shall be fixed and communicated to the Directors as early as possible, but not later than 9 months in advance. 

 

	 	4.2.2	At least 10 Business Days’ written notice shall be given to each Director of other Board meetings unless (a) clause 4.3.2 applies, (b) each of the Directors approves a shorter notice period, or
(c) the Chairman determines, acting reasonably, that there is a significant and time sensitive matter that requires shorter notice to be given, in which case the Chairman may convene a meeting (a “Short Notice Meeting”) by
giving at least 24 hours’ written notice to each other Director.  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -11- 

	 	4.2.3	An agenda identifying in reasonable detail the matters to be discussed at a Board meeting together with copies of any relevant papers to be discussed at the meeting shall be provided to each Director, if practicable, at
the same time as notice is given of such meeting and otherwise at least 7 days prior to the date on which the meeting is to be held. In the case of a Short Notice Meeting, the notice convening the meeting shall set out in as much detail as possible
the reasons for the meeting. If any matter is not identified in reasonable detail, the Directors shall not decide on it, unless all the Directors agree. 

  

	 	4.2.4	Notice of meetings, the agenda and copies of any relevant papers may be delivered to the Directors by email, unless and until any Director instructs the Company otherwise with respect to delivery to him.

  

	4.3	Quorum at Board meetings 

  

	 	4.3.1	No business shall be transacted at any meeting of the Board unless a quorum is present at the time when the meeting proceeds to business and remains present during the transaction of such business. Subject to clause
4.4, the quorum for transacting business at any Board meeting shall be at least one A Director and at least one B Director. A Director shall be regarded as present for the purposes of a quorum if represented by an attorney appointed in accordance
with clause 4.6. 

  

	 	4.3.2	If a quorum is not present at a duly convened Board meeting, the meeting shall be adjourned to another date by notice given in accordance with clause 4.2, except that in this case, only 5 Business Days’ notice of
the adjourned meeting needs to be given. The quorum at such adjourned meeting shall be as set out in clause 4.3.1. 

  

	4.4	Voting at Board meetings 

 On any vote on a resolution of the Directors, one B Director
will have one vote and one B Director will have two votes (which, if cast, must be cast together and cannot be split) and each A Director, Management Director, and Board Nominee will have one vote; provided, however, that the B
Directors shall each have one vote (a) if, as a result of a change in law, the B Directors are not required to have an aggregate of 3 votes between them in order for MDLZ to obtain the benefit of Section 243(c) of the Internal Revenue Code
of 1986, as amended, or any successor provision or (b) at any time (and for as long as) the number of Directors is less than 11. Subject to the specific requirements in clause 6 relating to Reserved Matters (a) resolutions of the Directors
shall be decided by simple majority vote and (b) if a vote of the Directors is tied, the Chairman (or the Director acting as chairman at the relevant meeting in accordance with clause 3.4.4) will have a casting vote. 

 

	4.5	Conflict of interest 

  

	 	4.5.1	 In respect of any right of action by the Company or any other Group Company against the Shareholder who appointed
him or any of its Affiliates or any right 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -12- 

	 	
of action by the Shareholder who appointed him or any of its Affiliates against the Company or any other Group Company, a Director shall not be entitled to receive board papers, attend or be
counted in the quorum or vote at a Board meeting on any resolution in respect of any such matters unless otherwise agreed in writing by the Shareholder that did not appoint him. 

 

	 	4.5.2	A Management Director shall not be entitled to vote at a Board meeting on any resolution relating to (a) his appointment or removal from the Board or (b) his own remuneration. 

 

	4.6	Power of attorney 

 Any Director shall be entitled to authorise any other Director, at
any time, to act on his behalf by the appointment of such other Director as his attorney under a specific power of attorney. Any such appointment shall be confirmed in writing (which can be by email) to the Company. 

 

	4.7	Participation in Board meetings 

 The intention is that Quarterly Meetings will be held
in person and other Board meetings will be held in person wherever this is practicable. That said, a Director (or his attorney) may participate in a Board meeting by means of a conference telephone or similar form of communications equipment which
allows all persons participating in the meeting to hear and speak to each other throughout the meeting. A person participating in this way is deemed to be present in person at the meeting and is counted in the quorum and entitled to vote. If all the
Directors participating in the meeting are not in the same place, they may decide that the meeting is to be treated as taking place wherever any of them is. 
  

	4.8	Written resolution of Directors 

  

	 	4.8.1	At least 5 Business Days’ written notice of a proposed Directors’ written resolution without a meeting of the Board shall be given to each Director, unless each of the Directors approves a shorter notice
period. Such notice shall be accompanied by relevant papers no less detailed than those which would be provided in advance of a Board meeting in accordance with clause 4.2. 

 

	 	4.8.2	A Directors’ written resolution is adopted when the requisite voting majority of Directors (determined in accordance with clause 4.4) have signed one or more copies of it. A written resolution signed by an attorney
appointed in accordance with clause 4.6 need not also be signed by his appointor and, if it is signed by his appointor, it need not be signed by the attorney in that capacity. 

 

	 	4.8.3	Once a Directors’ written resolution has been adopted, it shall be treated as if it had been a decision taken at a Board meeting in accordance with this Agreement. 

 

	4.9	No breach of duty 

 A Director shall not be in breach of his duties to the Company by
reason of his acting in accordance with this clause 4.9 or otherwise in accordance with the terms of this Agreement and the Articles. Accordingly, each Shareholder authorises each Director: 

 

	 	4.9.1	to act as a Director notwithstanding his appointment by a Shareholder for the purposes of representing such Shareholder’s interests and monitoring and evaluating its investment in the Company and the Group;

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -13- 

	 	4.9.2	to receive and deal with Confidential Information and other documents and information relating to any Group Company or its business or assets and to use and apply such information in representing the interests of the
Shareholder that appointed him; 

  

	 	4.9.3	to disclose any Confidential Information to any director, officer or employee of any Shareholder that appointed him or any director, officer or employee of its Shareholder Group Entities to the extent necessary for the
purposes of monitoring and evaluating such Shareholder’s participation in the Company and the Group; and 

  

	 	4.9.4	to keep confidential any information relating to the Shareholder that appointed him or any of its Affiliates that is subject to obligations of confidence and which such Shareholder is not otherwise obliged to disclose
to the other Shareholder or any Group Company pursuant to the terms of this Agreement and not to use or apply such information in performing his duties to the Company or any Group Company. 

 

	5.	THE EXECUTIVE TEAM 

  

	5.1	Appointment of the Executive Team 

  

	 	5.1.1	It is intended that the Executive Team at Closing shall be the executive team of Keurig Green Mountain, Inc. as of the closing of the Merger with such modifications as may be approved from time to time by the Board, and
that the individual previously identified by MDLZ and Maple Holdings to assume the position of new CEO of the Company, will take office following the Closing in accordance with the terms of employment to be entered into between such individual and
the Company. 

  

	 	5.1.2	The appointment or removal of the Executive Team after Closing (other than as contemplated by clause 5.1.1) shall be determined by the Board. The Executive Team shall comprise different individuals to the Executive Team
in place from time to time at JDE (as such term is defined in the JDE Shareholders Agreement); provided, that this restriction shall not be applicable in the event that, following the requisite consents being obtained, the Company and JDE are
reorganized in order to facilitate an IPO under circumstances where the businesses of JDE and the Company are combined for such IPO. 

  

	5.2	Responsibilities of the Executive Team 

 Subject to the Reserved Matters and the Board
Authority Matters, the Board may delegate to the Executive Team the power to manage and administer the day-to-day activities of the Group in accordance with the
Strategic Plan, the Annual Contract, the Articles and this Agreement under the overall direction and supervision of the Board. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -14- 

	5.3	Remuneration of the Executive Team 

 The Board shall agree on a remuneration policy for
the Executive Team having regard to the recommendations of the Compensation Committee. The Executive Team and other senior employees of the Group shall be incentivised (among other things) on the basis of the Group’s performance against the
Annual Contract and shall not receive any remuneration or benefit of whatever nature from any of the Shareholders or their respective Affiliates without the prior consent of the Board. A Management Director shall not be entitled to vote on his or
her own remuneration. 
  

	5.4	Oversight of Governance Policies 

  

	 	5.4.1	The Board shall cause the CFO to submit to the Board a shortlist of suitably qualified and competent candidates for the appointment of a person who is knowledgeable regarding the implementation and operation of the
Governance Policies (the “Compliance Officer”). 

  

	 	5.4.2	The Compliance Officer shall have the duties and responsibilities set out in part C of schedule 4. 

  

	6.	RESERVED MATTERS AND BOARD AUTHORITY MATTERS 

  

	6.1	The Company shall not take, and shall procure that no other Group Company takes, any action in respect of any Reserved Matter without either: 

 

	 	6.1.1	the prior approval of the Board given by way of a Board resolution adopted at a validly convened Board meeting, with a majority of the A Directors and a majority of the B Directors voting in favour; or

  

	 	6.1.2	the prior written approval of a majority of the A Directors and a majority of the B Directors, given by way of a Board written resolution adopted in accordance with clause 4.8. 

 

	6.2	Each Reserved Matter shall be considered and, if thought fit, approved independently of each other Reserved Matter. Approval of a Reserved Matter constituted by a proposal shall not constitute approval of another
Reserved Matter constituted by the same proposal. 

  

	6.3	If a Reserved Matter or other action approved by the Board in accordance with this Agreement also requires the approval of Shareholders under applicable Law, the Company and the Shareholders shall procure that a
Shareholder meeting is convened or a Shareholders’ written resolution is passed as soon as reasonably practical following approval of the Reserved Matter by the Board in accordance with clause 6.1 and each Shareholder undertakes to use its
voting rights to give effect to the Reserved Matter so approved. 

  

	6.4	Schedule 2 contains a non-exhaustive list of actions by a Group Company which must be considered by the Board of the Company at a duly convened Board meeting (“Board Authority Matters”).

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -15- 

	6.5	In determining whether a matter is a Reserved Matter or a Board Authority Matter, a series of related transactions shall be construed as a single transaction, and any amounts involved in the related transactions shall
be aggregated. 

  

	7.	DEADLOCK 

  

	7.1	Deadlock 

  

	 	7.1.1	A deadlock (a “Deadlock”) shall have occurred if a bona fide proposal in respect of any Reserved Matter has not been approved in accordance with clause 6.1 and the A Shareholder or the B Shareholder (as
the case may be) notifies the other in writing that it regards such proposal (the “Deadlock Matter”) as not having been agreed and that a Deadlock has arisen (a “Deadlock Notice”). 

 

	 	7.1.2	While a Deadlock exists, each Shareholder shall exercise all such rights and powers as are available to it to enable the Group to continue operating in the ordinary course of its business and in accordance with the
terms of this Agreement, provided that no action shall be taken in relation to the matter which is the subject of the Deadlock, save as contemplated by clause 7.2. 

 

	7.2	Escalation 

  

	 	7.2.1	Following the giving of a Deadlock Notice, the A and B Shareholders shall immediately refer the Deadlock Matter to: 

  

	 	(a)	in the case of the A Shareholder, the chairman, senior partner or chief executive officer of the JAB Holding Company Group as notified by the A Shareholder to the B Shareholder from time to time. At Closing, the A
Shareholder Escalation Representative shall be Olivier Goudet; and 

  

	 	(b)	in the case of the B Shareholder, the chief executive officer of Mondelēz International, Inc. from time to time, 

(together, the “Escalation Representatives”).  

 

	 	7.2.2	The Escalation Representatives shall, for a period of 20 Business Days starting on the Business Day after the date on which the Deadlock Notice was given (the “Deadlock Resolution Period”), attempt in
good faith to resolve the Deadlock. 

  

	 	7.2.3	If the Escalation Representatives resolve the Deadlock Matter within the Deadlock Resolution Period, the Shareholders shall procure (in so far as they are able) that the Company acts and, if relevant, the Company shall
procure that any other Group Company acts, in accordance with the instructions given by the Escalation Representatives. 

  

	 	7.2.4	Subject to clause 16.7.6, if the Escalation Representatives fail to resolve the Deadlock Matter within the Deadlock Resolution Period, the Company shall not take any action relating to the Deadlock Matter and this
Agreement shall continue to apply in accordance with its terms. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -16- 

	8.	SHAREHOLDER MEETINGS 

 All Shareholder meetings shall take place in accordance with
applicable Law and the Articles. 
  

	9.	STRATEGIC PLAN AND ANNUAL CONTRACT 

  

	9.1	Schedule 11 contains (a) the contents requirements for the Strategic Plan and the Annual Contract and (b) the schedule for delivery of drafts and approval by the Board. 

 

	9.2	The Management Directors shall provide an update of the Group’s performance against the Annual Contract at each Quarterly Meeting. 

 

	10.	ACCOUNTING AND REPORTING 

  

	10.1	Accounting principles 

 The Company shall prepare its financial statements (including its
consolidated financial statements) and management accounts in accordance with US GAAP and shall procure that the financial statements are reviewed and audited in accordance with US GAAP. 

 

	10.2	Reporting to the Shareholders 

 The Company shall supply the Shareholders with the items
listed in part A of schedule 6 in accordance with the deadlines set out therein and, on a timely basis, such other information as MDLZ may reasonably require in order to comply with the public disclosures described in part B of that schedule or to
meet its or its Affiliates’ respective audit requirements. 
  

	10.3	Access to information 

  

	 	10.3.1	Each Shareholder and its authorised representatives shall be allowed access at all reasonable times to examine (and at its expense to take copies of) the books and records of the Group and to discuss the Business and
affairs of the Group with the Executive Team and other relevant employees of the Group. 

  

	 	10.3.2	Each Shareholder reserves the right to undertake an audit of any Group Company (including to investigate compliance with Anti-Bribery Laws and Sanctions Laws) at its own cost, either by its own internal audit staff or
by external advisers. Such Shareholder shall give the Company at least 10 Business Days’ written notice of its intention to carry out such an audit. The Company shall procure that each Group Company co-operates with any audit required by a
Shareholder pursuant to this clause 10.3.2. 

  

	11.	GROUP FUNDING 

  

	11.1	Except as set forth in this clause 11, neither Shareholder shall be obliged or required to provide any funding or to provide any undertaking, covenant, guarantee or performance bond or any other recourse to a
Shareholder, in respect of or pursuant to any financing arrangement of the Group. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -17- 

	11.2	In the event that, as of the end of any Financial Year, a Tax Benefit Shortfall exists, Maple Holdings shall promptly contribute cash to the Company, in exchange for no additional shares, in an amount equal to the
difference between (a) such Tax Benefit Shortfall, minus (b) the MDLZ Contribution Amount. 

  

	11.3	In the event that, with respect to any Financial Year, MDLZ has received (or become entitled to) any Tax refund, MDLZ shall promptly contribute cash to the Company, in exchange for no additional shares, in an amount
equal to such Tax refund received by MDLZ (or to which MDLZ is entitled to receive) with respect to such Financial Year to the extent directly related to a Tax Cost of the Company for such Financial Year (such amount, the “MDLZ Contribution
Amount”). 

  

	12.	DIVIDEND POLICY 

  

	12.1	Subject to the requirements of applicable Law, the Company shall distribute to the Shareholders at such times as the Board determines, which may be on a quarterly basis within 60 days after each of
March 31, June 30, September 30 and December 31, but in any event no later than six months after the end of each Financial Year following Closing, pro rata dividends which in the aggregate are in an amount equal to the
difference between: 

  

	 	12.1.1	the higher of (a) 40% of the Net Operating Profit of the Group with respect to such Financial Year reduced as necessary to comply with any restrictions contained in definitive credit documents entered into in
connection with the Closing Debt Documents and any other financing or refinancing permitted hereunder that restrict the ability of members of the Group to make distributions to the Company and (b) $100,000,000; provided, that, in the
event that any portion of the principal amount of the Loan shall have been repaid, the amount in this clause 12.1.1(b) shall be reduced, by an amount up to the Excess Applicable Dividend Amount, as necessary to comply with any restrictions contained
in definitive credit documents entered into in connection with the Closing Debt Documents and any other financing or refinancing permitted hereunder that restrict the ability of members of the Group to make distributions to the Company), minus

  

	 	12.1.2	the quotient of: 

  

	 	(a)	the product of 

  

	 	(i)	the amount of interest accrued under the Loan during such Financial Year, times 

  

	 	(ii)	the difference between 

  

	 	(A)	1, minus 

  

	 	(B)	for the first Financial Year, 38%, and for each subsequent Financial Year, the MDLZ Tax Rate for the preceding Financial Year, divided by 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -18- 

	 	(b)	the difference between 

  

	 	(i)	1, minus 

  

	 	(ii)	the product of 

  

	 	(A)	for the first Financial Year, 38%, and for each subsequent Financial Year, the MDLZ Tax Rate for the preceding Financial Year, times 

 

	 	(B)	the difference between 

  

	 	(1)	1, minus 

  

	 	(2)	the dividends received deduction rate applicable to MDLZ’s receipt of a dividend payable by the Company in such Financial Year 

(the difference between the amounts set forth in clauses 12.1.1 and 12.1.2, the “Dividend Policy”); provided,
that the amount set forth in clause 12.1.1 for 2016 shall be prorated such that the actual amount payable for such year shall equal the amount multiplied by the quotient of N divided by 365, where N is the number of days from (but excluding) the
date on which the Closing occurs to (and including) 30 September 2016 (unless the Financial Year is changed to 31 December, in which case, such period shall end on (and include) 31 December 2016). 

 

	12.2	The Company shall procure (so far as it is able) and the Shareholders shall procure (so far as they are able) that: 

  

	 	12.2.1	the amount of dividends to be distributed by each Group Company (other than the Company) is such amount that is permitted by applicable Law in order to allow the Company to meet its obligations under clause 12.1 and the
Loan; and 

  

	 	12.2.2	all resolutions for the declaration or payment of dividends or other payments consistent with this clause 12 are duly passed. 

  

	12.3	In the event that payment of a dividend in connection with this clause 12 would result in a material tax liability for the A Shareholder, the B Shareholder or the Company, the Company and the A and B Shareholders will
work together to determine an alternative payment method. 

  

	13.	OTHER POLICIES 

 The Group will be managed in a way that is consistent in all material
respects with the Governance Policies. The amendment of any Governance Policy is a Reserved Matter. 
  

	14.	COVENANTS - NON-COMPETE AND NON-SOLICITATION 

  

	14.1	Subject to clause 14.3, each Shareholder shall not (and shall procure that its Affiliates shall not), without the prior written consent of the A and B Shareholders, either alone or jointly with, through or as
adviser to, or agent of, or manager for, any person, directly or indirectly: 

  

	 	14.1.1	carry on or be engaged, concerned or interested in or assist a business which competes, directly or indirectly, with the Business as carried on at any time during the term of this Agreement (unless otherwise agreed by
the Shareholders); 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -19- 

	 	14.1.2	do or say anything which is harmful to the goodwill or reputation of the Business or any Group Company or which could reasonably lead a person who is dealing or has at any time during the term of this Agreement dealt
with the Business or any Group Company to cease to deal with the Business or any Group Company on substantially equivalent terms to those previously offered or at all. 

 

	14.2	The restrictions contained in clause 14.1 shall apply to a Shareholder and its Affiliates until the end of the period of two years from the date on which such Shareholder ceases to be a party to this
Agreement. 

  

	14.3	Nothing contained in clause 14.1 shall preclude or restrict a Shareholder or any of its Affiliates from: 

  

	 	14.3.1	subject to clause 14.4, acquiring control of a company or business which has as an incidental part of its activities an activity which would be prohibited by this clause (a “Competing Business
Portion”); 

  

	 	14.3.2	holding not more than 5% of the issued share capital of any company which competes with the Business whose shares are listed on a recognised stock exchange; 

 

	 	14.3.3	offering any service or goods similar to those previously supplied as part of the Business but subsequently discontinued and not supplied by any Group Company at the time when the similar service or goods are offered;

  

	 	14.3.4	continuing to carry on or be engaged, concerned or interested in any business or person that, prior to a change in the scope of the Business agreed in accordance with this Agreement, did not compete with the Business,
but thereafter competes with the Business as a result of such modification; 

  

	 	14.3.5	in the case of Maple Holdings and its Affiliates, (i) conducting the business of Peet’s Coffee & Tea Inc. and Caribou Coffee Company, Inc. and their respective subsidiaries in the retail/fast moving
consumer goods/out of home channels in the United States of America, Canada and Mexico and (ii) operating Coffee Shops anywhere in the world; 

  

	 	14.3.6	in the case of MDLZ and its Affiliates, the development, manufacturing, marketing and sales of chocolate beverages through multiple delivery systems, including on-demand brewing systems; 

 

	 	14.3.7	in the case of MDLZ and its Affiliates, conducting the business of Dong Suh Foods Corporation and its subsidiaries in South Korea in the ordinary course; 

 

	 	14.3.8	in the case of MDLZ and its Affiliates, until 2 July 2016, conducting the Royal Tea Blend business in Costa Rica and Nicaragua; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -20- 

	 	14.3.9	[Intentionally left blank]; 

  

	 	14.3.10	in the case of Maple Holdings and its Affiliates and MDLZ and its Affiliates, holding shares in JDE and conducting the business of JDE and its subsidiaries; and 

 

	 	14.3.11	in the case of (a) Maple Holdings and its Affiliates [ * * * ] and (b) MDLZ and its Affiliates from the earlier of (x) the expiry of a period of 18 months from the date of this Agreement and (y) [ *
* * ], the development, manufacturing, marketing and sales of (i) on-demand brewing systems (whether done directly or indirectly, or through third parties) for the delivery of cold and ambient beverages of all kinds (other than Coffee Beverages
and Tea Beverages) and (ii) products that are used in combination with such on-demand brewing systems under owned brands or brands licensed from third parties (other than Coffee Products and Tea Products), and (iii) related accessories, in
each case in all distribution channels anywhere in the world. In the case of MDLZ and its Affiliates, for the purposes of this clause 14.3.11, the definitions of Coffee Beverages, Tea Beverages, Coffee Products and Tea Products shall not include
powdered soft drinks products within the corresponding MDLZ category in existence as of the date of this Agreement, wherever those products may be sold from time to time. 

 

	14.4	Acquisitions of a Competing Business Portion 

 If a Shareholder or any of its
Affiliates (the “Acquiring Shareholder”) acquires control of a company or business with a Competing Business Portion, it shall offer to sell the Competing Business Portion to the Company at fair market value. If the Board, excluding
for the purposes of voting only any Directors appointed by the Acquiring Shareholder, chooses not to buy the Competing Business Portion, the Acquiring Shareholder shall as soon as reasonably practicable sell, or procure that its Affiliate sells, it
to a third party except to the extent that the Competing Business Portion (i) is not a business engaged in the development, manufacturing, marketing and sales of on-demand brewing systems, and (ii) operates in the United States, Canada or
Mexico.  
  

	14.5	Other Interests 

  

	 	14.5.1	The Shareholders acknowledge that each of them or their Affiliates own businesses outside of their investment in the Group (each, a “Non JV Business”) and each Shareholder undertakes, either directly or
indirectly, not to share any commercially sensitive information in relation to any Non JV Business with the other or a Group Company and not to share any commercially sensitive information relating to any Group Company with any Non JV Business. In
the event that this Agreement is amended to permit a Shareholder to compete with the Business as an exception to the prohibitions in clause 14.1, the Shareholders and the Company acknowledge and agree that this Agreement will need to
be further amended to ensure that adequate antitrust compliance and information sharing procedures are put in place. 

  

	 	14.5.2	 Nothing in clause 14.1 shall preclude Olivier Goudet, one of the non-executive Board members appointed by Maple
Holdings, from holding a non-executive board position at Mars Incorporated. However, Maple Holdings undertakes 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -21- 

	 	
that it has obtained written confirmation from Olivier Goudet that he shall not (a) share any commercially sensitive information in relation to the Business in connection with the
performance of his/her duties as a member of the board of Mars Incorporated; and (b) share any commercially sensitive information in relation to the coffee or tea business of Mars Incorporated in connection with the performance of his duties as
a member of the Board. 

  

	14.6	New Opportunity 

  

	 	14.6.1	If a Shareholder identifies or becomes aware of any opportunity relevant to the Business in the territory referred to in clause 2.1.2 which is not expressly carved out by clause 14.3 (the “New
Opportunity”), then (unless it considers that the New Opportunity does not merit consideration by the Company) the relevant Shareholder (the “Referring Shareholder”) shall notify the Board in writing with reasonable details
as to the nature of the New Opportunity as soon as reasonably practicable and, in any event, before any material negotiations commence with any third party. 

 

	 	14.6.2	If the Board, excluding for the purposes of voting only any Directors appointed by the Referring Shareholder, chooses to pursue the New Opportunity (subject always to the requisite approval if the New Opportunity is a
Reserved Matter), the Shareholders shall procure that the Group uses all reasonable endeavours to implement the New Opportunity as soon as reasonably practicable. 

 

	 	14.6.3	If (i) a Shareholder considers that a New Opportunity does not merit consideration by the Company or (ii) the Board (a) chooses to pursue the New Opportunity, but does not enter into a transaction within
six months or (b) chooses not to pursue the New Opportunity, then unless the New Opportunity has already been considered and rejected by JDE in accordance with the provisions of the JDE Shareholders Agreement, the Referring Shareholder shall
procure that the New Opportunity is offered to JDE to the extent that such New Opportunity would also constitute a New Opportunity (as such term is defined in the JDE Shareholders Agreement) for JDE (a “Relevant Opportunity”). If
(i) JDE chooses (or has already chosen) not to pursue the New Opportunity in accordance with the provisions of the JDE Shareholders Agreement or (ii) such New Opportunity is not a Relevant Opportunity, then neither Shareholder, nor any
Affiliate, shall be entitled to proceed on its own with such New Opportunity. 

  

	14.7	Non-solicitation 

  

	 	14.7.1	Each Shareholder undertakes to the other and to the Company that for a period of 2 years from Closing it shall not (and shall procure that its Affiliates shall not), without the prior written consent of the other
Shareholder, directly or indirectly engage or employ, or solicit or contact with a view to his engagement or employment by another person, a person who is or has at any time during the term of this Agreement or in the 6 months prior to the date of
Closing been a director, officer, employee or manager of the Business or any Group Company where the person in question either has Confidential Information or knowhow or would be in a position to exploit the Business’ or Group’s trade
connections. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -22- 

	 	14.7.2	The Company undertakes to each Shareholder that for a period of 2 years from Closing it shall not, without the prior written consent of the relevant Shareholder, either alone or jointly with, through or as adviser to,
or agent of, or manager for, any person, directly or indirectly, engage or employ, or solicit or contact with a view to his engagement or employment by another person, a person who is or has at any time during the term of this Agreement or in the 6
months prior to the date of Closing been a director, officer, employee or manager of a Shareholder, except in accordance with the provisions of the Global Contribution Agreement. 

 

	 	14.7.3	Nothing in this clause 14.7 shall prohibit a party from engaging or employing any person who has responded to a bona fide recruitment advertisement not specifically targeted at that person. 

 

	14.8	Each undertaking in this clause 14 constitutes an entirely separate undertaking. If one or more of the undertakings is held to be against the public interest or unlawful or in any way an unreasonable restraint of
trade, the remaining undertakings shall continue to be valid and effective. 

  

	14.9	The Shareholders consider that the restrictions contained in this clause 14 are reasonable, but if any such restriction shall be found to be void or ineffective but would be valid and effective if any part of it
were deleted or the period or area of application reduced such restriction shall apply with such modification as may be necessary to make it valid and effective. 

 

	15.	TRANSFERS OF SHARES 

  

	15.1	Restrictions on transfers prior to an Initial IPO 

 Except as otherwise permitted
pursuant to clause 15.2, prior to an Initial IPO no Shareholder shall do, or agree to do, directly or indirectly, any of the following without the prior written consent of the other Shareholders unless the proposed transferor is the A Shareholder or
the B Shareholder in which case consent shall only be required from the other one: 
  

	 	15.1.1	sell, assign, transfer or otherwise dispose of, or grant any option over, any of its Shares or any legal or beneficial interest in any of its Shares; 

 

	 	15.1.2	create or permit to subsist any Encumbrance over any of its Shares or any interest in any of its Shares; 

  

	 	15.1.3	create any trust in respect of or confer any interest in any of its Shares or any interest in any of its Shares; 

  

	 	15.1.4	direct (by way of renunciation or otherwise) that another person should, or assign any right to, receive any Share or any interest in that Share; or 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -23- 

	 	15.1.5	enter into any agreement, arrangement or understanding in respect of the votes or the right to receive dividends or any other rights attached to any of its Shares. 

 

	15.2	Permitted transfers 

 Subject to compliance with clause 17, prior to an Initial IPO, a
Shareholder may transfer its Shares: 
  

	 	15.2.1	to a Shareholder Group Entity in accordance with clause 15.3; 

  

	 	15.2.2	after 2 July 2018, in accordance with clauses 15.4 to 15.6 (if applicable); and 

  

	 	15.2.3	in accordance with clause 16 (if applicable) following the occurrence of an Exit Event. 

  

	15.3	Transfers to Shareholder Group Entities 

  

	 	15.3.1	A Shareholder may transfer all (but not only some) of its Shares to a Shareholder Group Entity at any time on giving prior written notice to the other Shareholders, copied to the Company, provided that:

  

	 	(a)	in the case of the A Shareholder, such transfer would not cause a deemed termination and reformation of a partnership for US tax purposes, unless: 

 

	 	(i)	the A Shareholder has consulted with the B Shareholder and the B Shareholder has determined in its reasonable judgement that the transfer would not have a material adverse impact on the B Shareholder; or

  

	 	(ii)	the A Shareholder indemnifies the B Shareholder for any US tax paid as a result of such termination and reformation; 

  

	 	(b)	the transferee shall first have entered into a Deed of Adherence in the form set out in schedule 8; 

  

	 	(c)	if the transferee ceases to be a Shareholder Group Entity, the transferee shall prior to such cessation transfer all the Shares held by it to the transferring Shareholder or to another Shareholder Group Entity in
accordance with and as permitted by this Agreement; and 

  

	 	(d)	the transferring Shareholder shall procure that the Shareholder Group Entity to whom Shares are transferred in accordance with this clause 15.3.1 complies with the terms of this Agreement. 

 

	 	15.3.2	Following a transfer to a Shareholder Group Entity in accordance with this clause 15.3 any references in this Agreement to Shares held by a Shareholder shall be deemed to be a reference to Shares held by the
Shareholder Group Entity to whom it has transferred Shares in accordance with this clause 15.3. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -24- 

	15.4	Certain Permitted Transfers 

  

	 	15.4.1	After 2 July 2018: 

  

	 	(a)	the B Shareholder may invoke the provisions of clause 15.5 (a “ROFO Process”); 

  

	 	(b)	the A Shareholder may invoke the provisions of clause 15.6 (an “IPO Process”). 

  

	 	15.4.2	The B Shareholder may also invoke an IPO Process in the circumstances set out in clause 15.5.5. 

  

	 	15.4.3	Once a Shareholder has initiated a ROFO Process or an IPO Process (an “Initial Process”), the other Shareholder may not serve a competing notice or a Default Notice:  

 

	 	(a)	if the Initial Process is a ROFO Process, before the date which is 15 Business Days after the first to occur of (i) expiry of the Offer Period (if no Offer is made) and (ii) the date on which a Response Notice
is given (or deemed to be given) which constitutes a rejection of an Offer; and 

  

	 	(b)	if the Initial Process is an IPO Process, before the date which is 15 Business Days (if the competing notice is a Default Notice) or 3 months (if the competing notice is a ROFO Notice or an IPO Notice) after the first
to occur of (i) expiry of the Consideration Period if no IPO Acceptance Notice is given and (ii) the date of a Termination Notice. 

  

	 	15.4.4	For the avoidance of doubt, any IPO Process is with respect to a listing of a Shareholder’s Shares only. Any issuance of new Shares in connection with an IPO shall be a Reserved Matter. 

 

	 	15.4.5	Following an Initial IPO, the provisions of clauses 15.1 to 15.6 shall no longer apply and clause 15.7 shall apply. 

  

	15.5	Right of First Offer Process 

  

	 	15.5.1	Subject to clause 15.4, if the B Shareholder wishes to transfer its Shares (the “Sale Shares”) it shall serve a written notice (a “ROFO Notice”) on the A Shareholder. 

  

	 	15.5.2	Within [ * * * ] Business Days of the date of the ROFO Notice (the “Offer Period”), the A Shareholder may by notice in writing to the B Shareholder (an “Offer”) make a bona fide offer
to acquire all of the Sale Shares. The Offer must set out the price per Sale Share (the “Offer Price”) and any other terms on which the A Shareholder offers to acquire the Sale Shares. Once made, an Offer shall be irrevocable and
binding and shall be accepted or rejected by the B Shareholder in accordance with clause 15.5.3. 

  

	 	15.5.3	Within [ * * * ] Business Days of the date of the Offer (the “Acceptance Period”), the B Shareholder must inform the A Shareholder in writing (a “Response Notice”) whether it
accepts or rejects the Offer. Failure to deliver a Response Notice within the Acceptance Period will be deemed a rejection of the Offer.  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -25- 

	 	15.5.4	If the Response Notice constitutes an acceptance of the Offer, it shall also state the date, place and time on which the sale and purchase of the Sale Shares shall be completed, which shall not be earlier than [ * * * ]
Business Days after the date of the Response Notice. The sale and purchase of the Sale Shares shall take place in accordance with clause 17. 

  

	 	15.5.5	If no Offer is made, or a Response Notice is given (or deemed to be given) which constitutes a rejection of an Offer, the B Shareholder shall not be entitled to transfer its Shares but shall be entitled:

  

	 	(a)	to serve an IPO Notice under clause 15.6 within [ * * * ] Business Days of the expiry of the Offer Period (if no Offer is made) or the date on which a Response Notice of an Offer is given (or deemed to be given) which
constitutes a rejection; or 

  

	 	(b)	invoke a further ROFO Process, provided that only one ROFO Notice may be served per Quarter. 

  

	 	15.5.6	The A Shareholder may, by written notice to the B Shareholder, assign any rights it has under this clause 15.5 to the Company and in this event the Company agrees to be bound by the provisions of this clause 15 as if it
were the A Shareholder. For the avoidance of doubt, any acquisition of Shares by the Company in accordance with this clause 15.5 will not require approval as a Reserved Matter. 

 

	15.6	IPO Process 

  

	 	15.6.1	Subject to clause 15.4 and, if applicable, clause 15.6.8(b), the A or B Shareholder (the “Transferring Shareholder”) may by notice in writing (an “IPO Notice”) to the other one (the
“Other Shareholder”) and the Company call for an initial public offering of Shares held by it on a securities exchange (an “IPO”). The IPO Notice shall indicate the number of Shares the Transferring Shareholder
wishes to sell in the IPO subject to the provisions of this clause 15.6. The Board shall determine the applicable exchange taking into account the recommendations of the Valuer and market liquidity and available capital and such other factors as the
Board deems necessary. 

  

	 	15.6.2	 Within [ * * * ] Business Days of receipt of an IPO Notice (or, if clause 15.6.9 applies, the date on which an
election is made to continue with an IPO), the Company shall engage and instruct an independent investment bank with expertise in initial public offerings mutually selected by the A and B Shareholders that shall not (unless they agree otherwise) be
an underwriter in the competitive process referred to in clause 15.6.4 (the “Valuer”) to determine and report to the A and B Shareholders and the Company within [ * * * ] Business Days of its appointment (the
“Report”) on (i) the value of the Company (the “Report Value”); (ii) an indicative price or price range for the Shares subject to the IPO (the “IPO Value”); (iii) whether the market
conditions, business and other relevant factors are conducive and favorable for  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -26- 

	 	
an IPO; (iv) the most favorable securities exchange for the IPO; (v) the number of Shares that can be included in the IPO without adversely affecting the price that can be achieved for
the Shares through the IPO and (vi) its non-binding recommendation as to what the post IPO capital structure should be and what changes (if any) would need to be made to the rights attaching to the Shares subject to the IPO and/or the Shares to
be retained by the A and B Shareholders post IPO under this Agreement to make the Shares subject to the IPO suitable for listing. It is acknowledged that the aim should be for as many rights to be retained as possible. 

 

	 	15.6.3	The Transferring Shareholder shall have [ * * * ] Business Days from delivery of the Report to consider the Report (the “Consideration Period”). If the Transferring Shareholder wishes to pursue an IPO
at a value that equals or exceeds the Report Value or the IPO Value, as the case may be, then it shall notify the Other Shareholder and the Company in writing of the same within the Consideration Period, indicating the number of Shares it wishes to
sell in the IPO (if different from the number included in the IPO Notice) (the “IPO Acceptance Notice”). The Other Shareholder shall respond in writing within [ * * * ] Business Days of receipt of an IPO Acceptance Notice indicating
whether or not it wishes to sell any of its Shares in the IPO subject to any reduction in accordance with clause 15.6.5. 

  

	 	15.6.4	If the Transferring Shareholder serves an IPO Acceptance Notice, the Company shall select mutually acceptable underwriter(s) through a competitive process and take all necessary actions to implement the IPO as soon as
practicable and in any event within [ * * * ] months of the date of the IPO Acceptance Notice. The Shareholders shall provide all reasonable assistance in connection with the IPO, including all reasonable assistance to facilitate any due diligence
process, giving such warranties and lock ups and entering into such agreements as are common for an IPO of a comparable size and scope, approving all such matters as may require Shareholder approval and procuring the approval of all such matters as
require Board approval in each case as may be reasonably required to implement the IPO. 

  

	 	15.6.5	The Transferring Shareholder (and the Other Shareholder if it delivers a notice under clause 15.6.3) shall be entitled to sell up to such number of the Shares specified in the IPO Acceptance Notice (and, if applicable,
in a notice delivered under clause 15.6.3) in the Company as the lead underwriter confirms can be sold without adversely affecting the price that can be achieved for Shares through the IPO. If any reduction in the number of Shares subject to the IPO
is required, this should be applied: 

  

	 	(a)	if the Transferring Shareholder is the A Shareholder, pro rata between the A Shares and the B Shares; and 

  

	 	(b)	if the Transferring Shareholder is the B Shareholder, first against any Shares proposed to be sold by the A Shareholder, so that the B Shareholder will sell the maximum number of IPO Shares possible. 

 

	 	15.6.6	 All expenses incurred by the Company in connection with an IPO shall be paid by the Company. The expenses
incurred by a Transferring Shareholder in 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -27- 

	 	
connection with an IPO shall be for its own account, including the underwriting commissions payable to underwriters in connection with its sale of Shares pursuant to the IPO. If the Other
Shareholder has delivered a notice under clause 15.6.3 and is also selling Shares into the IPO, any such expenses shall be borne by the selling Shareholders pro rata to the number of Shares each one actually sells in the IPO in accordance with
clause 15.6.5. 

  

	 	15.6.7	In the event that the actual price obtainable by the Transferring Shareholder for the Shares subject to the IPO is less than the Report Value or the IPO Value, as the case may be, the Transferring Shareholder may (in
its sole discretion) by written notice to the Other Shareholder and the Company (a “Termination Notice”) elect to terminate the IPO Process, with respect to such Shares and any Shares of the Other Shareholder if it delivered a
notice under clause 15.6.3, and clause 15.6.8 shall apply. 

  

	 	15.6.8	If no IPO Acceptance Notice is served or a Termination Notice is served subsequent to an IPO Acceptance Notice or a withdrawal notice is given in accordance with clause 15.6.9, the Transferring Shareholder shall not be
entitled to transfer its Shares but shall be entitled: 

  

	 	(a)	if the Transferring Shareholder is the A Shareholder, to serve another IPO Notice in accordance with clause 15.6, provided that only one IPO Notice may be served per Quarter; and 

 

	 	(b)	if the Transferring Shareholder is the B Shareholder, to invoke a further ROFO Process in accordance with clause 15.5 provided that only one IPO Notice may be served per Quarter. 

 

	 	15.6.9	The Shareholders acknowledge and agree that, as at the date of this Agreement, the expectation is that any initial public offering will be with respect to the combined businesses of the Company and JDE (or
“Combined IPO”). If, at the time an IPO Notice is given, an initial public offering of JDE has not taken place, the A Shareholder and B Shareholder shall in conjunction with the Board, the A shareholder and B shareholder of JDE and
the JDE Board, consider in good faith whether a Combined IPO would be preferable at such time and, if so, the process to achieve that. For the avoidance of doubt, while the parties may have regard to the provisions of clause 15.6 of this Agreement
and the JDE Shareholders Agreement in determining process, the process for achieving a Combined IPO as well as the terms and conditions on which any Shareholder may be prepared to agree to, and participate in, any Combined IPO, shall be a Reserved
Matter. If no agreement to pursue a Combined IPO is reached within [ * * * ] days of the date of the IPO Notice (the “Combined IPO Consideration Period”), the Transferring Shareholder may elect in writing within [ * * * ] Business
Days of the expiry of the Combined IPO Consideration Period to (a) continue with the IPO following the process provided for in clauses 15.6 (and the time period in clause 15.6.2 shall run from the date of that election) or (b) withdraw the
IPO Notice. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -28- 

	15.7	Transfers after an Initial IPO 

 Following an Initial IPO, the provisions of clauses
15.1, 15.2 and 15.4 to 15.6 (inclusive) shall not apply and a Shareholder may sell Shares: 
  

	 	15.7.1	to a Shareholder Group Entity in accordance with clause 15.3; 

  

	 	15.7.2	in the market through facilities on which the relevant Shares are listed (and the Company shall, upon request by such Shareholder and at the Company’s cost, take all corporate actions required by applicable Laws,
including the exchange on which the Shares are listed, to facilitate such sale); 

  

	 	15.7.3	in accordance with clause 15.8 or 15.9 (if applicable) relating to off market sales; 

  

	 	15.7.4	in the case of the A Shareholder, to any shareholder of its ultimate parent entity in order to facilitate a sale by such person in accordance with clause 15.7.2; and 

 

	 	15.7.5	in accordance with clause 16 (if applicable) following the occurrence of an Exit Event. 

  

	15.8	Off market sales by the A Shareholder 

  

	 	15.8.1	If the A Shareholder proposes to sell Shares representing [ * * * ] or more of the outstanding issued share capital of the Company to a Third Party purchaser (which shall include for these proposes a consortium of
multiple parties) (a “Single Purchaser”) in one or a series of privately negotiated transactions (or in a private or public placement if the A Shareholder is aware that a material portion of the Shares to be sold through such
transaction will be, or is reasonably likely to be, resold to a Single Purchaser) (a “Single Purchaser Sale”), the A Shareholder shall serve a written notice on the B Shareholder including the identity of the potential Single
Purchaser, the number of Shares it proposes to sell, the proposed purchase price for such Shares and such other information reasonably required to enable the B Shareholder to make an informed assessment of whether to participate in the Single
Purchaser Sale (a “Tag Along Notice”). 

  

	 	15.8.2	Within [ * * * ] Business Days of the date of the Tag Along Notice, the B Shareholder must inform the A Shareholder in writing (a “Tag Along Response Notice”) whether it intends to participate in the
Single Purchaser Sale on the terms set out in the Tag Along Notice. If the B Shareholder does not deliver a Tag Along Response Notice within such period, it shall be deemed to have irrevocably declined to participate in the Single Purchaser Sale.

  

	 	15.8.3	 The B Shareholder shall be entitled to sell in the Single Purchaser Sale the same proportion of its Shares as the
proportion of the Shares proposed to be sold by the A Shareholder in the Single Purchaser Sale bears to the total number of Shares held by the A Shareholder immediately prior to delivery of the Tag Along Notice. If the Single Purchaser is unwilling
to purchase all the 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -29- 

	 	
Shares proposed to be sold following delivery of a Tag Along Response Notice, the number of Shares to be sold in the Single Purchaser Sale shall be reduced pro rata between the Shares to be sold
to the Single Purchaser by the A Shareholder and the Shares to be sold by the B Shareholder. 

  

	 	15.8.4	If a proposed Single Purchaser Sale has not been completed within [ * * * ] Business Days of receipt of a Tag Along Notice, the A Shareholder shall procure termination of the Single Purchaser Sale. 

 

	 	15.8.5	This clause 15.8 will cease to apply once the A Shareholder holds less than [ * * * ] of the Shares. 

  

	15.9	Off market sales by the B Shareholder 

  

	 	15.9.1	If the B Shareholder proposes to enter into a Single Purchaser Sale with respect to Shares representing [ * * * ] or more of the outstanding issued share capital of the Company, it shall serve written notice on the A
Shareholder including the identity of the Single Purchaser and the number of Shares it proposes to sell (a “Transfer Notice”). 

  

	 	15.9.2	A Single Purchaser Sale shall not be entered into or completed without the consent of the A Shareholder which must not be unreasonably withheld, taking into account the number of, and rights attaching to, the Shares
proposed to be transferred. Consent shall be deemed to have been given unless, within [ * * * ] Business Days of the date of the Transfer Notice, the A Shareholder serves a written notice of objection on the B Shareholder specifying in reasonable
detail the reasons why it does not consent to the Single Purchase Sale. 

  

	 	15.9.3	If a proposed Single Purchaser Sale which has received consent (or is deemed to have been consented to) in accordance with clause 15.9.2 has not been completed within 20 Business Days of receipt of a Transfer Notice,
the B Shareholder shall procure termination of the Single Purchaser Sale. 

  

	 	15.9.4	This clause 15.9 shall cease to apply once the A Shareholder holds less than [ * * * ] of the Shares or B Shareholder holds less than [ * * * ] of the Shares. 

 

	15.10	Circumvention of restrictions 

 Each Shareholder shall not, and shall procure that its
Affiliates shall not, except as otherwise permitted under this Agreement, employ or be entitled to employ any device or technique or participate in any transaction or arrangements with any person designed to circumvent or avoid the provisions and
restrictions set out in this clause 15 or clause 16. 
  

	16.	EXIT EVENTS 

  

	16.1	Each party shall promptly inform the Board and the Shareholders as soon as it becomes aware that an Exit Event has occurred. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -30- 

	16.2	Defaulting Shareholder is the B Shareholder 

  

	 	16.2.1	Except as provided in clause 16.2.2, if the Defaulting Shareholder is the B Shareholder and the Exit Event is not an Insolvency Event, the Non-defaulting Shareholder shall be entitled to serve written notice on the
Defaulting Shareholder no later than [ * * * ] Business Days after the later of (i) the date on which it becomes aware of the occurrence of an Exit Event and (ii) the relevant date in clause 15.4.3 (if applicable) requiring it to sell all
(but not only some) of the Shares held by the Defaulting Shareholder (the “Call Shares”) to the Non-defaulting Shareholder in cash at the Transfer Value (such notice, a “Call Notice”). 

 

	 	16.2.2	If the Exit Event is a [ * * * ]. 

  

	16.3	Defaulting Shareholder is the A Shareholder 

 If the Defaulting Shareholder is the A
Shareholder and the Exit Event is not an Insolvency Event, the Non-defaulting Shareholder shall be entitled to serve written notice on the Defaulting Shareholder no later than [ * * * ] Business Days after the later of (i) the date on which it
becomes aware of the occurrence of an Exit Event and (ii) the relevant date in clause 15.4.3 (if applicable) requiring it to buy all (but not only some) of the Shares held by the Non-defaulting Shareholder (the “Put Shares”) in
cash at the Transfer Value (such notice, a “Put Notice” and, together with a Call Notice, a “Default Notice”). 
  

	16.4	Exit Event is an Insolvency Event 

 If the Exit Event is an Insolvency Event, the
Non-defaulting Shareholder shall be entitled to serve a Call Notice on the Defaulting Shareholder no later than [ * * * ] Business Days after becoming aware of the occurrence of such Insolvency Event. 

 

	16.5	Terms of Default Notice 

  

	 	16.5.1	A transfer of Shares pursuant to a Default Notice shall be subject to the following terms: 

  

	 	(a)	the Default Notice shall be irrevocable and unconditional; and 

  

	 	(b)	unless clause 16.6 applies, completion of the sale and purchase of the Call Shares or Put Shares (as the case may be) shall take place on the later of: 

 

	 	(i)	the [ * * * ] Business Day following the expiry of a period of [ * * * ] Business Days from the date of the Default Notice if the relevant Exit Event is a Terminating Breach which is capable of remedy but has not been
remedied in full (at the Defaulting Shareholder’s cost) to the satisfaction of the Non-defaulting Shareholder; 

  

	 	(ii)	the [ * * * ] Business Day following the date of the Default Notice with respect to any other Exit Event; and 

  

	 	(iii)	the [ * * * ] Business Day following the date on which the Transfer Value is agreed or determined, 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -31- 

 (the “Transfer Date”) and otherwise in accordance with clause 17. 

 

	 	16.5.2	For the avoidance of doubt: 

  

	 	(a)	only the B Shareholder is entitled to serve a Default Notice following a Acorn/JAB Change of Control Event, a Competitor Event, an Insolvency Event relating to the A Shareholder or an event described in paragraphs
(b) and (c) of the definition of Terminating Breach or paragraph (a) to the extent of a breach by the A Shareholder; and 

  

	 	(b)	only the A Shareholder is entitled to serve a Default Notice following a MDLZ Change of Control Event, an Insolvency Event relating to the B Shareholder or paragraph (a) of the definition of Terminating Breach to
the extent of a breach by the B Shareholder. 

  

	16.6	Completion of transfers 

  

	 	16.6.1	The purchasing Shareholder will use its best endeavours to secure financing on commercially reasonable terms and conditions to enable completion of the sale and purchase of the Call Shares or Put Shares (as the case may
be) by the Transfer Date. 

  

	 	16.6.2	If, notwithstanding its best endeavours, the purchasing Shareholder is not able to fund the Transfer Value by the Transfer Date, it shall be entitled to serve a notice (a “Deferral Notice”) on the
selling Shareholder deferring completion of the sale and purchase of the Call Shares or Put Shares (as the case may be) to a date which is as soon as possible after the Transfer Date but in any event not later than [ * * * ] months after the date of
the Default Notice (the “Longstop Date”). 

  

	 	16.6.3	The A Shareholder may, by written notice to the B Shareholder, assign any rights it has under clauses 16.2 and 16.4 to the Company and in this event the Company agrees to be bound by the provisions of this clause 16 as
if it were the A Shareholder. For the avoidance of doubt, any acquisition of Shares by the Company in accordance with this clause 16 will not require approval as a Reserved Matter. 

 

	16.7	Exit Events 

 For the purposes of this clause 16 an “Exit Event” shall
be deemed to have occurred when: 
  

	 	16.7.1	a Terminating Breach has occurred which, if capable of remedy, has not been remedied within [ * * * ] Business Days of the Defaulting Shareholder being served with written notice identifying the breach and requiring it
to be remedied; 

  

	 	16.7.2	 at any time prior to an Initial IPO, Maple Holdings ceases to be Controlled by Acorn Holdings B.V. and/or Acorn
Holdings B.V. ceases to be Controlled by 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -32- 

	 	
JAB Holdings B.V. other than as the result of a bona fide reorganisation of its business/a merger into any successor entity as part of a merger transaction or equivalent pursuant to which all or
substantially all of the persons who are beneficial owners of the outstanding securities immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities of the entity resulting from such
transaction in substantially the same proportions (a “Acorn/JAB Change of Control”); 

  

	 	16.7.3	at any time prior to an Initial IPO, a [ * * * ]; 

  

	 	16.7.4	at any time prior to an Initial IPO (i) a Restricted Person described in paragraph (b) of the definition acquires any shares in Acorn Holdings B.V. except to the extent of shares acquired by investors in a
shareholder of Acorn Holdings B.V. which is a limited partnership on a distribution of shares in Acorn Holdings B.V. in accordance with terms of such partnership’s governing documents or (ii) a Restricted Person described in paragraphs
(a) or (b) of the definition acquires any shares from Acorn Holdings B.V. or JAB Holdings B.V. or any of its Affiliates (a “Competitor Event”); 

 

	 	16.7.5	the A Shareholder or B Shareholder is subject to an Insolvency Event; 

  

	 	16.7.6	after the third anniversary of Closing, the B Shareholder withholds its approval to the Reserved Matter set out in paragraph 19 of schedule 1 for two consecutive Financial Years and the Escalation Representatives fail
to resolve the issue as a Deadlock Matter within the Deadlock Resolution Period, 

  

	 	16.7.7	a JDE Exit Event has occurred in respect of an Affiliate of the A or B Shareholder, 

 the A or B
Shareholder in respect of which an Exit Event has occurred shall be a “Defaulting Shareholder” and the other one shall be the “Non-defaulting Shareholder”. 

 

	17.	COMPLETION OF SHARE TRANSFERS 

  

	17.1	Transfer terms 

  

	 	17.1.1	Shares shall be transferred free of all Encumbrances and together with all rights attaching thereto as at the date of the relevant transfer. 

 

	 	17.1.2	Prior to an Initial IPO, a Shareholder must transfer all (but not only some) of its Shares (unless clause 15.6 applies) and must transfer both the legal and beneficial ownership of the relevant Shares.

  

	 	17.1.3	All Shareholder Instruments held by such Shareholder must be transferred at the same time and to the same transferee as the Shares. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -33- 

	17.2	Completion of transfer 

 Except in connection with or following an Initial IPO, the
completion of any transfer of Shares under this Agreement shall be made in accordance with the following terms: 
  

	 	17.2.1	the purchaser shall not be a Restricted Person; 

  

	 	17.2.2	the seller shall deliver to the purchaser a duly executed stock power in favour of the purchaser and a certified copy of any authority under which such transfer will be executed; 

 

	 	17.2.3	the purchaser shall cooperate with respect to such stock power; 

  

	 	17.2.4	the purchaser shall pay the aggregate transfer price in respect of the relevant Shares to the seller by banker’s draft for value on the date of completion or in such other manner as the purchaser and the seller may
agree prior to completion; 

  

	 	17.2.5	the purchaser shall (if it is not already a party to this Agreement) enter into a Deed of Adherence substantially in the form set out in schedule 8; and 

 

	 	17.2.6	the seller shall do all such other acts and execute all such other documents in a form satisfactory to the purchaser as the purchaser may reasonably require to give effect to the transfer of Shares to it.

  

	17.3	Failure to transfer 

  

	 	17.3.1	If clause 16.2 or clause 16.4 applies and the Defaulting Shareholder fails to comply with its obligations to transfer Call Shares in accordance with clause 16.5.1(b), the Company shall authorise a person to execute and
deliver the necessary transfer on its behalf. The Company shall receive the purchase money in respect of such transfer in trust for that Shareholder (and the Company shall not be required to account to such Shareholder for any interest accrued on
such amount) and the receipt of the Company for the purchase money shall be a good discharge for the purchaser, who shall not be bound to see the application of the purchase money. The Company shall, subject to the instrument of transfer being duly
executed, cause the purchaser to be registered as holder of the relevant Shares. Once registration has taken place in purported exercise of the power contained in this clause 17.3 the validity of the proceedings shall not be questioned by any
person. 

  

	 	17.3.2	If clause 15.5.4 or clause 16.5.1(b) (in so far as it relates to a sale and purchase of Put Shares) applies and a Shareholder fails to comply with its obligations to transfer Shares in accordance with those clauses:

  

	 	(a)	the Defaulting Shareholder shall be deemed to have waived its right to exercise any of its powers or rights in relation to the management of, and participation in the profits of, the Company under this Agreement, the
Articles or otherwise; and 

  

	 	(b)	the provisions of clauses 15, 17.1 and 17.2.1 shall cease to apply to the non-defaulting Shareholder with respect to the Shares held by it and the non-defaulting Shareholder shall be free to transfer its Shares to a
Third Party without restriction. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -34- 

	17.4	Validity of Share transfers 

 A transfer of a Share to any person shall only be valid if
the transfer has been carried out in accordance with this Agreement and the Articles and in no other circumstances. Any purported transfer of Shares made other than as provided for in this Agreement shall be void. Unless the Shareholders determine
otherwise prior to an IPO, Shares can only be held by persons that have become a party to this Agreement by executing a Deed of Adherence in accordance with clause 17.2.5. The Shareholders undertake that they shall consent to the execution of Deed
of Adherence by any proposed transferee of Shares to whom the transfer of such Shares is allowed in accordance with the terms of this Agreement. 
  

	17.5	Step down of rights following B Shareholder transfer 

 With effect from the date on
which, solely as a result of transfer(s) by the B Shareholder, the B Shareholder holds less than [ * * * ] of the Shares, this Agreement shall be amended as set out in schedule 13 (the “Step Down”). Save as amended by schedule 13,
this Agreement shall remain in full force and effect unless and until terminated in accordance with clause 20. 
  

	18.	REGULATORY CONSENTS FOR TRANSFERS 

  

	18.1	If a transfer of Shares is permitted by, or required to be effected under, this Agreement but requires or is likely to require a Regulatory Consent, the Shareholders and the Company: 

 

	 	18.1.1	agree that the completion of such transfer shall be conditional upon such Regulatory Consent being obtained; 

  

	 	18.1.2	agree that any procedure or time period to be followed under this Agreement to effect the transfer shall, subject to clause 18.2, be extended until such time as the relevant Regulatory Consent has been obtained;

  

	 	18.1.3	shall at the purchaser’s cost use reasonable endeavours to assist the purchaser in obtaining such Regulatory Consent including, but not limited to: 

 

	 	(a)	providing and/or procuring that the Company and each relevant Group Company provide all information necessary and reasonably within their control which the purchaser may reasonably request, to enable the purchaser to
determine which Regulatory Consents are required in connection with the transfer or the issue; and 

  

	 	(b)	ensuring that all such information necessary and reasonably within their control which the purchaser may reasonably request for making (or responding to any requests for further information following) any notification,
submission, communication or filing in connection with the seeking of the Regulatory Consent is available to the person required to obtain the Regulatory Consent or who is dealing with the notification, submission, communication or filing, and is
accurately and promptly provided upon request, 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -35- 

 provided that any commercially sensitive information may be provided on a counsel to counsel
basis or directly to the relevant authority. 
  

	18.2	If any Regulatory Consent has not been obtained within [ * * * ] months of the application being made (the “Regulatory Longstop Date”), the relevant purchaser shall not be entitled to acquire the Shares
unless, immediately before the expiry of the [ * * * ] month period, Regulatory Consent has not been obtained but is still in process, in which case the Regulatory Longstop Date shall be deemed to be extended until the earlier of (i) the date
on which Regulatory Consent is obtained or (ii) the date on which Regulatory Consent becomes incapable of being obtained, provided that the process continues to be diligently pursued. 

 

	19.	NEW ISSUES OF SHARES 

  

	19.1	In the event that the Company proposes to issue further Shares (“New Shares”) after having obtained the necessary consent in accordance with clause 6, the Company shall not allot the New Shares other
than in accordance with this clause 19, provided that the provisions of the clause 19.3 shall not apply (i) to the issue of Management Equity or (ii) the issue of New Shares in connection with any mergers or acquisitions or joint venture
transactions in each case save where, following the issue of such New Shares, the B Shareholder’s aggregate holding of Shares would be reduced to below [ * * * ] of the Shares, in which case the provisions of clause 19.3 shall apply to that
Shareholder. 

  

	19.2	The Company shall not issue any further B Shares except to the B Shareholder. 

  

	19.3	The Company shall issue a notice to the Shareholders confirming its intention to issue New Shares and shall make an offer to each Shareholder to allot to it a proportion of the New Shares as nearly as practicable equal
to the proportion in nominal value of the Shares held by it as at close of business on the date before such offers (“Relevant Proportion”). Shareholders may take up all or part or none of the New Shares offered to them.

  

	19.4	The notice shall specify; 

  

	 	19.4.1	the proposed allotee(s) of the New Shares and confirmation that such allotees are not Restricted Person(s); 

  

	 	19.4.2	the class of Shares proposed to be issued and details of the rights to be attached to such New Shares; 

  

	 	19.4.3	the number of New Shares to which the relevant Shareholder is entitled to subscribe; 

  

	 	19.4.4	the price per New Share; and 

  

	 	19.4.5	the time (being not less than [ * * * ] Business Days from the date of the notice) within which, if the offer is not accepted by the relevant Shareholder irrevocably and in writing to the Company, it shall be deemed to
be declined. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -36- 

	19.5	The Company shall not allot any of the New Shares to any person until the expiration of the time period specified in the notice given under clause 19.4.5. 

 

	19.6	If New Shares are issued in conjunction with other Shareholder Instruments the Board may make it a condition of the offer that each Shareholder subscribes for his Relevant Proportion of such Shareholder Instruments.

  

	19.7	No New Shares shall be allotted to any person who is not a Shareholder unless and until such person has become a party to this Agreement by executing and delivering to the Company and the Shareholders a Deed of
Adherence substantially in the form of schedule 8. 

  

	20.	DURATION AND TERMINATION 

  

	20.1	Duration and termination 

  

	 	20.1.1	Subject to clause 20.2, this Agreement shall continue in full force and effect without limit in time until the earlier of: 

  

	 	(a)	the date on which each Shareholder agrees in writing to terminate it; 

  

	 	(b)	the date on which all of the Shares are owned by one party to the Agreement; 

  

	 	(c)	the date on which the Company is wound up. 

  

	 	20.1.2	Upon a Shareholder ceasing to hold any Shares in compliance with this Agreement and the Articles, it shall cease to be a party to this Agreement and clause 20.2 shall apply. 

 

	20.2	Effect of termination and survival 

 Except as agreed otherwise by the Shareholders, the
occurrence of any of the events specified in clause 20.1 shall not: 
  

	 	20.2.1	relieve any Shareholder from any liability or obligation in respect of any matters, undertakings or conditions which have not been observed or performed by such Shareholder prior to the occurrence of such event; and

  

	 	20.2.2	affect the Surviving Provisions, which shall continue to remain in full force and effect and, unless a Surviving Provision provides otherwise, shall continue to apply for a period of three years after the occurrence of
such event; or 

  

	 	20.2.3	affect a Shareholder’s accrued rights and obligations prior to the occurrence of such event. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -37- 

	21.	WARRANTIES 

  

	21.1	Each Shareholder warrants to the other that as at the date of this Agreement: 

  

	 	21.1.1	it is a limited liability company, duly incorporated under the laws of its jurisdiction of incorporation, and has been in continuous existence since incorporation; 

 

	 	21.1.2	it has the right, power and authority, and has taken all action necessary, to execute, deliver and exercise its rights, and perform its obligations, under this Agreement and each Transaction Document to which it is a
party; and 

  

	 	21.1.3	its obligations under this Agreement and each Transaction Document to which it is a party are, or when the relevant document is executed will be, enforceable in accordance with its terms. 

 

	22.	CONFIDENTIALITY 

  

	22.1	Confidential Information 

 “Confidential Information” means all
information of any nature and in any form, including, in writing or orally or in a visual or electronic form or in a magnetic or digital form relating directly or indirectly to: 

 

	 	22.1.1	the provisions of this Agreement, the Exchange Agreement, the Loan or any transactions contemplated herein or therein; 

  

	 	22.1.2	discussions and negotiations in respect of this Agreement, the Exchange Agreement and the Loan; 

  

	 	22.1.3	any Group Company or the business or assets of any Group Company; and 

  

	 	22.1.4	any Shareholder or any of its Affiliates or its or their respective business or assets. 

Confidential Information excludes: 
  

	 	22.1.5	any information that at the date of disclosure by or on behalf of a party is publicly known or at any time after that date becomes publicly known through no fault of the party to whom such information was disclosed;

  

	 	22.1.6	any information that was properly and lawfully in the receiving party’s possession prior to the time that it was disclosed to it by another party. 

 

	22.2	Use of Confidential Information 

 Subject to clause 22.3, each party shall: 

 

	 	22.2.1	save in the case of a Group Company in relation to the information described in clause 22.1.3, treat and keep all Confidential Information as confidential and shall not, without the prior written consent of the other
parties, directly or indirectly disclose such Confidential Information to any person; and 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -38- 

	 	22.2.2	in the case of a Shareholder, only use the Confidential Information for the purpose of managing, monitoring or evaluating its participation in the Company or for the purpose of a member of the Group. 

 

	22.3	Permitted disclosure of Confidential Information 

  

	 	22.3.1	The restrictions in clause 22.2 shall not apply to the disclosure of Confidential Information: 

  

	 	(a)	with the prior written consent of the other parties; 

  

	 	(b)	by a Shareholder to any Director appointed by it or to any of its Shareholder Group Entities, or to any of its or their respective directors, officers or employees whose duties include the management, monitoring or
evaluation of such Shareholder’s participation in the Company and the Group and who, in the reasonable opinion of that Shareholder, need to know such information in order to discharge such duties; 

 

	 	(c)	as a result of the authority conferred on Directors by clause 4.9.3; 

  

	 	(d)	by a Shareholder to its Representatives; 

  

	 	(e)	to the extent required by law or regulation (subject to clause 23.2 save, in the case of MDLZ, with respect to the information described in part B of schedule 6); 

 

	 	(f)	to bona fide potential purchasers of interests in the Company or to their professional advisers or finance providers provided that such persons need to know the information for the purposes of considering, evaluating,
advising on or furthering the potential purchase and provided that the disclosure is limited to information regarding the terms of this Agreement and the Articles and the business and assets of the Group; 

 

	 	(g)	to a party’s finance providers or rating agencies for bona fide purposes. 

  

	 	22.3.2	A party shall ensure that each person to whom Confidential Information is disclosed by it in accordance with this clause 22.3 complies with all the provisions of this Agreement as if it were a party to this
Agreement, and such party shall be responsible for any breach of the provisions of this Agreement by any such person. 

  

	23.	ANNOUNCEMENTS 

  

	23.1	No announcement, communication or circular in connection with the existence or the subject matter of this Agreement shall be made or issued by or on behalf of any Shareholder or any of its Affiliates without the prior
written approval of the A and B Shareholders or the A or B Shareholder if the Shareholder making the announcement is an A or B Shareholder (such approval not to be unreasonably withheld or delayed). 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -39- 

	23.2	If a Shareholder is required by Law to make an announcement, communication or circular in connection with the existence or the subject matter of this Agreement, such Shareholder shall, where and to the extent not
prohibited by such Law, only make such announcement or disclosure after consultation with the other Shareholder and after taking into account the other Shareholder’s reasonable requirements as to its timing, content and manner of making. If a
Shareholder is unable to consult with the other Shareholder before the announcement, communication or circular or disclosure is made, it shall to the extent not prohibited by such law or regulation inform the other Shareholder of the circumstances,
timing, content and manner of making of the announcement or disclosure immediately after such announcement or disclosure is made. 

  

	24.	FURTHER ASSURANCES AND UNDERTAKINGS 

  

	24.1	Each Shareholder agrees to comply with all of its obligations under this Agreement and the Articles. 

  

	24.2	Each Shareholder shall procure (so far as it is able) that each Group Company acts in a manner consistent with this Agreement, including for the avoidance of doubt the Governance Policies, and complies with all of its
obligations under this Agreement, the Governance Policies, the Articles and the Loan and gives full effect to the terms of this Agreement, the Governance Policies, the Articles and the rights and obligations of the parties as set out in this
Agreement, the Governance Policies, the Articles and the Loan. 

  

	24.3	Each Shareholder shall procure (so far as it is able) that its Affiliates comply with all applicable provisions of this Agreement and the Articles, and shall be liable for any breach of such provisions by any such
Affiliate. 

  

	24.4	Each Shareholder shall procure that any Director appointed by it from time to time acts in a manner consistent with this Agreement and exercises his voting rights and other powers and authorities in order to procure (so
far as he is able) that the Company complies with all of its obligations under this Agreement, the Articles and the Loan and gives full effect to the terms of this Agreement and the Articles and the rights and obligations of the parties as set out
in this Agreement and the Articles. 

  

	24.5	The Company agrees to comply with all of its obligations under this Agreement, the Articles and the Loan and shall procure (so far as it is able) that the other Group Companies do the same. 

 

	25.	SUPREMACY OF THIS AGREEMENT 

 If there is any conflict or inconsistency between the
provisions of this Agreement and the Articles or the articles of any other Group Company, this Agreement shall prevail. Each Shareholder shall exercise all voting and other rights and powers available to it so as to give effect to the provisions of
this Agreement and, if necessary, to procure (so far as it is able) any required amendment to the Articles and each Shareholder and the Company shall procure any required amendment to the articles of association of any other Group Company. Nothing
in this Agreement shall be deemed to constitute an amendment of the Articles or any previous articles of association of the Company. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -40- 

	26.	ENTIRE AGREEMENT AND NON-RELIANCE 

  

	26.1	This Agreement constitutes the entire agreement between the parties relating to the subject matter of this Agreement to the exclusion of any terms implied by Law to the extent that they may be excluded by contract and
supersedes any previous agreements between the parties in relation to the matter dealt with in this Agreement. In this clause 26, “this Agreement” shall include the Loan and all other documents entered into pursuant to this Agreement.

  

	26.2	Each Shareholder acknowledges and agrees that it has not relied on or been induced to enter into this Agreement by a representation, warranty or undertaking (whether contractual or otherwise) that is not expressly set
out in this Agreement. 

  

	26.3	Each party acknowledges and agrees that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection with this Agreement shall be for breach of the terms of this
Agreement (whether by way of damages, injunction or specific performance or otherwise) to the exclusion of all other rights and remedies (including those in tort or arising under statute). 

 

	26.4	Nothing in this clause 26 shall have the effect of restricting or limiting any liability arising as a result of any fraud, wilful misrepresentation or wilful concealment. 

 

	27.	COSTS 

 Except where this Agreement or relevant document provides otherwise, each party
shall pay its own costs relating to the negotiation, preparation, execution and performance by it of this Agreement and of each document referred to in it. 
  

	28.	GENERAL 

  

	28.1	Effectiveness 

 This Agreement takes effect on Closing. 

 

	28.2	Variation 

  

	 	28.2.1	Subject to clause 28.2.2, a variation of this Agreement is valid only if it is in writing and signed by or on behalf of each party other than by or on behalf of a Shareholder holding only Management Equity.

  

	 	28.2.2	Clause 28.2.1 shall not apply to the extent that approval of a Reserved Matter in accordance with this Agreement would also constitute a variation of this Agreement. 

 

	28.3	Waiver 

 The failure to exercise or delay in exercising a right or remedy provided by
this Agreement or by law does not impair or constitute a waiver of the right or remedy or an impairment of or a waiver of any other rights or remedies. No single or partial exercise of any right or remedy provided by this Agreement or by law
prevents further exercise of the right or remedy or the exercise of another right or remedy. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -41- 

	28.4	Cumulative rights 

 The rights and remedies contained in this Agreement are cumulative
and not exclusive of any rights or remedies provided by law. 
  

	28.5	No Partnership 

 Nothing in this Agreement and no action taken by a party under this
Agreement shall be deemed to constitute a partnership between or involving any of the parties or constitute any party the agent of any other party for any purpose. 
  

	28.6	Severance 

  

	 	28.6.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision is
legal, valid and enforceable and gives effect to the commercial intention of the Shareholders. 

  

	 	28.6.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under clause 28.6.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable, be
deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under clause 28.6.1, not be affected. 

 

	28.7	Damages not an adequate remedy 

 Each party acknowledges and agrees that damages alone
would not be an adequate remedy for a breach of this Agreement and that each party shall be entitled to seek the remedies of injunction, specific performance and other relief for any threatened or actual breach of this Agreement under applicable
Law. 
  

	28.8	Further assurance 

 Each party agrees to take all such action or procure that all such
action is taken as is reasonable in order to implement the terms of this Agreement or any transaction, matter or thing contemplated by this Agreement. 
  

	29.	ASSIGNMENT 

  

	29.1	This Agreement shall be binding on and enure for the benefit of each party’s successors in title. Save in connection with a transfer made to a Shareholder Group Entity in accordance with clause 15.3 no party shall,
without the prior written consent of the other parties, assign, transfer, grant any security interest over or create any trust in respect of, or purport to assign, transfer, grant any security interest over or create any trust in respect of, any of
its rights or obligations under this Agreement. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -42- 

	30.	NOTICES 

  

	30.1	A notice or other communication under or in connection with this Agreement (a “Notice”) shall be: 

  

	 	30.1.1	in writing; 

  

	 	30.1.2	in the English language; and 

  

	 	30.1.3	delivered personally or sent by pre-paid recorded delivery, fax, email or courier using an internationally recognised courier company to the party due to receive the Notice to the address set out in clause 30.3.

 A party may change its notice details by giving not less than five Business Days written notice of the change to the other
parties. 
  

	30.2	Deemed delivery 

 Unless there is evidence that it was received earlier, a Notice is
deemed given if: 
  

	 	30.2.1	delivered personally or sent by courier, when left at the address referred to in clause 30.3; 

  

	 	30.2.2	sent by pre-paid recorded delivery, at 9.30 a.m. on the second Business Day after posting it; 

  

	 	30.2.3	sent by fax, when confirmation of its transmission has been recorded by the sender’s fax machine; and 

  

	 	30.2.4	sent by email, when the email is sent, provided that no notification is received of non delivery and a copy of the Notice is sent by another method referred to in this clause 30.2 within one Business Day of sending the
email. 

 Any Notice given outside Working Hours in the place to which it is addressed shall be deemed not to have been given
until the start of the next period of Working Hours in such place. 
  

	30.3	Addresses for notices 

 The addresses referred to in clause 30.1.3 are: 

 

									
	Name of party	  	Address	  	Fax No.	  	Email	  	Marked for the
attention of
					
	MDLZ	  	Three Parkway North, Deerfield, IL 60015, United States of America	  	-	  	[ * * * ]	  	[ * * * ]
					
	Maple Holdings	  	c/o Joh. A. Benckiser s.à.r.l.5 rue GoetheL-1637 Luxembourg	  	N/A	  	[ * * * ]	  	[ * * * ]

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -43- 

									
	Name of party	  	Address	  	Fax No.	  	Email	  	Marked for the
attention of
					
	The Company	  	33 Coffee Lane, Waterbury, Vermont 05676	  	N/A	  	CEO	  	CEO
					
	with a copy to:	  		  		  		  	
					
	Maple Holdings and MDLZ	  		  		  		  	

  

	31.	GOVERNING LAW 

 This Agreement and any non-contractual or other obligations arising out
of or in connection with it are governed by Delaware law. 
  

	32.	ARBITRATION 

  

	32.1	Any dispute, controversy or claim arising from or connected with this Agreement, including one regarding the existence, validity or termination of this Agreement or the consequences of its nullity or relating to any
non-contractual or other dispute arising from or connected with this Agreement shall be referred to and finally resolved by arbitration administered by The London Court of International Arbitration (“LCIA”) in accordance with the
LCIA Arbitration Rules then in effect (the “LCIA Rules”), except as modified herein. 

  

	32.2	The arbitral tribunal shall consist of three arbitrators. The claimant(s) shall nominate one arbitrator and the respondent(s) shall nominate one arbitrator, and the two arbitrators thus nominated, once appointed by the
London Court of International Arbitration (the “LCIA Court”), shall nominate a third arbitrator as chairman of the arbitral tribunal within fifteen days of the last of their appointments. In the event that the claimant(s) or the
respondent(s) fail(s) to nominate an arbitrator within the time limits specified by the LCIA Rules, or the party nominated arbitrators fail to agree the chairman of the arbitral tribunal within the time limits specified in the preceding sentence,
such arbitrator shall be appointed promptly by the LCIA Court. 

  

	32.3	The seat of the arbitration shall be New York, New York, all hearings shall (unless otherwise agreed in writing by the parties or determined by the tribunal) take place in New York, New York, and the language of the
arbitration shall be English. 

  

	32.4	 By agreeing to arbitration, the parties do not intend to deprive any court of its jurisdiction to issue a
pre-arbitral injunction, pre-arbitral attachment, or other preliminary relief in aid of arbitration. In any such action, each of the parties irrevocably and unconditionally (i) consents and submits to the jurisdiction and venue of the Courts of
the State of New York and the Federal Courts of the United States of America located within the Borough of Manhattan, New York City, New York (the “New York Courts”); (ii) waives, to the fullest extent it may effectively do so,
any objection, including any objection to the laying of venue or based on the grounds of 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -44- 

	 	
forum non conveniens or any right of objection to jurisdiction on account of its place of incorporation or domicile, which it may now or hereafter have to the bringing of any such action
or proceeding in any New York Court; and (iii) consents to service of process in the manner provided for Notices in clause 30 herein, or in any other manner permitted by applicable Law. Without prejudice to such provisional remedies as may be
available under the jurisdiction of a court, the arbitral tribunal shall have full authority to grant provisional remedies and to direct the parties to request that any court modify or vacate any temporary or preliminary relief issued by such court,
and to award damages for the failure of any party to respect the arbitral tribunal’s orders to that effect. 

  

	32.5	The award of the tribunal shall be final and binding upon the parties thereto, and judgment upon the award may be entered or enforced in any court of competent jurisdiction. 

 

	33.	JURISDICTION 

 Each of the parties irrevocably submits to the non-exclusive jurisdiction
of the New York Courts to support and assist the arbitration process under clause 32, including if necessary the grant of interlocutory relief pending the outcome of that process. 

 

	34.	COUNTERPARTS 

 This Agreement may be executed in any number of counterparts, each of
which when executed and delivered is an original and all of which together evidence the same agreement. This Agreement shall not come into effect until each party has executed at least one counterpart. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -45- 

 SCHEDULE 1 

RESERVED MATTERS 

General Corporate 
  

	1.	Amending: 

  

	1.1	the memorandum of association or the articles of association of the Company or the rights attaching to the shares in the capital of the Company, other than to the extent required in connection with matters specifically
approved or permitted under this schedule 1; and 

  

	1.2	in any material respect, the memorandum of association or the articles of association of any other Group Company or the rights attaching to the shares in the capital of any other Group Company other than to the extent
required in connection with matters specifically approved or permitted under this schedule 1. 

  

	2.	Passing any resolution to wind-up any Group Company or filing any petition for the winding-up of any Group Company or entering into or proposing any arrangement or composition with the creditors of any Group Company.

  

	3.	Applying for an administration order or appointing a receiver or administrator in respect of any Group Company. 

  

	4.	Applying for the admission to listing or trading on any stock exchange or market of any shares in the capital of any Group Company or any depository receipts representing shares in the capital of any Group Company other
than an IPO implemented following the process set out in clauses 15.6.1 to 15.6.8. 

  

	5.	[Intentionally left blank] 

  

	6.	[Intentionally left blank] 

  

	7.	Amending the terms of reference of any committee of the Board constituted pursuant to clause 3.6. 

  

	8.	Amending any Governance Policy (but in relation to any Governance Policy adopted after Closing, only to the extent such Governance Policy was proposed by the B Shareholder). 

Share Capital and Dividends 
  

	9.	Allotting, granting or issuing any shares in the capital of any Group Company or any options in respect of, securities convertible or exchangeable into, shares in the capital of any Group Company, other than (i) to
a Group Company which is wholly-owned (directly or indirectly) by the Company or (ii) up to [ * * * ] of the then issued and outstanding Shares in connection with any profit sharing, bonus or other incentive scheme of any nature for a director
or employee of any Group Company (“Management Equity”). 

  

	10.	 Altering the capital structure of any Group Company (including a reduction in the share capital of any Group
Company, the purchase or redemption of any share capital 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -46- 

	 	
by any Group Company or the consolidation, sub-division, conversion or cancellation of any share capital of any Group Company) other than as part of a solvent reorganization of the Group.

  

	11.	Any Group Company declaring or paying any dividend or declaring or making any other distribution or passing a resolution to retain or allocate profits other than (i) dividends paid or distributions made by a
wholly-owned Group Company (which, for this purpose only, includes Train Station Cafe, Inc. and Group Companies which are not wholly-owned solely by virtue of the presence of nominee shareholders holding shares for the benefit of a Group Company or
to satisfy requirements of applicable Law or (ii) in accordance with clause 12. 

  

	12.	[Intentionally left blank] 

  

	13.	Any transfer of shares in any Group Company other than the Company, other than (i) in connection with a disposal approved in accordance with paragraph 15, or (ii) a transfer to another Group Company which is
wholly-owned (directly or indirectly) by the Company. For the purpose of this paragraph 13, “transfer” shall mean each of the following: 

  

	13.1	selling, assigning, transferring or otherwise disposing of, or granting any option over, any share of any Group Company other than the Company or any legal or beneficial interest in any shares of any Group Company other
than the Company 

  

	13.2	creating any trust in respect of or conferring any interest in any shares of any Group Company other than the Company or any interest in any shares of any Group Company other than the Company; 

 

	13.3	directing (by way of renunciation or otherwise) that another person should, or assigning any right to, receive any share of any Group Company other than the Company or any interest in any share of any Group Company
other than the Company; and 

  

	13.4	entering into any agreement, arrangement or understanding in respect of the votes or the right to receive dividends or any other rights attached to any shares of any Group Company other than the Company.

 Corporate structure 
  

	14.	In any Financial Year, any Group Company acquiring (whether in a single transaction or series of transactions) or merging with, or agreeing to acquire or merge with any undertaking, company, business (or any material
part of any business) or any shares or securities in any person, in each case for an aggregate consideration in excess of [ * * * ]. 

  

	15.	Any Group Company disposing of (whether in a single transaction or series of transactions) any undertaking, company, business (or any material part of any business) or the closing down of any business operations, for a
disposition value in excess of [ * * * ]. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -47- 

	16.	Any Group Company entering into any material joint venture, partnership or profit sharing agreement (and, for this purpose, arrangements entered into in the ordinary course of business are not “material”).

 Business Activities 
  

	17.	Any material change to the nature of the Business. 

  

	18.	Any Group Company carrying on any business other than the Business except for activities, if any, being carried on immediately prior to Closing which do not constitute the Business as described in schedule 12.

  

	19.	Adopting the Strategic Plan, or amending or acting in a manner materially inconsistent with the adopted Strategic Plan. 

  

	20.	Incurring capital expenditure which is in aggregate in excess [ * * * ] in any Financial Year except as agreed in the context of the Strategic Plan; incurring capital expenditure with respect to the Cold Business which
is in aggregate in excess of [ * * * ] in any Financial Year; taking actions which are reasonably likely to result in the incurrence of losses with respect to the Cold Business which are in aggregate in excess of [ * * * ] in any Financial Year;

  

	21.	Any Group Company entering into, terminating or varying the terms of any transaction, agreement or arrangement (or waiving its rights thereunder) between such Group Company and a Shareholder or any of its Affiliates or
the shareholders of Acorn Holdings B.V. from time to time or their Affiliates or any of its or their respective directors, including any agreements entered into pursuant to clause 2.2.3. 

 

	22.	[Intentionally left blank] 

 Finance 

 

	23.	Any Group Company borrowing or raising money (including by way of the issue of public or non publically traded debt securities which are not convertible into equity) which would result in the Group’s aggregate
leverage ratio being higher than the Group’s aggregate leverage ratio immediately following Closing based on definitions of indebtedness and EBITDA as defined in the definitive credit documents entered into prior to Closing in connection with
the transaction contemplated by the Global Contribution Agreement other than any refinancing of any previously incurred Financial Debt on terms that are materially consistent with or better than the currently outstanding Financial Debt.

  

	24.	Any Group Company entering into a facility that contains any provision that may restrict the ability of the Company to pay distributions in accordance with this Agreement or amending an existing facility to include such
a provision other than (i) the entry into or amendment of the Closing Debt Documents and (ii) the entry into or amendment of a facility for the purpose of refinancing the debt issued under the Closing Debt Documents, provided in the case
of (i) and (ii) the restrictions are materially consistent with or better than those contained in the Closing Debt Documents. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -48- 

	25.	Any Group Company creating an Encumbrance over any of its assets or property or any shares or interest in any shares of any Group Company (other than liens arising in the ordinary course of business or charges arising
pursuant to retention of title clauses in the ordinary course of business or otherwise arising by operation of Law) except for the purpose of securing borrowings (or indebtedness in the nature of borrowings) from lenders (i) in the ordinary
course of business of amounts not exceeding [ * * * ] in aggregate and (ii) pursuant to any Financial Debt of the Group permitted pursuant to this Agreement. 

 

	26.	Any Group Company granting any credit or giving any guarantee or indemnity in respect of any other person’s obligations or indebtedness (other than another Group Company which is wholly-owned (directly or
indirectly) by the Company) other than (i) in the ordinary course of business and on arms-length terms or (ii) pursuant to the terms of any equity incentive plans to employees of a Group Company. 

Auditing and Reporting 
  

	27.	Appointing or removing the Auditors or the auditors of any other Group Company or altering any Group Company’s financial accounting period. 

 

	28.	Adopting any new accounting policies, except as required by applicable Law or US GAAP or to comply with the provisions of clause 2.3.2(d). 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -49- 

 SCHEDULE 2 

BOARD AUTHORITY MATTERS 
  

	1.	Acquiring or disposing of any undertaking, business, company or securities of a Group Company, or closing down any business operation with a value of less than [ * * * ]. 

 

	2.	Borrowing or raising Financial Debt which is in aggregate in excess of [ * * * ] in any Financial Year, except drawing down under an existing revolving credit facility. 

 

	3.	The approval of any Management Director taking a directorship with a company that is not a Group Company. 

  

	4.	Appointing or removing any executive committee member or regional general manager or any amendment to their employment contract. 

  

	5.	Appointing investment bankers. 

  

	6.	Adopting any Annual Contract and any material departure from the adopted Annual Contract. 

  

	7.	Adopting a budget for extraordinary expenses, including consultant engagements. 

  

	8.	Approving the annual accounts of the Company and the annual consolidated accounts of the Group. 

  

	9.	Entering into any material amendment, termination or waiver of any material contract or commitment of any Group Company other than in the ordinary course of business. 

 

	10.	Any matter requiring Board consideration in respect of which the audit, compensation or other committee has advised pursuant to its terms of reference. 

 

	11.	All material decisions relating to a material part of the workforce of any Group Company. 

  

	12.	Establishing or materially amending any profit sharing bonus or other incentive scheme of any nature for a director or employee of any Group Company. 

 

	13.	All decisions to be taken by the Board which may have major reputational implications for the Group and/or either Shareholder. 

  

	14.	The approval of any treasury and hedging policies including foreign currency exposure and the use of financial and commodity derivatives by any Group Company. 

 

	15.	Instituting, settling or compromising any legal, arbitration or other proceedings in excess of [ * * * ] (other than debt collection in the ordinary course of business). 

 

	16.	Amending the corporate or trading name of any Group Company. 

  

	17.	Granting a licence or right over the name of any Group Company or any Intellectual Property pertaining to the name of any Group Company, other than in the ordinary course of business. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -50- 

 SCHEDULE 3 

BOARD COMPOSITION AT CLOSING 
  

							
	A Directors	  	B Directors	  	Management Director	  	Board Nominee
				
	 1.      Bart Becht

(Chairman)
  

2.      Peter Harf

 
 3.      Olivier
Goudet
  

4.      Byron Trott

 
 5.      Alexandre
Van Damme
  

6.      Alejandro Santo Domingo

 
 7.      Anna-Lena
Kamenetzky
	  	 1.      Brian Gladden

 
 2.      Gerhard
Pleuhs
	  	Brian Kelley	  	None

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -51- 

 SCHEDULE 4 

COMMITTEES 
 PART A:
AUDIT COMMITTEE TERMS OF REFERENCE 
  

	1.	Composition and Meetings of the Audit Committee 

  

	1.1	The Audit Committee comprises not less than two Directors, including at least one A Director and at least one B Director. 

  

	1.2	The initial composition of the Audit Committee shall be Bart Becht, Byron Trott, Olivier Goudet, Alejandro Santo Domingo and up to 2 members identified by MDLZ prior to Closing. 

 

	1.3	The chairman of the Audit Committee shall be appointed by the B Shareholder. 

  

	1.4	The chairman will ensure that the Committee receives information and papers in a timely manner to enable full and proper consideration to be given to the issues. 

 

	1.5	The quorum for meetings of the Audit Committee is two of its members which must include one A Director and one B Director. 

  

	1.6	No one other than an Audit Committee member is entitled to attend meetings of the Audit Committee but others may attend by invitation. The Audit Committee may invite any officer, director, employee of or adviser to the
Group to attend for all or part of any meeting as and when appropriate and necessary. 

  

	1.7	The external auditor and CFO will be invited to attend meetings of the Audit Committee on a regular basis. 

  

	1.8	Meetings of the Audit Committee are to be held at least four times in each Financial Year at appropriate times in the financial reporting and audit cycle and otherwise as required. Any of the Committee members, the CFO,
head of internal audit (if appointed) or the Company’s external auditors may request a meeting of the Audit Committee if he considers it necessary. 

  

	1.9	At least 10 Business Days’ written notice of an Audit Committee meeting shall be given to each member of the Audit Committee and any other person required to attend. Supporting papers shall be sent to the Audit
Committee members and to other attendees as appropriate, at the same time. 

  

	2.	Authorisations 

 The Audit Committee is authorised by the Board to: 

 

	2.1	investigate any activity within its terms of reference; 

  

	2.2	obtain any information it requires from any employee of a Group Company and to call any employee to be questioned at a meeting of the Audit Committee as and when required (and all employees are directed to co-operate with any request made by the Audit Committee); 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -52- 

	2.3	make recommendations to the Board; 

  

	2.4	obtain, at the Company’s expense, such independent, legal, accounting or other professional advice on any matter it deems reasonably necessary; and 

 

	2.5	secure the attendance of other persons at its meetings if it considers this necessary. 

  

	3.	Duties of the Audit Committee 

 The duties of the Audit Committee are: 

External audit 
  

	3.1	in respect of the external audit: 

  

	 	3.1.1	to consider and make recommendations to the Board in relation to the appointment, reappointment and removal of the external auditors. If an auditor resigns, the Audit Committee shall investigate the issues leading to
this and decide whether any action is required; 

  

	 	3.1.2	to oversee the selection process for new auditors and ensure that all tendering firms have such access as is necessary to information and individuals during the duration of the tendering process; 

 

	 	3.1.3	to consider and approve the remuneration of the external auditors, including fees for both audit and non-audit services and that the level of fees are appropriate to enable an
effective and high quality audit to be conducted; 

  

	 	3.1.4	to approve the terms of engagement of the external auditors, including the engagement letter issued at the start of each audit and the scope of the audit and to discuss with the external auditors before the audit starts
the nature and scope of the audit. The scope shall include a review of all transactions between a Group Company and a Shareholder or any of its Affiliates or the Shareholders of Acorn Holdings B.V. from time to time or their Affiliates;

  

	 	3.1.5	to meet regularly with the external auditors, including once at the planning stage before the audit and once after the audit at the reporting stage. The Audit Committee shall meet the external auditors at least once in
each Financial Year, without management being present, to discuss its remit and any issues arising from the audit; 

  

	 	3.1.6	to review the findings of the audit with the external auditors. This shall include, but not be limited to, the following: 

  

	 	(a)	a discussion of any major issues which arose during the audit; 

  

	 	(b)	key accounting and audit judgements; 

  

	 	(c)	level of errors identified during the audit; and 

  

	 	(d)	the effectiveness of the audit process. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -53- 

	 	3.1.7	to keep under review the scope and results of the audit, the audit fee and its cost effectiveness, taking into consideration relevant professional and regulatory requirements; 

 

	 	3.1.8	to review: 

  

	 	(a)	any representation letters requested by the external auditors before they are signed by management; and 

  

	 	(b)	the external auditor’s management letter and response to the auditor’s findings and recommendations; 

  

	 	3.1.9	to develop and implement a policy on the supply of non-audit services by the external auditors to avoid any threat to auditor objectivity and independence, taking into account any
relevant ethical guidance on the matter, and to keep such policy under review; 

  

	 	3.1.10	to assess annually the external auditor’s independence and objectivity taking into account relevant professional and regulatory requirements and the relationship with the external auditors as a whole, including the
provision of any non-audit services; 

  

	 	3.1.11	to satisfy itself that there are no relationships (such as family, employment, investment, financial or business) between the external auditors and the Group (other than in the ordinary course of business) which could
adversely affect the auditor’s independence and objectivity; 

  

	 	3.1.12	to monitor the external auditor’s compliance with relevant ethical and professional guidance on the rotation of external audit partners, the level of fees paid by the Company compared to the overall fee income of
the firm, office and partner and other related requirements; 

  

	 	3.1.13	to assess annually the qualifications, expertise and resources of the external auditors and the effectiveness of the audit process which shall include a report from the external auditors on their own internal quality
procedures; 

  

	 	3.1.14	to evaluate the risks to the quality and effectiveness of the financial reporting process and to consider the need to include the risk of the withdrawal of their auditor from the market in that evaluation; and

  

	 	3.1.15	to discuss problems and reservations arising from audits and any matters the auditors may wish to discuss (in the absence of executive directors, where necessary); 

Financial statements 
  

	3.2	to review and monitor the integrity of the financial statements of the Company and the Group including the annual accounts and any other formal document or announcements relating to financial performance, reviewing
significant financial reporting issues and judgements which they contain; 

  

	3.3	the Audit Committee shall review and challenge where necessary: 

  

	 	3.3.1	the consistency of, and any changes to, significant accounting policies both on a year-on-year basis and across the Company and/or the
Group; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -54- 

	 	3.3.2	the methods used to account for significant or unusual transactions where different approaches are possible; 

  

	 	3.3.3	whether the Company and/or the Group has followed appropriate accounting standards and made appropriate estimates and judgements, taking into account the views of the external auditors; 

 

	 	3.3.4	the clarity and completeness of disclosure in the Company’s and other members of the Group’s financial reports and the context in which statements are made; and 

 

	 	3.3.5	where the Audit Committee is not satisfied with any aspect of the proposed financial reporting by the Company, to report its views to the Board. 

 

	3.4	to submit the documents referred to in paragraph 3.3 to the Board for its approval and to determine what information should be brought to the Board’s attention in connection with that submission;

 Internal controls and risk management systems 
  

	3.5	to keep under review the adequacy and effectiveness of the Group’s internal financial controls and internal control and risk management systems; 

Internal audit 
  

	3.6	where an internal audit function exists: 

  

	 	3.6.1	review and approve the remit of the internal audit function and ensure the function has the necessary resources and access to information to enable it to fulfil its mandate, and is equipped to perform in accordance with
appropriate professional standards for internal auditors; 

  

	 	3.6.2	to consider and make recommendations to the Board regarding the appointment and removal of the head of the internal audit function; 

  

	 	3.6.3	to review and assess the annual internal audit plan; 

  

	 	3.6.4	receive a report on the results of the internal auditor’s work on a periodic basis; 

  

	 	3.6.5	to review and monitor management’s responsiveness to the findings and recommendations of the internal auditor; 

  

	 	3.6.6	to meet the head of internal audit at least once in each Financial Year, without management being present, to discuss their remit and any issues arising from the internal audit reviews carried out and give the head of
the internal audit function a right of direct access to the Audit Committee; and 

  

	 	3.6.7	monitor and review the effectiveness of the company’s internal audit function, in the context of the Company’s overall risk management system; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -55- 

	3.7	where external auditors are being considered to undertake aspects of the internal audit function, to consider the effect this may have on the effectiveness of the Group’s overall arrangements for internal control
and investor perceptions; 

 Whistleblowing, Compliance and Fraud 

 

	3.8	to review the adequacy and security of the Group’s procedures by which employees and contractors may, in confidence, raise concerns about possible wrongdoing in matters of financial reporting or other matters. The
Audit Committee shall ensure that these arrangements allow proportionate and independent investigation of such matters and appropriate follow up action; 

  

	3.9	to review the Group’s procedures for detecting fraud; 

  

	3.10	to review the Group’s systems and controls for the prevention of bribery and receive reports on non-compliance; 

 

	3.11	to review the adequacy and effectiveness of the Group’s anti-money laundering systems and controls; and 

 

	3.12	to review regular reports from the Compliance Officer and keep under review the adequacy and effectiveness of the company’s compliance function. 

 

	4.	Other matters 

 The Audit Committee shall: 

 

	4.1	have access to sufficient resources reasonably required in order to carry out its duties; 

  

	4.2	give due consideration to laws and regulations and any other applicable rules as appropriate; 

  

	4.3	oversee any investigation of activities which are within its terms of reference; and 

  

	4.4	from time to time review its constitution and terms of reference to ensure it is operating at maximum effectiveness and recommend any changes it considers necessary to the Board for approval. 

 

	5.	Reporting 

 The Audit Committee chairman shall: 

 

	5.1	report formally to the Board on its proceedings after each meeting on all matters within its duties and responsibilities; 

  

	5.2	make such recommendations to the Board as it deems appropriate on any area within its remit where action or improvement is desirable; and 

 

	5.3	promptly circulate minutes of Audit Committee meetings to all members of the Audit Committee and, once agreed, to all members of the Board. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -56- 

 PART B: COMPENSATION COMMITTEE TERMS OF REFERENCE 

 

	1.	Composition and Meetings of the Compensation Committee 

  

	1.1	The Compensation Committee comprises not less than two Directors, including at least one A Director and at least one B Director. 

  

	1.2	The initial composition of the Compensation Committee shall be Bart Becht, Peter Harf, Alexandre Van Damme and up to 2 members identified by MDLZ prior to Closing. 

 

	1.3	The chairman of the Compensation Committee shall be appointed by the A Shareholder. 

  

	1.4	The chairman will ensure that the Committee receives information and papers in a timely manner to enable full and proper consideration to be given to the issues. 

 

	1.5	The quorum for meetings of the Compensation Committee is two of its members which must include one A Director and one B Director. 

  

	1.6	No one other than a Committee member is entitled to attend meetings of the Compensation Committee but others may attend by invitation. The Compensation Committee may invite any officer, director, employee of or adviser
to the Group to attend for all or part of any meeting as and when appropriate and necessary. 

  

	1.7	Meetings of the Compensation Committee are to be held at least twice in each Financial Year and at such other times as determined by the Compensation Committee. Any of the Committee members may request a meeting of the
Compensation Committee if he or she considers it necessary. 

  

	1.8	At least 10 Business Days’ written notice of a Compensation Committee meeting shall be given to each member of the Compensation Committee and any other person required to attend. Supporting papers shall be sent to
the Compensation Committee members and to other attendees as appropriate, at the same time. 

  

	1.9	No Committee member shall participate in any discussion or decision on their own compensation. 

  

	2.	Authorisations 

 The Compensation Committee is authorised by the Board to: 

 

	2.1	undertake any activity within its terms of reference; 

  

	2.2	make recommendations to the Board; 

  

	2.3	obtain information it requires (including, without limitation, information on the compensation of any employee) from any employee of a Group Company; 

 

	2.4	obtain, at the Company’s expense, such legal or other independent professional advice as it deems reasonably necessary to fulfil its responsibilities; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -57- 

	2.5	obtain, at the Company’s expense, but within any budgetary constraints imposed by the Board, compensation consultants, and to commission or purchase any relevant reports, surveys or information which it deems
necessary to help fulfil its duties; 

  

	2.6	obtain the advice and assistance of any of the Company’s executives provided their role in providing such advice and assistance is clearly separated from their role within the business; and 

 

	2.7	secure the attendance of any person with relevant experience and expertise at Committee meetings if it considers this appropriate. 

  

	3.	Duties of the Compensation Committee 

 The duties of the Compensation Committee are to consider plans and
make recommendations to the Board in respect of: 
  

	3.1	the leadership needs of the Group with a view to ensuring the continued ability of the Group to compete effectively in the marketplace; 

 

	3.2	the orderly succession of the Executive Team and other senior managers, so as to maintain an appropriate balance of skills and experience within the Group; 

 

	3.3	the compensation policy for the Executive Team and other senior managers, including pension rights and any compensation payments and their cost (taking into account all factors deemed necessary when determining the
compensation policy, the object of which shall be to ensure that the Executive Team and other senior managers are provided with appropriate, stretching incentives to encourage enhanced performance and are, in a fair and responsible manner, rewarded
for their contributions to the long-term success of the Group). No Director or member of the Executive Team and other senior managers shall be involved in any decisions as to their own compensation; 

 

	3.4	the ongoing appropriateness and relevance of the Group’s compensation policy, benefits policies and pension schemes; 

  

	3.5	the other provisions of the service agreements of the Executive Team and other senior managers (in particular the term, any notice period and compensation commitment on early termination); 

 

	3.6	the design and determination of targets for any performance-related pay schemes operated by the Group and the total annual payments made under such schemes; 

 

	3.7	the design, oversight and administration of any share incentive plans; 

  

	3.8	the policy for, and scope of, pension arrangements for each Management Director, members of the Executive Team and other senior managers; 

 

	3.9	contractual terms on termination to ensure that any payments made are fair to the individual and the Company, that failure is not rewarded and that the duty to mitigate loss is fully recognised; 

 

	3.10	pay and employment conditions across the Group especially when determining annual salary increases; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -58- 

	3.11	any major changes in employee benefits and compensation structures (including pension) throughout the Company or Group; and 

  

	3.12	any other matters as referred to the Compensation Committee by the Board. 

 The duties of the Compensation
Committee shall be limited to providing advice and recommendations to the Board in respect of matters referred to above and shall not include taking any decision to approve, proceed with or implement any such matters. 

 

	4.	Other matters 

 The Compensation Committee shall: 

 

	4.1	have access to sufficient resources reasonably required in order to carry out its duties; 

  

	4.2	give due consideration to laws, regulations and any other applicable rules, as appropriate; 

  

	4.3	oversee any investigation of activities which are within its terms of reference; and 

  

	4.4	from time to time review its constitution and terms of reference to ensure it is operating at maximum effectiveness and recommend any changes it considers necessary to the Board for approval. 

 

	5.	Reporting 

 The Compensation Committee’s chairman shall: 

 

	5.1	report formally to the Board on its proceedings after each meeting on all matters within its duties and responsibilities; 

  

	5.2	make recommendations to the Board as it deems appropriate on any area within its remit where action or improvement is desirable; and 

 

	5.3	promptly circulate minutes of the Compensation Committee meetings to all members of the Compensation Committee and, once agreed, to all members of the Board, unless a conflict of interest exists. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -59- 

 PART C: COMPLIANCE OFFICER DUTIES AND RESPONSIBILITIES 

The Compliance Officer is authorised by the Board to: 
  

	1.	monitor on behalf of the parties the Company’s compliance with its obligations under clause 2.3 and receive any anonymous reports of non-compliance by the Company; 

 

	2.	develop, initiate, maintain and revise policies and procedures for the general operation of the Governance Policies and related activities to prevent illegal, unethical or improper conduct; 

 

	3.	manage the day-to-day operation of the Governance Policies; 

  

	4.	periodically review the Governance Policies to ensure the continuing currency and relevance of the Governance Policies in providing guidance to management, employees and anyone working on the Group’s behalf and to
make recommendations to the Board if he considers any amendments to the Governance Policies to be necessary or desirable; 

  

	5.	respond to actual or alleged violations of Anti-Bribery Laws, and the Governance Policies by evaluating and/or recommending the initiation of investigative procedures; 

 

	6.	develop and oversee a system for uniform handling of violations of Anti-Bribery Laws and the Governance Policies; 

  

	7.	identify potential areas of compliance vulnerability and risk, develop/implement corrective action plans for resolution of issues and circumstances that could reasonably be expected to result in the violation of
Anti-Bribery Laws or the Governance Policies including providing general guidance on how to avoid or deal with similar situations in the future; 

  

	8.	as promptly as practicable following discovery thereof, notify the Board of (A) any violation or significant risk of violation of any Anti-Bribery Law relating to the Group and (B) any material violation of
the Governance Policies; and 

  

	9.	provide information to the Shareholders, upon request and at regular intervals, regarding compliance by the Company with Anti-Bribery Laws. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -60- 

 SCHEDULE 5 

[RESERVED] 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -61- 

 SCHEDULE 6 

ACCOUNTING AND INFORMATION RIGHTS 
 PART
A 
  

			
	 Item
	  	 Deadline

		
	Consolidated audited financial statements of the Group (and information required from JV to complete Mondelēz International, Inc.’s SEC-required disclosures summarized in Part B below)	  	By 20 February of the next Financial Year1
		
	Quarterly unaudited consolidated management accounts of the Group (P&L/BS/CF/Statement of Other Comprehensive Income (“OCI”) as per audited statements) and information required from the Company to complete
Mondelēz International, Inc.’s SEC-required disclosures summarized in Part B below	  	Within 17 calendar days of the end of each financial quarter2
		
	Monthly unaudited consolidated management accounts of the Group (P&L / BS/CF/OCI as per audited statements)	  	Within 30 calendar days of the end of each month3
		
	Annual accounts for each member of the Group (except where accounts or audits are not legally required)	  	Promptly after such accounts become available
		
	Statement of progress against current Annual Contract	  	Within 30 calendar days of end of each month
		
	High level statement of progress against current Strategic Plan	  	Bi annually
		
	Written details (including estimate of potential liability) of any proceedings threatened or commenced against the Group which, if successful, would likely have a material adverse effect on the Group	  	Within 60 calendar days of the end of each financial quarter

  

	1 	Income statement information and OCI and related investment accounts to be provided to Mondelēz International, Inc. on a preliminary basis by the 10 th Business
Day of the end of the Financial Year and confirmed or updated (as the case may be) as well as balance sheet information by 25 January 

	2 	Income statement information and OCI and related investment accounts to be provided to Mondelēz International, Inc. on a preliminary basis by the 10 th day of
the end of each financial quarter 

	3 	Income statement information and OCI to be provided to Mondelēz International, Inc. on a preliminary basis by the 10th day of the end of each month

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -62- 

 PART B 
  

			
	Mondelēz International, Inc. SEC Required Disclosures	  	 Following items need to be disclosed in the footnotes to the Mondelēz International, Inc. financial statements (10K/Q):

 
 •    Name of each
investment and percentage of ownership
  

•    Accounting policy of Mondelēz International, Inc.

 
 •    Difference, if any,
between the amount in which the investment is carried and the share of the net assets of the underlying equity (the percentage of net assets noted above)
  

•    Summarized information of the assets, liabilities and results of operations (or the
filing of separate financial statements) of the investments carried under the equity method
  

•    Material effects of possible changes that would affect the share of earnings

 
 •    Basis of
presentation

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -63- 

 SCHEDULE 7 

GOVERNANCE POLICIES 
  

	1.	Records and Information Compliance 

  

	2.	Antitrust & Compliance 

  

	3.	Policy against Money Laundering 

  

	4.	Custom & Trade Laws 

  

	5.	Interacting with Government Officials 

  

	6.	Policy against Corruption & Bribery 

  

	7.	External Business Gifts & Entertainment 

  

	8.	Charitable Contribution Standards 

  

	9.	Guidelines for Trade Associations 

  

	10.	Speaking Up & Investigations 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -64- 

 SCHEDULE 8 

DEED OF ADHERENCE 
 THIS DEED OF
ADHERENCE is made on [                    ] 
 BY
[                    ], a company incorporated in
[                    ] (registered number
[                    ]), whose registered office is at
[                    ] (the “New Shareholder”). 

INTRODUCTION: 
  

	(A)	The New Shareholder has agreed to acquire [all of the] [insert number] [A/B/ [                    ] ordinary]
shares] [and loanstock] / [insert number] of [specify class of shares] in the capital of [                    ] (the
“Company”) held [directly/indirectly] by [insert Shareholder]. 

  

	(B)	This Deed is made in compliance with clause 17.2.5 of the shareholders’ agreement dated
[                    ] between
[                    ] [and/,]
[                    ] and the Company (the “Shareholders’ Agreement”) under which it is a condition of the transaction
referred to in (A) above that the New Shareholder executes a deed of adherence to the Shareholders’ Agreement prior to such acquisition. 

  

	(C)	Words and expressions defined in the Shareholders’ Agreement shall have the same meaning when used in this Deed. 

IT IS AGREED as follows: 
  

	1.	The New Shareholder confirms that it has been given and has read a copy of the Shareholders’ Agreement and covenants with and for the benefit of each person named in the schedule to this Deed and for the benefit of
any other person who becomes a party to the Shareholders’ Agreement after the date of this Deed to adhere to and be bound by the provisions of the Shareholders’ Agreement, and to perform the obligations imposed by the Shareholders’
Agreement which are to be performed on or after the date of this Deed, in all respects as if the New Shareholder were an original party to the Shareholders’ Agreement and were named in it as a Shareholder with the intent that the New
Shareholder shall also be entitled to the benefit of the Shareholders’ Agreement as if it had been an original party to the Shareholders’ Agreement and was named in it as a Shareholder. 

 

	2.	[The definition of Shareholder Group Entity in relation to the New Shareholder for the purpose of clause 15.3 is
[                    ]4.] 

 

	3.	The details of the New Shareholder for the purposes of clause 30 of the Shareholders’ Agreement is set out below: 

Address: [                    ] 

Fax number: [                    ] 

Marked for the attention of:
[                    ] 
  

	4 	If New Shareholder is not a Maple Holdings or MDLZ group entity 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -65- 

	4.	The terms of clauses [31, 32 and 33] shall apply to this Deed as if incorporated in full herein. 

[NB. Deed of Adherence to be signed by all Shareholders] 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -66- 

 SCHEDULE 9 

AGREED FORM DOCUMENTS 
  

	1.	Governance Policies 

  

	2.	Articles 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -67- 

 SCHEDULE 10 

TRANSFER VALUE 
  

	1.	Following delivery of a Default Notice, each of the Defaulting and Non-defaulting Shareholder shall: 

  

	 	(a)	engage and instruct one internationally recognized investment banking firm (each an “Appraiser”) to assist it in satisfying its obligations hereunder; 

 

	 	(b)	permit the Appraisers to consult with one another in advance of the submission of the Appraisals (defined below) in order to share their views on any matters they deem relevant to the submission of the Appraisals; and

  

	 	(c)	simultaneously submit to the other on the date which is 30 Business Days’ of the date of the Default Notice (unless some other date is mutually agreed) a proposed equity value for the Put or Call Shares (as the
case may be) based on a Public Market Valuation of the Company prepared by, or with the assistance of, the Appraiser appointed by it (an “Appraisal”). In determining the price for the Put or Call Shares (as the case may be) the
Public Market Valuation shall be allocated across all the Shares on a pro rata basis. The Appraisal shall include appropriate supporting information describing the methods by which the Public Market Valuation was determined. 

 

	2.	If the higher of the Appraisals is equal to or less than [ * * * ] of the lower of the Appraisals, the Transfer Value will be the average of the two Appraisals. 

 

	3.	If the higher of the Appraisals is more than [ * * * ] of the lower of the two Appraisals, the Defaulting Shareholder and Non-defaulting Shareholder shall, within 60 days of the date of the Default Notice, jointly
select a third internationally recognized investment banking firm (the “Independent Appraiser”). 

  

	4.	The Independent Appraiser shall: 

  

	 	(a)	not be affiliated with either the Defaulting or the Non-defaulting Shareholder; 

  

	 	(b)	unless the Defaulting Shareholder and the Non-defaulting Shareholder agree otherwise, not have been engaged in the preceding 12 months to perform material financial advisory services for either Shareholder or its
Affiliates; and 

  

	 	(c)	otherwise not reasonably be expected to be unable to deliver impartial advice with respect to the Appraisal to the Shareholders. 

  

	5.	The Independent Appraiser shall be given the Appraisals and shall, within 45 days of his appointment, notify each of the Defaulting and the Non-defaulting Shareholders in writing which Appraisal such firm considers to
most closely approximate the actual equity value of the Put or Call Shares (as the case may be) on the basis of the actual Public Market Valuation of the Company (the “Final Appraisal”). 

 

	6.	If paragraph 5 applies, the Final Appraisal shall be the Transfer Value. 

  

	7.	 The Company shall provide, and each Shareholder shall procure that, each of the Appraisers, and the Independent
Appraiser (if any) has such access to the accounting 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -68- 

	 	
records and other relevant information and materials relating to the Group and access to the Group’s management as such Appraiser or the Independent Appraiser may reasonably request for the
purposes of determining the Public Market Valuation of the Company and the equity value of the Put or Call Shares (as the case may be) in accordance with this schedule 10. Any information provided by the Company to one Appraiser in response to a
request or otherwise shall be provided to the other Appraiser at the same time and any management or other presentations shall be made jointly to both Appraisers. 

 

	8.	Each of the Defaulting Shareholder and the Non-defaulting Shareholder shall bear the costs of the Appraiser appointed by it and the Company shall bear the costs of the Independent Appraiser. 

 

	9.	For the purposes of this schedule, “Public Market Valuation” means: a public market valuation of the Company based on customary valuation methodologies: 

 

	 	(i)	made with reference to a group of publicly traded companies in the consumer packaged goods sector that are financially and operationally comparable to, and having size, capitalisation, business and geographic mix, other
business and growth and margin characteristics (and any other characteristics deemed relevant in the professional opinion of the Appraiser) similar to, the Company; 

 

	 	(ii)	taking into consideration the recent financial performance, condition and results of operations of the Company as well as the Company’s financial projections and operating assumptions contained in the prevailing
Strategic Plan and Annual Contract; 

  

	 	(iii)	not including any discounts to such valuation due to the illiquid nature of the Shares or, prior to an Initial IPO, any discount relating to the fact that the Company is not a public company; 

 

	 	(iv)	based on (A) the valuation of the Group taken as a whole, (B) an assumption that the Company will remain independent and have the continued ownership of its subsidiaries and (C) an assumption that any
commercial contracts between the Shareholders and the Company and their respective Affiliates in existence at that time shall remain in full force and effect and continue in accordance with their terms; and 

 

	 	(v)	taking into account whether or not any items are non-recurring. 

  

	10.	Notwithstanding anything contained herein to the contrary, following an Initial IPO, none of the procedures or provisions set forth in clauses 1 to 9 of this schedule 10 shall be applicable and the “Transfer
Value” will be the volume weighted average price of the Company’s listed Shares for the 30 trading days ended 10 trading days prior to the earlier of (i) the date on which a public announcement was made of a matter constituting an
Exit Event and (ii) the date on which the Non-defaulting Shareholder became aware of the occurrence of an Exit Event. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 -69- 

 SCHEDULE 11 

STRATEGIC PLAN AND ANNUAL CONTRACT 
 The
provisions set forth below set forth the parties’ understanding with respect to the preparation and content of the Strategic Plan and the Annual Contract. The Shareholders have formed the Company and combined their respective Coffee Businesses
with the following common goals and aspirations which are expected to guide the Company’s long-term strategy, unless the parties agree otherwise in accordance with this Agreement: 

 

	 	•	 	To become a global challenger in the coffee industry via organic and acquisitive growth. 

  

	 	•	 	To become a ‘blue chip’ fast moving consumer goods company with a long-term goal to have a flexible, efficient capital structure consistent with an investment grade company in the absence of acquisitions.

  

	 	•	 	To be best in class in terms of cost and working capital management. 

  

	 	•	 	To invest for long-term growth of the Company. 

  

	 	•	 	To maximize Shareholder value and returns. 

  

	1.	Preparation of Strategic Plan 

  

	 	1.1.	The first full Strategic Plan will be presented to the Board for approval prior to 31 December 2016. Thereafter, the Company shall adopt a Strategic Plan annually with respect to the three Financial Years
commencing the next Financial Year. The Strategic Plan will address the high level strategic priorities for the Company over that period, and will include the items listed below under Strategic Plan. The Strategic Plan, as approved, is intended to
represent the Board’s ratification of management’s proposed key strategic priorities for the Company over the underlying Strategic Plan period. 

  

	 	1.2.	The first full Strategic Plan will be presented to the Board for approval prior to 31 December 2016.The Executive Team shall prepare a draft of the Strategic Plan for the Strategic Plan period commencing as
of the following year and present it to the Board for consideration by no later than [ * * * ] in each Financial Year. The Board shall consider and, if thought fit, approve the draft Strategic Plan as a Reserved Matter by the end of April.

  

	2.	Preparation of Annual Contract 

  

	 	2.1.	The Annual Contract will be presented to the Board for approval at least annually in accordance with the Company’s then prevailing budgeting schedule. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - 70 - 

	3.	Interplay Between Strategic Plan and Annual Contract 

  

	 	3.1.	As detailed in the table below, the Strategic Plan developed by management and approved by the Board is intended to outline the long term vision and plan for the Business over the Strategic Plan period. The
Annual Contract is management’s commitment to deliver against specified targets on an annual basis, taking into consideration the trajectory established by the underlying Strategic Plan and adjusted for the then current business parameters /
drivers on an annual timeframe. 

  

	 	3.2.	The Shareholders acknowledge and agree that the projections included in the Strategic Plan are a key element of the Board’s governance and oversight of management and its vision for the Company. However,
while management should have regard to the projections (and the other elements of the Strategic Plan) in formulating an Annual Contract, it is acknowledged that the primary purpose of the projections in the Strategic Plan is to help define and
determine the Company’s strategic direction over the next 3 years as opposed to directing how the overall long term plan should be translated by management into specific short term targets in an Annual Contract. The Shareholders recognize that
actual results achieved or actions taken may differ from what is implied by such projections. 

  

	 	3.3.	The Shareholders acknowledge and agree that deviations from the Strategic Plan and/or Annual Contract in any underlying Strategic Plan / Annual Contract planning period may be necessary or desirable to adjust for
unforeseen events, including but not limited to in reaction to competitive changes, commodity price volatility or changes in the economic climate. To this extent, it is acknowledged that actual results achieved or actions taken by management in any
Annual Contract period to address those unforeseen events may be inconsistent with the prevailing Strategic Plan and that such inconsistencies in and of themselves shall not be considered deviations from the Strategic Plan requiring approval by MDLZ
as a Reserved Matter. 

  

	4.	Status Quo 

  

	 	4.1.	If in any Financial Year a draft Strategic Plan is not approved, the Group shall be managed in a way that is consistent with the long term strategy of the Company as manifested in the prevailing Strategic Plan
with appropriate adjustments for changes in the competitive or economic environment. 

  

	 	4.2.	If in any Financial Year a draft Annual Contract is not approved, the Group shall be managed in a manner consistent with the prevailing Strategic Plan. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - 71 - 

 Purposes and Contents of Annual Contact and Strategic Plan 

 

			
	 Strategic Plan
	  	 Annual Contract

	 Purpose and Process
  

•       Long-term plan for the Business

 

•       Identifies key strategic issues and opportunities to address

 

•       Defines vision for the business, including priorities with respect to
geographic portfolio, product segments, branding, innovation, growth/margin ambition
  

•       Makes major decisions that drive the three-year business plan,
beginning with the subsequent financial year
  
 Contents

 

•       Situation Assessment

 
 •    Market share
performance vs. competitors
  

•    Key consumer trends

 
 •    Commodity price
projections and hedging strategy
  

•    Synthesis of issues and opportunities

 

•       Strategic Priorities for Company and all Regions

 
 •    Where to play:
priority markets and product segments
  

•    How to win: priorities and decisions regarding required actions/investments

 
 •    M&A
priorities
  

•       Financial Plan

 
 •    Three year
projected income statement, balance sheet, cash flow statement for the total entity by year
  

•    Year 3 p&l by key reporting entity (region), with comparison to current period
p&l
  

•       Financial Policy

 
 •    Decisions regarding
uses of free cash flow, including capital expenditures, capital structure/ debt refinancing, dividend policy, acquisitions
	  	 Purpose and Process
  

•       Annual operational plan for the Business

 
 Contents
  

•       Planned Full Income Statement, Balance Sheet, cash flow statements for
total entity including capital structure, debt portion, dividend, CAPEX, OWC Performance, split in volume, price, mix and market growth assumption
  

•       Budget phasing total entity per month for full income statement.

 

•       Performance split per segment up to contribution margin after A&P,
including volume, price, mix.
  

•       For all regions, income statement up to EBITDA, split per segment up
to contribution margin after A&P, CAPEX and OWC performance, including volume, price, mix.
  

•       Commodity hedging and currency assumptions.

 

•       Total marketing plans, including new product launches, product pricing
and brand positioning/activation plans.
  

•       Full detail overview of cost saving initiatives and restructuring
activities.
  

•       R&D overview of innovations pipeline and status.

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 

  
 - 72 - 

 SCHEDULE 12 

NON-BUSINESS ACTIVITIES 
 1. Development,
marketing and sale of [ * * * ] system for [ * * * ] for at home and away from home use currently being developed under a joint development agreement with [ * * * ] relating to [ * * * ] for use with [ * * * ] and others’ [ * * * ]. 

2. Development, marketing and sale of [ * * * ] system for [ * * * ] for at home and away from home use currently in development in the [ * * * ] space to
create an in-home system that will brew/mix water and [ * * * ]. 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 73 - 

 SCHEDULE 13 

AMENDMENTS FOLLOWING STEP DOWN RIGHTS 
  

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

			
	Less than [ * * * ] but more than (or equal to) [ * * * ]	  	 •       Board Composition
	  	 •       Clause 3.2.3 shall be deleted in its entirety and
replaced with the following:
  
 “The B Shareholder shall be entitled to appoint one
non-executive B Director to the Board and to remove the B Director appointed by it from time to time.”
  

•       Clause 4.4. shall be deleted in its entirety and replaced with the
following:
  
 “Subject to clause 4.5, on any vote on a resolution of the Directors,
each Director will have one vote. Subject to the specific requirements in clause 6 relating to Reserved Matters (a) resolutions of the Directors shall be decided by simple majority vote, calculated in accordance with the preceding sentence and (b)
if a vote of the Directors is tied, the Chairman (or the Director acting as chairman at the relevant meeting in accordance with clause 3.4.4) will have a casting vote.”

			
		  	 •       Appointment of Executive Team
	  	 •       Clause 5.1.2 shall be deleted in its entirety and
replaced with the following
  
 “The appointment or removal of the Executive Team
shall be determined by the Board. The Board will cooperate to create a shortlist of candidates taking into account recommendations from both Shareholders, and the Board will appoint candidates from that
list.”

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 74 - 

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

			
		  	 •       Reserved Matters
	  	 •       Paragraph 1 of schedule 1 shall be deleted in its
entirety and replaced with the following words:
  
 “Amending:

 
 1.1 the memorandum of association or the articles of association of the Company or the
rights attaching to the shares in the capital of the Company, other than to the extent required in connection with matters specifically approved or permitted under this schedule 1 and only to the extent that such amendments would adversely impact
the B Shareholder; and
  
 1.2 in any material respect, the memorandum of association or
the articles of association of any other Group Company or the rights attaching to the shares in the capital of any other Group Company other than to the extent required in connection with matters specifically approved or permitted under this
schedule 1 and only to the extent that such amendments would adversely impact the B Shareholder.
  

•       Each of paragraphs 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 22, 23, 24, 25, 26, 27 and 28 of schedule 1 shall be deleted in their entirety and replaced with the words “[intentionally blank]”
  

•       The last sentence of clause 15.4.4 shall be deleted in its
entirety.
  

•       The definition of “Initial IPO” shall be deleted in its
entirety and replaced with:
  
 ““Initial IPO” means completion of
the first to occur of (i) an IPO of Shares held by a Shareholder following an IPO Process and (ii) and IPO of New Shares in the Company;”

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 75 - 

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

			
		  	 •       Reporting to Shareholders
	  	 •       Clause 10.2 shall be deleted in its entirety and
replaced with the following:
  
 “The Company shall supply each Shareholder with all
information, and within such timeframes as may reasonably be required by it in order to comply with applicable Laws or to meet its or its Affiliates’ respective audit requirements.”

			
	Less than [ * * * ]	  	 •       Board Composition
	  	 •       Definition of “B Director” in schedule 14
shall be deleted in its entirety.
  

•       Definition of “Directors” in schedule 14 shall be deleted in
its entirety and replaced with the following:
  
 “Director” means an A
Director or a Management Director, as the case may require, and “Directors” shall be construed accordingly.”
  

•       Clause 3.2.3 shall be deleted in its entirety and replaced with the
words “[intentionally blank]”.
  

•       Clause 3.3.1 shall be deleted in its entirety and replaced with the
following:
  
 “Any appointment or removal of an A Director by the A Shareholder
shall be made by the A Shareholder giving written notice to the Company. The appointment or removal shall, to the extent permitted by Law, take effect immediately upon receipt of the notice by the Company or such later date specified by the
A Shareholder in the notice.
  

•       Clause 3.3.2 shall be deleted in its entirety and replaced with the
following:
  
 “If an A Director dies, resigns, is removed or retires, the
A Shareholder may appoint another Director in accordance with this clause 3.”

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 76 - 

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

			
		  		  	 •       Clause 4.3.1 shall be deleted in its entirety and
replaced with the following:
  
 “No business shall be transacted at any meeting of
the Board unless a quorum is present at the time when the meeting proceeds to business and remains present during the transaction of such business. Subject to clause 4.4, the quorum for transacting business at any Board meeting shall be at least 2 A
Directors. A Director shall be regarded as present for the purposes of a quorum if represented by an attorney appointed in accordance with clause 4.6.”
  

•       Clause 4.4 shall be deleted in its entirety and replaced with the
following:
  
 “Subject to clause 4.5, on any vote on a resolution of the Directors
each A Director and Management Director will have one vote. Resolutions of the Directors shall be decided by simple majority vote, calculated in accordance with the preceding sentence and if a vote of the Directors is tied, the Chairman (or the
Director acting as chairman at the relevant meeting in accordance with clause 3.4.4) will have a casting vote.”
  

•       Paragraph 1.1 of part A of schedule 4 shall be deleted in its entirety
and replaced with the following:
  
 “The Audit Committee comprises not less than two
Directors, including at least one A Director.”

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 77 - 

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

			
		  		  	 •       Paragraph 1.5 of part A of schedule 4 shall be
deleted in its entirety and replaced with the following:
  
 “The quorum for meetings
of the Audit Committee is two of its members which must include one A Director.”
  

•       Paragraph 1.1 of part B of schedule 4 shall be deleted in its entirety
and replaced with the following:
  
 “The Compensation Committee comprises not less
than two Directors, including at least one A Director.”
  

•       Paragraph 1.5 of part A of schedule 4 shall be deleted in its entirety
and replaced with the following:
  
 “The quorum for meetings of the Compensation
Committee is two of its members which must include one A Director.”

			
		  	 •       Appointment of Executive Team
	  	 •       Clause 5.1.2 shall be deleted in its entirety and
replaced with the following:
  
 “The appointment or removal of the Executive Team
shall be determined by the Board.”

			
		  	 •       Reserved Matters
	  	 •       Clause 2.2.1 shall be deleted in its entirety and
replaced with the following;
  
 “Each Shareholder and the Company agrees that the
business of the Group shall be confined to the Business, unless a change in the Business is approved by the Board.”
  

•       Clauses 6.1, 6.2 and 6.3 shall be deleted in their entirety and
replaced with the words “[intentionally blank]”.
  

•       Clause 6.5 shall be deleted in its entirety and replaced with the
following:
  
 “In determining whether a matter is a Board Authority Matter,
a

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 78 - 

					
	 Percentage ownership
	  	 Item
	  	 Amendments to Shareholders’ Agreement

		  		  	 series of related transactions shall be construed as a single transaction, and any amounts involved in the related transactions shall be
aggregated.”
  

•       The last sentence of clause 13 shall be deleted in its entirety.

 

•       The last sentence of clause 15.4.4 shall be deleted in its
entirety.
  

•       Schedule 1 shall be deleted in its entirety and replaced with the
words “[intentionally blank]”.
  

•       Paragraph 1.2 of schedule 11 shall be deleted in its entirety and
replaced with the following:
  
 “The Executive Team shall prepare a draft of the
Strategic Plan for the Strategic Plan period commencing as of the following year and present it to the Board for consideration by no later than 1 April in each Financial Year. The Board shall consider and, if thought fit, approve the draft
Strategic Plan by the end of April.”

			
		  	 •       Reporting to Shareholders
	  	 •       Clause 10.2 shall be deleted in its entirety and
replaced with the following:
  
 “The Company shall supply each Shareholder with all
information, and within such timeframes, as may reasonably be required by it in order to comply with applicable Laws or to meet its or its Affiliates’ respective audit requirements.”

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 79 - 

 SCHEDULE 14 

INTERPRETATION 
  

	1.	INTERPRETATION 

  

	1.1	In this Agreement: 

 “[ * * * ] anniversary” has the meaning set out in
clause 16.2.2; 
 “A Director” means a non-executive director of the Company appointed by the A Shareholder in
accordance with clause 3.3.1; 
 “A Shareholder” means Maple Holdings and any Shareholder Group Entity to
which Shares are transferred in accordance with clause 15.3;  
 “A Shares” means the A ordinary shares
in the capital of the Company; 
 “Acceptance Period” has the meaning set out in clause 15.5.3; 

“Acorn/JAB Change of Control” has the meaning set out in clause 16.7; 

“Acquiring Shareholder” has the meaning set out in clause 14.4; 

“Affiliate” means, in relation to a person, any parent, subsidiary or any other subsidiaries of any such parent and any
other person which Controls, is Controlled by or is under common Control with such person, but excluding any Group Company in the case where such person is a Shareholder; 

“Agent” means, with respect to an entity, any director, officer, employee or other representative of such entity; any
person for whose acts such entity may be vicariously liable; and any other person that acts for or on behalf of, or provides services for or on behalf of, such entity, in each case, while acting in his capacity as such; 

“Annual Contract” means the annual contract from time to time for the Group prepared and approved in accordance with
schedule 11; 
 “Anti-Bribery Laws” means, to the extent applicable to a Group Company, any of its Agents, or
any Shareholder (as applicable) from time to time, the US Foreign Corrupt Practices Act 1977, as amended, any rules and regulations thereunder, the Bribery Act 2010, any rules and regulations thereunder, any similar laws or regulations in
any jurisdiction (including any other anti-corruption or anti-bribery law or regulation applicable to a company whose shares are listed on a stock exchange in the United States of America, or any other such law or regulation of the United States of
America that has extraterritorial reach), and any other national and international laws enacted to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions; 

“Appraisal” has the meaning set out in paragraph 1(c) of schedule 10; 

“Appraiser” has the meaning set out in paragraph 1(a) of schedule 10; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 80 - 

 “Articles” means the certificate of incorporation and bylaws of the
Company from time to time, initially being that in the agreed form; 
 “Audit Committee” means the audit
committee of the Board;  
 “Auditors” means the auditors of the Company from time to time; 

“B Director” means a non-executive director of the Company appointed by the B Shareholder in accordance with
clause 3.3.1;  
 “B Shareholder” means MDLZ and any Shareholder Group Entity to which Shares are
transferred in accordance with clause 15.3;  
 “B Shares” means the B ordinary shares of in the capital
of the Company; 
 “Board” means the board of directors of the Company from time to time; 

“Board Authority Matters” has the meaning set out in clause 6.4; 

“Board Nominee” has the meaning set out in clause 3.2.5; 

“Business” has the meaning set out in clause 2.1.1; 

“Business Day” means any day (other than a Saturday or Sunday) when banks in Amsterdam and New York City are open for
the transaction of normal business; 
 “Call Shares” has the meaning set out in clause 16.2.1; 

“Call Notice” has the meaning set out in clause 16.2.1; 

“CEO” means the chief executive officer of the Group from time to time; 

“CFO” means the chief financial officer of the Group from time to time; 

“Chairman” has the meaning set out in clause 3.4.1; 

“Chocolate Beverages” means beverages which contain chocolate and/or cocoa as the main and/or predominant ingredient and/or
flavour; 
 “Closing” means the date of this Agreement; 

“Closing Debt Documents” the definitive credit documents entered into in connection with the Merger; 

“Coffee” has the meaning set out in clause 2.1.1(b)(i); 

“Coffee Beverages” has the meaning set out in clause 2.1.1(b)(i); 

“Coffee Products” has the meaning set out in clause 2.1.1(b)(i); 

“Coffee Shop” means a branded retail outlet the primary business of which is the sale of brewed Coffee Beverages and
Tea Beverages for immediate consumption; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 81 - 

 “Cold Business” means any business of the Group relating to cold or
ambient beverages (other than Coffee Beverages and Tea Beverages) dispensed through an on-demand brewing system, including the KOLD beverage system and products that are used in combination with it; 

“Compensation Committee” means the compensation committee of the Board;  

“Competing Business Portion” has the meaning set out in clause 14.3.1; 

“Competitor Event” has the meaning set out in clause 16.7; 

“Compliance Officer” has the meaning set out in clause 5.4.1; 

“Confidential Information” has the meaning set out in clause 22.1; 

“Consideration Period” has the meaning set out in clause 15.6.3; 

“Control” means the power of a person (or persons acting in concert) to secure that the affairs of another are
conducted directly or indirectly in accordance with the wishes of that person (or persons acting in concert) including by means of: 
  

	 	(a)	in the case of a company, being the beneficial owner of more than 50% of the issued share capital of or of the voting rights in that company, or having the right to appoint or remove a majority of the directors or
otherwise control the votes at board meetings of that company by virtue of any powers conferred by the articles of association, shareholders’ agreement or any other document regulating the affairs of that company; or 

 

	 	(b)	in the case of a partnership, being the beneficial owner of more than 50% of the capital of that partnership, or having the right to control the composition of or the votes of the majority of the management of that
partnership by virtue of any powers conferred by the partnership agreement or any other document regulating the affairs of that partnership; 

and “Controlled” shall be construed accordingly. For these purposes, “persons acting in concert”, in
relation to a person, are persons which actively co-operate, pursuant to an agreement or understanding (whether formal or informal) with a view to obtaining, maintaining or consolidating Control of that person; 

“Deadlock” has the meaning set out in clause 7.1.1; 

“Deadlock Matter” has the meaning set out in clause 7.1.1; 

“Deadlock Notice” has the meaning set out in clause 7.1.1; 

“Deadlock Resolution Period” has the meaning set out in clause 7.2.2; 

“Deed of Adherence” means a deed substantially in the form set out in schedule 8;  

“Default Notice” has the meaning set out in clause 16.3; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 82 - 

 “Deferral Notice” has the meaning set out in clause 16.6.2. 

“Defaulting Shareholder” has the meaning set out in clause 16.7; 

“Director” means a director of the Company appointed in accordance with clause 3.2; 

“Dividend Policy” has the meaning set out in clause 12.1; 

“Encumbrance” means any mortgage, charge, pledge, lien, option, restriction, right of first refusal, right of
pre-emption, third party right (for the purposes of paragraph 25 of schedule 1 only, granting security) or interest or other encumbrance (for the purposes of paragraph 25 of schedule 1 only, granting security) or security interest of any
kind, or another type of agreement or arrangement having similar effect including anything analogous to any of the foregoing under the laws of any jurisdiction; 

“Escalation Representatives” has the meaning set out in clause 7.2; 

“Excess Applicable Dividend Amount” means the difference between (i) $100,000,000 minus (ii) the product of
(x) the principal amount of the Loan then outstanding multiplied by (y) 0.055. 
 “Exchange Agreement” has the
meaning set forth in the Recitals. 
 “Executive Team” means the CEO, the CFO and all direct reports of the CEO
including legal;  
 “Exit Event” has the meaning set out in clause 16.7; 

“Final Appraisal” has the meaning set out in paragraph 5 of schedule 10; 

“Financial Debt” means all borrowings and other indebtedness by way of overdraft, acceptance credit or similar facilities,
loan stocks, bonds, debentures, notes, debt, supplier/customer factoring, inventory, financing, finance leases or sale and lease back arrangements or any other arrangements the purpose of which is to borrow money, together with forex, interest rate
or other swaps, hedging obligations, bills of exchange, recourse obligations on factored debts and obligations under other derivative instruments, in each case with the exception of (i) any debt which is owed by a Group Company (other than the
Company) to the Company or to another Group Company and (ii) ordinary trade credit; 
 “Financial Year” means,
in relation to the Company, a financial accounting period of 12 months starting on 1 October and ending on 30 September but, in the first year in which the Company is formed, means the period starting on the day the Company is formed
and ending on September 30, unless the Board determines to change the financial year to end on 31 December, in which case, such accounting period shall start 1 January (except is such change is made in the first year in which the
Company is formed, in which case it shall start on the day the Company is formed) and end on 31 December; 

“Government” or “Government Entity” means any agency, instrumentality, subdivision or other body of
any federal, regional, or municipal government, any  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 83 - 

 
commercial or similar entities that the government controls or owns (whether partially or completely), including any state-owned and state-operated companies or enterprises, any international
organizations such as the United Nations or the World Bank, and any political party; 
 “Government Official” means
(i) an employee, officer or representative of, or any person otherwise acting in an official capacity for or on behalf of a Government Entity; (ii) a legislative, administrative, or judicial official, regardless of whether elected or
appointed; (iii) an officer of or individual who holds a position in a political party; (iv) a candidate for political office; (v) an individual who holds any other official, ceremonial, or other appointed or inherited position with a
government or any of its agencies; or (vi) an officer or employee of a supra-national organization (e.g., World Bank, United Nations, International Monetary Fund, OECD); 

“Governance Policies” means the governance policies in the agreed form listed in schedule 7 and such other policies as
a Shareholder considers appropriate, necessary or desirable from time to time for the purpose of compliance by the Company or such Shareholder with applicable Law; 

“Group” means the Company and its subsidiaries from time to time and “Group Company” shall be
construed accordingly; 
 “Independent Appraiser” has the meaning set out in paragraph 3 of schedule 10;

 “Initial IPO” means completion of the first to occur of (i) an IPO of Shares held by a Shareholder
following an IPO Process and (ii) an IPO of New Shares in the Company which had received approval as a Reserved Matter; 

“Initial Process” has the meaning set out in clause 15.4.3; 

“Insolvency Event” means, in relation to a specified person, any of the following events: 

 

	 	(a)	an encumbrancer taking possession of, or a trustee being appointed in respect of, all or any material part of the business or assets of the person, or any mortgage or charge, howsoever created or arising, over any of
its assets being enforced; 

  

	 	(b)	the person having a receiver, administrative receiver, administrator, compulsory manager, trustee, liquidator or other similar officer over the whole or any material part of its assets or undertaking appointed;

  

	 	(c)	the person being unable or admitting inability to pay its debts as they fall due or having any voluntary arrangement proposed in relation to it or entering into any scheme of arrangement relating to any insolvency
(other than for the purpose of reconstruction or amalgamation upon terms and within such period as may previously have been approved in writing by the Non-Defaulting Shareholder); 

 

	 	(d)	 a petition being presented or any corporate action, legal proceedings or other step being taken for the purpose
of winding up the person which is not 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 84 - 

	 	
withdrawn within 15 Business Days or which cannot reasonably be shown to be frivolous, vexatious or an abuse of the process of the court or which relates to a claim to which the person has a
good defence and which is being contested in good faith by the person; 

  

	 	(e)	an order being made or resolution passed for the winding up of the person or a notice being issued convening a meeting for the purpose of passing any such resolution other than a solvent reorganisation which has the
prior written approval of the Non-Defaulting Shareholder; 

  

	 	(f)	any petition being presented, notice given or other step being taken for the purpose of the appointment of an administrator of the person or an administration order being made in relation to the person; or

  

	 	(g)	any act, event or circumstance analogous to any of the aforesaid occurring in any jurisdiction in which the person is incorporated or established; 

“Intellectual Property” means all industrial and intellectual property rights, whether registered or not, including pending
applications for registration of such rights and the right to apply for registration or extension of such rights including patents, petty patents, utility models, design patents, designs, copyright (including moral rights and neighbouring rights),
database rights, rights in integrated circuits and other sui generis rights, trade marks, trading names, company names, service marks, logos, the get up of products and packaging, geographical indications and appellations and other signs used in
trade, internet domain names, social media user names, rights in know how and any rights of the same or similar effect or nature as any of the foregoing anywhere in the world; 

“IPO” has the meaning set out in clause 15.6.1; 

“IPO Acceptance Notice” has the meaning set out in clause 15.6.3; 

“IPO Acceptance Period” has the meaning set out in clause 15.6.3; 

“IPO Notice” has the meaning set out in clause 15.6.1; 

“IPO Process” has the meaning set out in clause 15.4.1; 

“IPO Value” has the meaning set out in clause 15.6.2; 

“JDE” means Charger Top HoldCo B.V., a company incorporated under the laws of The Netherlands with its registered
office at Oosterdoksstraat 80, 1011 DK Amsterdam and with registered number 60612568;  
 “JDE Board” means
the board of directors of JDE from time to time; 
 “JDE Exit Event” means an Exit Event as such term is
defined in the JDE Shareholders Agreement; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 85 - 

 “JDE Shareholders Agreement” means the Agreement entered into on
7 May 2014 between (1) Delta Charger HoldCo B.V., (2) Mondelez Coffee HoldCo B.V. and (3) JDE, amended and restated as of the date hereof, as amended from time to time; 

“Law” means all civil and common law, statute, subordinate legislation, treaty, regulations, directive, decision,
by-law, ordinance, code, order, decree, injunction or judgment of any government, quasi-government, statutory, administrative or regulatory body, court or agency; 

“LCIA Court” has the meaning set out in clause 32.2; 

“LCIA Rules” has the meaning set out in clause 32.1; 

“Loan” has the meaning set forth in the Recitals. 

“Longstop Date” has the meaning set out in clause 16.6.2; 

“Management Director” means the director from time to time as appointed in accordance with clause 3.2.4, or under any
other clause hereunder to the extent such person is engaged as an executive officer of the Company; 
 “Management
Equity” has the meaning set out in paragraph 9 of schedule 1.  
 “Maple Tax Rate” means
with respect to any Financial Year, the weighted average combined U.S. federal and state Tax rate applicable to the Company and its U.S. subsidiaries that join together in the filing of a consolidated U.S. corporate income tax return; 

“[ * * * ]” means a transaction in which one [ * * * ]; 

“MDLZ Contribution Amount” has the meaning set out in clause 11.3; 

“MDLZ Tax Rate” means, with respect to any Financial Year, 38% or, if 5 percent higher or lower than such rate (i.e.
approximately 2 percentage points higher or lower), the weighted average combined U.S. federal and state Tax rate of MDLZ applicable to interest income received under the Loan during such Financial Year. MDLZ shall no later than 3 months after the
end of any Financial Year (a) notify Maple Holdings of the MDLZ Tax Rate for such Financial Year, (b) if it has determined that the MDLZ Tax Rate for such financial year differs from the rate of 38%, provide information to Maple Holdings
to support its determination, and (c) provide such information as Maple Holdings reasonably requests to substantiate its determination that the rate of 38% continues to apply for such Financial Year; 

“Net Operating Profit” means operating income before interest and taxes (including net income and/or royalties received from
interest in any unconsolidated ventures but excluding restructuring costs, integration costs, acquisition divestiture related costs, write downs of goodwill and impairment charges) less net interest expense and (ii) provisions for tax; 

“New Opportunity” has the meaning set out in clause 14.6.1; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 86 - 

 “New Shares” has the meaning set out in clause 19.1; 

“Non-defaulting Shareholder” has the meaning set out in clause 16.7; 

“Non JV Business” has the meaning set out in clause 14.5; 

“Notice” has the meaning set out in clause 30.1; 

“Offer” has the meaning set out in clause 15.5.2; 

“Offer Period” has the meaning set out in clause 15.5.2; 

“Offer Price” has the meaning set out in clause 15.5.2; 

“Other Shareholder” has the meaning set out in clause 15.6.1; 

“Public Market Valuation” has the meaning set out in paragraph 9 of schedule 10; 

“Put Notice” has the meaning set out in clause 16.3; 

“Put Shares” has the meaning set out in clause 16.3; 

“Quarter” means each period of three calendar months commencing on 1 January, 1 April, 1 July and
1 October in each Financial Year; 
 “Quarterly Meetings” has the meaning set out in clause 4.1.1;

 “Referring Shareholder” has the meaning set out in clause 14.6.1; 

“Regulatory Consent” means a consent, clearance, approval or permission or exhaustion of any applicable waiting period
necessary to enable a transferring Shareholder and/or purchaser of Shares to be able to complete a transfer of Shares under (a) the rules or regulations of any stock exchange on which it or any of its Affiliates is quoted; or (b) the rules
or regulations of any governmental, statutory or regulatory body including any competition, antitrust and/or merger control authority in those jurisdictions where the transferring shareholder, the purchaser of Shares, the Company or any of their
respective Affiliates carries on business; 
 “Regulatory Longstop Date” has the meaning set out in
clause 18.2; 
 “Relevant Proportion” has the meaning set out in clause 19.2; 

“Report” has the meaning set out in clause 15.6.2; 

“Report Value” has the meaning set out in clause 15.6.2; 

“Representatives” means the representatives, agents and professional advisers of a person (including attorneys,
financial advisers, consultants, accountants and other third party advisers). Solely with respect to the A Shareholder, Representatives shall expressly include the general partners and members of the board of directors, shareholder committees or
investment committees, as applicable of each of Acorn Holdings B.V., Donata Holding SE, Parentes Holding SE, JAB Holding sarl, JAB Holdings BV, Societe Familiale d’Investissements S.A., Quercus B.V. and BDT Oak Acquisition B.V. and their
respective limited partners; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 87 - 

 “Reserved Matters” means those matters as indicated in schedule 1; 

 “Response Notice” has the meaning set out in clause 15.5.3; 

“Restricted Person” means: 
  

	 	(a)	[ * * * ], as amended with the agreement of the A Shareholder and the B Shareholder at least every 3 years to reflect any changes in the competitive environment; 

 

	 	(b)	any person (including its Affiliates) known to the transferor or having made reasonable enquiry) to have been convicted of, or plead guilty to, a breach of Anti-Bribery Laws or Sanctions Laws and where an association
with such person would reasonably be expected to result in material reputational damage to the B Shareholder or any of its Affiliates; 

“Retained Tax Benefit” means the cumulative amount, from Closing through the end of the most recent Financial Year
preceding the determination of a Tax Benefit Shortfall, of the difference between: 
 (a) the applicable amount set forth in clause
12.1.1, minus 
 (b) the product of 
  

	 	(i)	the amount of interest accrued under the Loan during such Financial Year, times 

  

	 	(ii)	the difference between 

  

	 	(A)	1, minus 

  

	 	(B)	the Maple Tax Rate, minus 

 (c) the amount of dividends distributed or to be distributed by the
Company with respect to such Financial Year, minus 
 (d) any portion of the difference calculated under the foregoing clauses
(a)-(c) that has reduced the amount of a Tax Benefit Shortfall for any other Financial Year; 
 “ROFO Notice”
has the meaning set out in clause 15.5.1; 
 “ROFO Process” has the meaning set out in clause 15.4.1; 

“Sale Shares” has the meaning set out in clause 15.5.1; 

“Sanctions Laws” means any applicable export control and economic sanctions laws and regulations of the United States
of America, the United Kingdom, the European Union (or any Member State thereof), the United Nations and each other jurisdiction  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 88 - 

 
in which the Company operates or to which it is subject from time to time, including, without limitation, the US Export Administration Regulations, the US International Traffic in Arms
Regulations, the US Department of Treasury Office of Foreign Asset Control’s economic sanctions regulations, sanctions programmes maintained by Her Majesty’s Treasury and any applicable European Union restrictive measure that has been
implemented pursuant to any European Council or Commission Regulation or Decision adopted pursuant to a Common Position in furtherance of the European Union’s Common Foreign and Security Policy; 

“Shareholder Instruments” means any instrument, document or security granting a right of subscription for, or
conversion into, shares in the capital of any Group Company or loan notes or debt securities issued by a Group Company (other than the Loan); 

“Shareholder Group Entity” means, (i) in the case of Maple Holdings, Acorn Holdings B.V. and each of its
wholly-owned subsidiaries from time to time, (ii) in the case of MDLZ, Mondelēz International, Inc. and each of its wholly-owned subsidiaries from time to time and (iii) in the case of any other Shareholder, to its Affiliates from
time to time unless otherwise provided in the Deed of Adherence entered into by such Shareholder;  
 “Shareholders”
means Maple Holdings and MDLZ and any other person to whom Shares have been transferred or issued in accordance with the terms of this Agreement and who has executed a Deed of Adherence, and “Shareholder” shall mean any one of them;

 “Shares” means shares in the capital of the Company from time to time which is at Closing, the A Shares and
the B Shares; 
 “Short Notice Meeting” has the meaning set out in clause 4.2.2;  

“Single Purchaser” has the meaning set out in clause 15.8.1; 

“Single Purchaser Sale” has the meaning set out in clause 15.8.1; 

“Step Down” has the meaning given to it in clause 17.5;  

“Strategic Plan” means the strategic plan from time to time for the Group prepared and approved in accordance with
schedule 11; 
 “Surviving Provisions” means clause 1, clause 14.1, 14.2 and 14.3, clause 22, clause 23,
clause 24, clause 25, clause 26, clause 27, clause 28, clause 29, clause 30, clause 31, clause 32 and clause 33 of this Agreement; 

“Tag Along Notice” has the meaning set out in clause 15.8.1; 

“Tag Along Response Notice” has the meaning set out in clause 15.8.2; 

“Tax” means all national, federal, state, provincial, territorial, possession, county, local, or other taxes, levies, or
imposts, including any tax on income, profits, or gains, tax on net income, alternative or add-on minimum tax, gross income, gross receipts, 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 89 - 

 
sales, use, goods and services, harmonized sale, ad valorem, value added, transfer, franchise, profits, license, withholding, payroll, employment, excise, severance, stamp, capital stock,
occupation, property, royalty, capital, workers’ compensation, employer health, pension plan, anti-dumping, countervail, production, real property gains, social security or disability, environmental or windfall profit tax, premium, custom duty
or other tax, governmental fee, or other like assessment or charge of any kind whatsoever, any required estimated payments made with respect to any of the above, together with any interest, penalty, addition to tax or additional amount imposed by
any Taxing Authority responsible for the imposition of any such tax (United States or non-United States). For the avoidance of doubt, Tax includes any interest, penalty, addition to tax or additional amount imposed by any Taxing Authority only to
the extent such item is actually paid to or charged by the Taxing Authority, or involves the utilization of any Tax loss or other Tax Attribute to offset any Tax; 

“Tax Attribute” means any national, federal, state, provincial territorial, possession, county, or local net operating loss,
net capital loss, general business credit, foreign tax credit, charitable deduction, or any other loss, credit, deduction, or Tax attribute that could reduce any Tax (including, but not limited to, deductions, credits, alternative minimum net
operating loss carryforwards related to alternative minimum taxes or additions to the basis of property) or any equivalent thereof whether computed on a consolidated, combined or unitary basis; 

“Tax Benefit Shortfall” mean, with respect to any Financial Year, the difference between (a) the amount of interest
accrued on the Loan, multiplied by the Maple Tax Rate during such Financial Year, minus (b) the amount by which the Tax cost of the Group is reduced as a result of interest expense with respect to the Loan, determined on a with and without
basis (which may be a negative amount), minus (c) any Retained Tax Benefit as of the date of determination; 
 “Taxing
Authority” means any governmental authority of, including, but not limited to, any country, state, province, territory, possession, county, municipality, or other political subdivision responsible for the imposition or collection of any
Tax; 
 “Tea” has the meaning set out in clause 2.1.1(b)(ii); 

“Tea Beverages” has the meaning set out in clause 2.1.1(b)(ii); 

“Technical IP” means any Intellectual Property other than branding Intellectual Property such as trademarks, trading names,
company names, service marks, logos, the get up of products and packaging, geographical indications and appellations and other signs used in trade, internet domain names and social media user names; 

“Terminating Breach” means: 
  

	 	(a)	a breach by the A Shareholder or the B Shareholder of clause 14.1.1 or clause 15.1 of this Agreement; or 

  

	 	(b)	a breach by the A Shareholder of clause 2.3.1 or by a Group Company of clause 2, which will, or would reasonably be expected to, result in a liability for MDLZ; provided, however, that the existence of such a
breach shall be subject to confirmation by reputable outside counsel selected by MDLZ following a reasonable investigation of the circumstances; 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 90 - 

	 	(c)	implementation of a Reserved Matter in breach of clause 6 which has or is reasonably likely to have materially adverse consequences for the B Shareholder in its capacity as a Shareholder or a lender under the Loan. For
the purposes of this definition, implementation of any of the Reserved Matters included in paragraphs 4, 9, 11, 12, 13, 14 and 17 of schedule 1 shall always be considered to have materially adverse consequences for the B Shareholder;

 “Termination Notice” has the meaning set out in clause 15.6.7; 

“Third Party” means a bona fide third party which is not a Shareholder or an Affiliate of a Shareholder; 

“Transfer Date” has the meaning set out in clause 16.5.1(b); 

“Transfer Notice” has the meaning set out in clause 15.9.1; 

“Transfer Value” means the value determined in accordance with schedule 10; 

“Transferring Shareholder” has the meaning set out in clause 15.6.1; 

“USD” means the lawful currency of The United States of America from time to time;  

“Valuer” has the meaning set out in clause 15.6.2; 

“Working Hours” means 9.30 a.m. to 5.30 p.m. on a Business Day. 

 

	1.2	In this Agreement, a reference to: 

  

	 	1.2.1	(i) a “subsidiary” of an undertaking (“A”) is to any other undertaking, the business affairs of which can be directed by A either directly or indirectly, alone or together with group
entities, through the exercise or non-exercise of any voting power in any meeting of shareholders or in any meeting of managing directors or supervisory directors (if any) or managers or otherwise, whether by agreement or otherwise; and (ii) a
“parent” of an undertaking (“B”) is to any other undertaking who can direct the business affairs of B either directly or indirectly, alone or together with group entities, through the exercise or non-exercise of any voting
power in any meeting of shareholders or in any meeting of managing directors or supervisory directors (if any) or managers or otherwise, whether by agreement or otherwise; (iii) a parent shall be treated as the parent of undertakings in
relation to which any of its subsidiaries are, or are to be treated, as parents, and references to subsidiaries shall be construed accordingly; and (iv) a “wholly owned” undertaking of another undertaking (“C”)
includes an undertaking that C would own 100% of the shares or voting rights in, but for that undertaking having one or more nominee shareholders for legal, regulatory or administrative reasons;  

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 91 - 

	 	1.2.2	references to a “company” shall be construed so as to include any company, corporation or other body corporate, wherever and however incorporated or established; 

 

	 	1.2.3	any statute or statutory provision includes a reference to the statute or statutory provision as amended, modified or re-enacted or both from time to time (whether before or after the date of this Agreement) and any
subordinate legislation made under the statute or statutory provision (whether before or after the date of this Agreement); 

  

	 	1.2.4	a document in the “agreed form” is a reference to a document in a form approved and for the purposes of identification initialled by or on behalf of the Shareholders; 

 

	 	1.2.5	a “person” includes a reference to: 

  

	 	(a)	any individual, firm, company, corporation or other body corporate, unincorporated organisation, government, state or agency of state, local or municipal authority or government body or any joint venture, association,
organisation, trust or partnership, works council or employee representative body (whether or not having separate legal personality); 

  

	 	(b)	that person’s legal personal representatives, successors, permitted assigns and permitted nominees in any jurisdiction and whether or not having separate legal personality; 

 

	 	1.2.6	a “party” is a reference to a party to this Agreement (either by virtue of having executed this Agreement or having entered into a deed of adherence to it) and includes a reference to that party’s
legal personal representatives, successors and permitted assigns, and “parties to this Agreement” and “parties” shall be construed accordingly;  

 

	 	1.2.7	the phrase “so far as it is able” in the context of an obligation of a party to procure any action under this Agreement shall mean to the extent that such party is legally able to do so in its capacity
as a Shareholder or Director (as the case may be), including the exercise of all voting rights, powers and other rights (direct and indirect) available to it in that capacity and, in the case of directors, subject to their statutory fiduciary
duties; 

  

	 	1.2.8	a clause, part, paragraph or schedule, unless the context otherwise requires, is a reference to a clause, part, paragraph of, or schedule to, this Agreement; 

 

	 	1.2.9	(unless the context otherwise requires) the singular shall include the plural, and vice versa; 

  

	 	1.2.10	one gender shall include each gender; and 

  

	 	1.2.11	this Agreement, a Transaction Document or any other document referred to in this Agreement is a reference to that Transaction Document or other document as amended, varied, novated, supplemented or replaced from time to
time (other than in breach of the provisions of this Agreement). 

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 92 - 

	1.3	The ejusdem generis principle of construction shall not apply to this Agreement. Accordingly, general words shall not be given a restrictive meaning by reason of their being preceded or followed by words
indicating a particular class of acts, matters or things or by examples falling within the general words. Any phrase introduced by the terms “other”, “including”, “include” and “in particular” or any similar
expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms. 

  

	1.4	The schedules form part of this Agreement and shall have effect accordingly. 

  

	1.5	The headings in this Agreement do not affect its interpretation or construction. 

  

			
	EXECUTED by the parties	  	
		
	Signed by	  	)
	for and	  	)
	on behalf of	  	)
	MAPLE HOLDINGS II B.V.	  	)
		
	Signed by	  	)
	for and	  	)
	on behalf of	  	)
	MONDELĒZ INTERNATIONAL HOLDINGS LLC	  	)
		
	Signed by Joachim Creus and Markus Hopmann	  	)
	for and	  	)
	on behalf of	  	)
	MAPLE PARENT HOLDINGS CORP.	  	)

  
 CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [ * * * ]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
  

 UK-0020-Charger 

  
 - 93 -EX-10.3

 Exhibit 10.3 

MONDELĒZ INTERNATIONAL, INC. 

AMENDED AND RESTATED 2005 PERFORMANCE INCENTIVE PLAN 

(Amended and Restated as of March 15, 2016) 

Section 1. Purpose; Definitions. 
 The Plan supports
the Company’s ongoing efforts to increase shareholder value by allowing the Company to offer its senior leaders compensation opportunities intended to incent high performance and retention. 

The terms below are defined as follows for Plan purposes: 
  

	(a)	“Annual Incentive Award” means an Incentive Award made pursuant to Section 5(a)(vi) with a Performance Cycle of one year or less. 

 

	(b)	“Award” means the cash or equity earned by a Participant pursuant to a Grant. 

  

	(c)	“Board” means the Board of Directors of the Company. 

  

	(d)	“Cause” means termination because of: 

  

	 	(i)	Continued failure to substantially perform the Participant’s job’s duties (other than resulting from incapacity due to disability); 

 

	 	(ii)	Gross negligence, dishonesty, or violation of any reasonable rule or regulation of the Mondelēz Group where the violation results in significant damage to the Mondelēz Group; or 

 

	 	(iii)	Engaging in other conduct which adversely reflects on the Mondelēz Group in any material respect. 

  

	(e)	“Change in Control” has the meaning stated in Section 6. 

  

	(f)	“Code” means the U.S. Internal Revenue Code. 

  

	(g)	“Commission” means the U.S. Securities and Exchange Commission or any successor agency. 

  

	(h)	“Committee” means the Human Resources and Compensation Committee of the Board, any successor or such other committee or subcommittee as may be designated by the Board to administer the Plan. 

 

	(i)	“Common Stock” or “Stock” means the Class A Common Stock of the Company. 

  

	(j)	“Company” means Mondelēz International, Inc., a corporation organized under the laws of the Commonwealth of Virginia, or any successor. 

 

	(k)	“Deferred Stock Unit” means the Grant of that name described in Section 5(a)(v). 

  

	(l)	“Economic Value Added” means net after-tax operating profit less the cost of capital. 

  

	(m)	“Exchange Act” means the Securities Exchange Act of 1934. 

  

	(n)	“Fair Market Value” means, as applied to a specific date, the price of a share of Stock that is based on the opening, closing, actual, high, low or average selling prices of a share of Stock reported on any
established stock exchange or national market system including without limitation the NASDAQ Global Select Market and the National Market System of the National Association of Securities Dealers, Inc. Automated Quotation System on the applicable
date, the preceding trading day, the next succeeding trading day, or an average of trading days, as determined by the Committee in its discretion. Unless the Committee determines otherwise or unless otherwise specified in a Grant agreement, Fair
Market Value will be deemed to be equal to the closing price of a share of Stock on the most recent date on which shares of Stock were publicly traded. 

  

	(o)	“Grant” means a grant made under the Plan or, to the extent relevant, under any Prior Plan. 

  
 1 

	(p)	“Good Reason” means: 

  

	 	(i)	the assignment to the Participant of any duties substantially inconsistent with the Participant’s position, authority, duties or responsibilities in effect immediately prior to the Change in Control, or any other
action by the Mondelēz Group that results in a marked diminution in the Participant’s position, authority, duties or responsibilities, excluding for this purpose: 

 

	 	(A)	changes in the Participant’s position, authority, duties or responsibilities which are consistent with the Participant’s education, experience, etc.; or 

 

	 	(B)	an isolated, insubstantial and inadvertent action not taken in bad faith and that is remedied by the Mondelēz Group promptly after receipt of notice thereof given by the Participant; 

 

	 	(ii)	any material reduction in the Participant’s base salary, annual incentive or long-term incentive opportunity as in effect immediately prior to the Change in Control; 

 

	 	(iii)	the Mondelēz Group’s requiring the Participant to be based at any office or location other than any other location which does not extend the Participant’s home to work location commute as of the time of
the Change in Control by more than 50 miles; or 

  

	 	(iv)	any failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume
expressly and agree to perform this Plan in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place, as and to the extent required by Section 6 of the Plan.

 The Participant must notify the Company of any event purporting to constitute Good Reason within 45 days following the
Participant’s knowledge of its existence, and the Company shall have 30 days in which to correct or remove such Good Reason, or such event shall not constitute Good Reason. 

 

	(q)	“Incentive Award” means any Award that is either an Annual Incentive Award or awarded pursuant to a Long-Term Incentive Grant. 

 

	(r)	“Incentive Stock Option” means any Stock Option that is designated as being an Incentive Stock Option and complies with Section 422 of the Code. 

 

	(s)	“Long-Term Incentive Grant” means a Grant made pursuant to Section 5(a)(vi) with a Performance Cycle of more than one year. 

 

	(t)	“Long-Term Incentive Grant Target Value” means, in connection with a Change in Control, either: (i) if a Long-Term Incentive Grant is denominated and payable in cash, the target cash value of such
Long-Term Incentive Grant, or (ii) if a Long-Term Incentive Grant is denominated in shares, the product of the target number of shares under such Long-Term Incentive Grant multiplied by the closing share price of the Common Stock on the last
trading day immediately preceding the closing date of the Change in Control. 

  

	(u)	“Mondelēz Group” means the Company and each of its subsidiaries and affiliates. 

  

	(v)	“Non-Management Director” means a member of the Board who is not an employee of the Mondelēz Group. 

  

	(w)	“Nonqualified Stock Option” means any Stock Option that is not an Incentive Stock Option. 

  

	(x)	“Other Stock-Based Grant” means a Grant made pursuant to Section 5(a)(iii). 

  

	(y)	“Participant” means any eligible individual as set forth in Section 3 to whom a Grant is made. 

  

	(z)	“Performance Cycle” means the period selected by the Committee during which the performance of the Company or any organizational unit of the Mondelēz Group or any individual is measured for the purpose of
determining the extent to which a Grant or compensation subject to Performance Goals has been earned. 

  

	(aa)	 “Performance Goals” mean the objectives for the Company or any organizational unit of the Mondelēz Group or any individual that may be
established by the Committee for a Performance Cycle with respect to any performance-based Grants under the Plan. Performance Goals may be provided in absolute terms, or in relation to the Company’s peer group. The Company’s peer group
will be determined by the Committee, in its sole discretion. The Performance Goals for Grants that are intended to constitute “performance-based” 

  
 2 

	 	
compensation within the meaning of Section 162(m) of the Code must be based on one or more of the following criteria: net earnings or net income (before or after taxes), operating income,
earnings per share, net sales or revenue growth, adjusted net income, net operating profit or income, return measures (including, but not limited to, return on assets, capital, invested capital, net assets, equity, sales, or revenue), cash flow
(including, but not limited to, operating cash flow, free cash flow, cash flow return on equity, and cash flow return on investment), earnings before or after taxes, interest, depreciation, and/or amortization, gross or operating income margins,
productivity ratios, share price (including, but not limited to, share price growth measures and total shareholder return), cost control, margins, trade efficiency, overhead cost management, volume growth, volume/mix growth, pricing impact,
operating efficiency, market share, category growth, advertising and consumer spending, objective measures of customer satisfaction or employee satisfaction, case fill rate, pricing net of commodities, working capital, cash conversion days, taxes,
depreciation and amortization, volume or Economic Value Added. 

  

	(bb)	“Plan” means this Mondelēz International, Inc. 2005 Performance Incentive Plan, as amended and restated as of March 15, 2016. 

 

	(cc)	“Prior Plan” means the Mondelēz International, Inc. Amended and Restated 2006 Stock Compensation Plan for Non-Employee Directors. 

 

	(dd)	“Restricted Period” means the period during which a Grant may not be sold, assigned, transferred, pledged or otherwise encumbered. 

 

	(ee)	“Restricted Stock” means a Grant of shares of Common Stock pursuant to Section 5(a)(iv). 

  

	(ff)	“Restricted Stock Unit” means a Grant of that name described in Section 5(a)(v). 

  

	(gg)	“Spread Value” means, with respect to a share of Common Stock subject to a Grant, an amount equal to the excess of the Fair Market Value, on the date such value is determined, over the Grant’s exercise or
strike price, if any. 

  

	(hh)	“Stock Appreciation Right” or “SAR” means a Grant described in Section 5(a)(ii). 

  

	(ii)	“Stock Option” means an Incentive Stock Option or a Nonqualified Stock Option granted pursuant to Section 5(a)(i). 

For purposes of these definitions, any reference to a statute also refers to any regulations promulgated with respect to the statute and any successor or
amendment to the statute, regulation or legal standard. 
 Section 2. Administration. 

The Plan is administered by the Committee, which has the power to interpret the Plan and to adopt such rules and guidelines for carrying out the Plan as it may
deem appropriate. The Committee has the authority to adopt such modifications, procedures and subplans as may be necessary or desirable to comply with the laws, regulations, compensation practices and tax and accounting principles of the countries
in which the Mondelēz Group may operate to assure the viability of the benefits of Grants made to individuals employed in such countries and to meet the objectives of the Plan. 

Subject to the terms of the Plan, the Committee has the authority to determine those employees eligible to receive Grants and Awards and the amount, type and
terms of each Grant or Award and to establish and administer any Performance Goals applicable to such Grants or Awards. Subject to the terms of the Plan, the Committee has the authority to recommend to the Board those Non-Management Directors
eligible to receive Grants or Awards and the amount, type and terms of each Grant or Award. The Committee may delegate its authority and power under the Plan to one or more officers of the Company, subject to guidelines prescribed by the Committee,
but only with respect to Participants who are not Non-Management Directors or executive officers of the Company and/or otherwise subject to either Section 16 of the Exchange Act or Section 162(m) of the Code. 

Any determination made by the Committee or by one or more officers pursuant to delegated authority in accordance with the provisions of the Plan with respect
to any Grant or Award is made in the sole discretion of the Committee or such delegate, and all decisions made by the Committee or any appropriately designated officer pursuant to the provisions of the Plan are final and binding on all persons,
including the Company and Plan Participants. 

  
 3 

 Section 3. Eligibility. 

Salaried employees of the Mondelēz Group who are responsible for or contribute to the management, growth and profitability of the business of the
Mondelēz Group are eligible for Grants and Awards under the Plan. Non-Management Directors are also eligible for Grants and Awards under the Plan. Stock Options intending to qualify as Incentive Stock Options may only be granted to employees of
the Company and its subsidiaries, within the meaning of the Code, as selected by the Committee. 
 Section 4. Common Stock Subject to the Plan.

  

	(a)	Common Stock Available. The total number of shares of Common Stock reserved and available for distribution pursuant to the Plan is 243,691,747 shares, which consists of 150,000,000 shares that were approved in 2005,
18,000,000 shares that were approved in 2009, 75,000,000 shares that were added as of the May 21, 2014 Amendment and Restatement and 691,747 shares that remain available for issuance under the Prior Plan as of March 14, 2014. An amount not
to exceed 50% of the shares of Common Stock issuable under the plan as of May 21, 2014 may be issued pursuant to Grants of Restricted Stock, Restricted Stock Units, Deferred Stock Units or Other Stock-Based Grants, and Incentive Awards, except
that Other Stock-Based Grants with values based on Spread Values are not included in this limitation; and except further, that Grants of Restricted Stock, Restricted Stock Units, Deferred Stock Units and Other Stock-Based Grants, and Incentive
Awards made prior to May 21, 2014 are not included in this limitation. Except as otherwise provided in this Plan, any Grant made under the Prior Plan continues to be subject to the terms and conditions of the Prior Plan and the applicable Grant
agreement. Any adjustments, substitutions, or other actions that may be made or taken in accordance with Section 4(b) below in connection with the corporate transactions or events described in that section, will, to the extent applied to
outstanding Grants made under the Prior Plan, be deemed made from shares reserved for issuance under the Prior Plan, rather than this Plan, pursuant to the authority of the Board under the Prior Plan to make adjustments and substitutions in such
circumstances to the aggregate number and kind of shares reserved for issuance under the Prior Plan and to Grants made under the Prior Plan. To the extent any Grant under this Plan is exercised, cashed out, terminates, expires or is forfeited
without a payment being made to the Participant in the form of Common Stock, the shares subject to the Grant that were not used will be available for distribution in connection with Grants under this Plan; provided, however, that any shares which
are available again for Grants under this Plan will count toward the limit described in Section 5(b)(i). If a SAR or similar Grant based on Spread Value with respect to shares of Common Stock is exercised, the full number of shares of Common
Stock with respect to which the Grant is measured will nonetheless be deemed distributed for purposes of determining the maximum number of shares remaining available for delivery under the Plan. Similarly, any shares of Common Stock that are
withheld by the Company or tendered by a Participant (1) as full or partial payment of withholding or other taxes owed by the Participant related to an outstanding Stock Option or SAR or (2) as payment for the exercise or conversion price
of a Stock Option, SAR or similar Grant based on Spread Value under the Plan will be deemed distributed for purposes of determining the maximum number of shares remaining available for delivery under the Plan. 

 

	(b)	Adjustments for Certain Corporate Transactions 

  

	 	(i)	In the event of any merger, share exchange, reorganization, consolidation, recapitalization, reclassification, distribution, stock dividend, stock split, reverse stock split, split-up, spin-off, issuance of rights or
warrants or other similar transaction or event affecting the Common Stock in any case after adoption of the Plan by the Board, the Committee will make any adjustments or substitutions with respect to Grants made under the Plan and the Prior Plan as
it deems appropriate to reflect the occurrence of such event, including, but not limited to, adjustments (A) to the aggregate number and kind of securities reserved for issuance under the Plan, (B) to the limits set forth in
Section 5, (C) to the Performance Goals or Performance Cycles of any outstanding Grants, and (D) to the number and kind of securities subject to outstanding Grants and, if applicable, the grant or exercise price or Spread Value of
outstanding Grants. In addition, the Committee may make a Grant in substitution for incentive awards, stock grants, stock options or similar grants made to an individual who is, previously was, or becomes an employee of the Mondelēz Group in
connection with a transaction described in this Section 4(b)(i). Notwithstanding any provision of the Plan (other than the limitation set forth in Section 4(a)), the Committee has full discretion to determine the terms of any Grants made
in substitution. 

  
 4 

	 	(ii)	Specific Adjustments. 

  

	 	(A)	In connection with any of the events described in Section 4(b)(i), the Committee has the authority with respect to Grants made under the Plan and the Prior Plan (x) to issue Grants (including Stock Options,
SARs, and Other Stock-Based Grants) with a grant price that is less than Fair Market Value on the date of grant in order to preserve existing gain under any similar type of previous grant made by the Company or another entity to the extent that the
existing gain would otherwise be diminished without payment of adequate compensation to the holder of the grant for such diminution, and (y) except as may otherwise be required under an applicable Grant agreement, to cancel or adjust the terms
of an outstanding Grant as appropriate to reflect the substitution for the outstanding grant of equivalent value made by another entity. 

  

	 	(B)	In connection with a spin-off or similar corporate transaction, the Committee also has the authority with respect to Grants made under the Plan and the Prior Plan to make adjustments described in this Section 4(b)
that may include, but are not limited to, (x) the imposition of restrictions on any distribution with respect to Restricted Stock or similar Grants and (y) the substitution of comparable Stock Options to purchase the stock of another
entity or SARs, Restricted Stock Units, Deferred Stock Units or Other Stock-Based Grants denominated in the securities of another entity, which may be settled in the form of cash, Common Stock, stock of such other entity, or other securities or
property, as determined by the Committee; and, in the event of such a substitution, references in this Plan and the Prior Plan and in the applicable Grant agreements thereunder to “Common Stock” or “Stock” will be deemed to also
refer to the securities of the other entity where appropriate. 

  

	 	(iii)	In connection with any of the events described in Section 4(b)(i), with respect to Grants made under the Plan and the Prior Plan, the Committee is also authorized to provide for the payment of any outstanding
Grants in cash, including, but not limited to, payment of cash in lieu of any fractional shares, provided that no such payment fails to comply with the requirements of Section 409A of the Code to the extent that law applies to the recipient of
the cash payment. 

  

	 	(iv)	In the event of any conflict between this Section 4(b) and other provisions of the Plan or the Prior Plan, the provisions of this section control. Each Participant who receives a Grant under the Plan is deemed to
acknowledge and consent to the Committee’s ability to adjust Grants under the Prior Plan in a manner consistent with this Section 4(b). 

Section 5. Grants and Awards. 
  

	(a)	General. The types of Grants and Awards that may be made under the Plan are described below. Grants and Awards may be made singly, in combination or in tandem with other Grants and/or Awards. All Grant agreements are
incorporated in and constitute part of the Plan. 

  

	 	(i)	Stock Options. A Grant of a Stock Option represents the right to purchase a share of Stock at a predetermined grant price. Stock Options granted under the Plan may be in the form of Incentive Stock Options or
Nonqualified Stock Options, as specified in the Grant agreement but no Stock Option designated as an Incentive Stock Option will be invalid in the event that it fails to qualify as an Incentive Stock Option. The term of each Stock Option will be
stated in the Grant agreement, but no Stock Option will be exercisable more than ten years after the grant date. The grant price per share of Common Stock purchasable under a Stock Option may not be less than 100% of the Fair Market Value on the
date of grant, except as permitted by Section 4(b)(ii)(A). Subject to the applicable Grant agreement, Stock Options may only be exercised, in whole or in part, by following the administrative procedures applicable to the exercise of Stock
Options as are periodically communicated to Participants. If the exercise requires payment for the shares exercised (as well as applicable taxes), payment must be received in accordance with applicable payment requirements. Unless otherwise
determined by the Committee, payment in full or in part may also be made in the form of Common Stock already owned by the Participant valued at Fair Market Value on the day preceding the date of exercise or shares of Common Stock otherwise issuable
upon such exercise. 

  
 5 

	 	(ii)	Stock Appreciation Right. A Grant of a SAR represents the right to receive a cash payment, a share of Common Stock, or both (as determined by the Committee), with a value equal to the Spread Value on the date the
SAR is exercised. The grant price of a SAR will be stated in the applicable Grant agreement and will not be less than 100% of the Fair Market Value on the date of grant, except as permitted by Section 4(b)(ii)(A). Subject to the terms of the
applicable Grant agreement, a SAR will be exercisable, in whole or in part, by following the administrative procedures applicable to the exercise of SARs as are periodically communicated to Participants, but no SAR may be exercisable more than ten
years after the Grant date. 

  

	 	(iii)	Other Stock-Based Grant. An Other Stock-Based Grant is a Grant, other than a Stock Option, SAR, Restricted Stock, Restricted Stock Units, or Deferred Stock Unit, that is denominated in, valued in whole or in part
by reference to, or otherwise based on or related to, Common Stock. The grant, purchase, exercise, exchange or conversion of Other Stock-Based Grants made under this subsection (iii) will be on such terms and conditions and by such methods as
may be specified by the Committee. Where the value of an Other Stock-Based Grant is based on the Spread Value, the grant price for such a Grant will not be less than 100% of the Fair Market Value on the date of Grant. 

 

	 	(iv)	Restricted Stock. A Grant of Restricted Stock is a share of Common Stock that is subject to forfeiture during the Restricted Period upon such conditions as may be stated in the applicable Grant agreement. Except
as may be provided in the applicable Grant agreement, during the Restricted Period: 

  

	 	(A)	Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered; and 

  

	 	(B)	A Participant will have all the rights of a holder of Common Stock with respect to the Restricted Stock. 

  

	 	(v)	Restricted Stock Unit or Deferred Stock Unit. A Grant of a Restricted Stock Unit or a Deferred Stock Unit represents the right to receive a share of Common Stock, cash, or both (as determined by the Committee)
upon satisfaction of such conditions as may be set forth in the applicable Grant agreement. Except as may be provided in the applicable Grant agreement, neither Restricted Stock Units nor Deferred Stock Units may be sold, assigned, transferred,
pledged or otherwise encumbered during the Restricted Period. Except as may be provided in the applicable Grant agreement, a Participant will not have any of the rights of a holder of Common Stock with respect to Restricted Stock Units or Deferred
Stock Units unless and until shares of Common Stock are actually delivered in satisfaction of the restrictions and other conditions of such Restricted Stock Units or Deferred Stock Units. 

 

	 	(vi)	Incentive Awards. An Incentive Award is a performance-based Award that is expressed in U.S. currency or Common Stock or any combination of the two. Incentive Awards may either be Annual Incentive Awards or
Long-Term Incentive Grants. 

  

	(b)	Maximum Grants and Awards. Subject to the exercise of the Committee’s authority pursuant to Section 4: 

  

	 	(i)	The total number of shares of Common Stock subject to Stock Options and SARs granted during any calendar year to any Participant may not exceed 3,000,000 shares. 

 

	 	(ii)	The total amount of any Annual Incentive Award awarded to any Participant with respect to any Performance Cycle, taking into account the cash and the Fair Market Value of any Common Stock payable with respect to such
Award, may not exceed $10,000,000. 

  

	 	(iii)	The total amount of any Long-Term Incentive Grant made to any Participant with respect to any Performance Cycle may not exceed 400,000 shares of Common Stock multiplied by the number of years in the Performance Cycle
or, in the case of Grants expressed in currency, $8,000,000 multiplied by the number of years in the Performance Cycle. The maximum in this paragraph will be reduced pro-rata for any Participant who is not a Participant for the entire Performance
Cycle. 

  
 6 

	 	(iv)	No Grant of Restricted Stock, Restricted Stock Units, Deferred Stock Units, or Other Stock-Based Grants may be made in excess of 1,000,000 shares of Common Stock to any Participant in a calendar year, except that Other
Stock-Based Grants with values based on Spread Values are not subject to this limitation. 

  

	 	(v)	The maximum Fair Market Value on the date of Grant, as determined by the Committee, of the shares of Common Stock subject to Grants made to any Non-Management Director in any calendar year may not exceed $500,000.

  

	(c)	Performance-Based Grants. Grants made under the Plan may be performance-based through the application of Performance Goals and Performance Cycles. 

 

	(d)	Adjustment of Performance-Based Compensation. Awards that are intended to qualify as performance-based compensation under Section 162(m) of the Code may not be adjusted upward. The Committee retains the discretion
to adjust such Awards downward, either on a formulaic or discretionary basis or any combination, as the Committee determines, in its sole discretion. 

  

	(e)	Evaluation of Performance. The Committee may provide in any Grant intended to qualify as performance-based compensation for purposes of Section 162(m) of the Code that any evaluation of performance under the
applicable Performance Goal(s) may include or exclude the impact, if any, on reported financial results of any of the following events that occurs during a Performance Cycle: (a) asset write-downs; (b) litigation or claim judgments or
settlements; (c) changes in tax laws, accounting principles or other laws or provisions; (d) reorganization or restructuring programs; (e) acquisitions or divestitures; (f) foreign exchange gains and losses; and (g) gains
and losses that are treated as extraordinary items under Financial Accounting Standard No. 145 (Accounting Standards Codification 225). To the extent such inclusions or exclusions affect Grants to covered employees (as defined in
Section 162(m) of the Code), they must be prescribed in a form that meets the requirements of Section 162(m) of the Code for deductibility. 

  

	(f)	Vesting. Grants made under the Plan will vest at such time or times as may be determined by the Committee; provided, however, that no condition relating to the vesting of a Grant and/or Award that is based upon
Performance Goals may be based on a Performance Cycle of less than one year, and no condition that is based upon continued employment or the passage of time alone may provide for vesting of a Grant more rapidly than in installments over three years
from the date the Grant is made, except (i) upon the death, disability or retirement of the Participant, in each case as specified in the Grant agreement (ii) upon a Change in Control, as specified in Section 6 of the Plan,
(iii) for any Award paid in cash, (iv) for any Grants made to Non-Management Directors, and (v) for up to 12,184,587 (equal to 5% of the amount of shares of Common Stock subject to the Plan) shares of Common Stock that may be subject
to Grants without any minimum vesting period. 

 Section 6. Change in Control Provisions. 

 

	(a)	Impact of Event. Notwithstanding any other provision of the Plan to the contrary, in the event of a Change in Control (as defined below in Section 6(b)): 

 

	 	(i)	If, and to the extent that outstanding Grants, other than Annual Incentive Awards, under the Plan (A) are assumed by the successor corporation (or affiliate thereto) or (B) are replaced with equity grants that
preserve the existing value of the Grants at the time of the Change in Control and provide for subsequent payout in accordance with a vesting schedule, as applicable, that is the same or more favorable to the Participants than the vesting schedule
applicable to the Grants, then all of these Grants or substitute grants will remain outstanding and be governed by their respective terms and the provisions of the Plan subject to Section 6(a)(iv) below. 

 

	 	(ii)	 If, and to the extent that outstanding Grants, other than Annual Incentive Awards, under the Plan are not assumed or replaced in accordance with
Section 6(a)(i) above, then upon the Change in Control the following treatment (referred to as “Change-in-Control Treatment”) will apply to these Grants: (A) outstanding Grants of Stock Options and SARs will immediately vest and
become exercisable; (B) the restrictions and other conditions applicable to outstanding Restricted Stock, Restricted Stock Units, Deferred Stock Units and Other Stock-Based Grants, including vesting requirements, will immediately lapse, and
these grants will be free of all restrictions; and (C) outstanding Long-Term 

  
 7 

	 	
Incentive Grants will be subject to the treatment described in Section 6(a)(vi) below as if all Participants experienced a qualifying termination simultaneously upon the Change in Control
with the cash amount payable in a lump sum within forty-five (45) days of the Change in Control. 

  

	 	(iii)	If, and to the extent that outstanding Grants under the Plan are not assumed or replaced in accordance with Section 6(a)(i) above, then in connection with the application of the Change-in-Control Treatment stated
in Section 6(a)(ii) above (and Section 6(a)(vi) below, if applicable), the Board may, in its sole discretion, provide for cancellation of such outstanding Grants at the time of the Change in Control in which case a payment of cash,
property or a combination thereof will be made to each affected Participant upon the consummation of the Change in Control that is determined by the Board in its sole discretion and that is at least equal to the excess (if any) of the value of the
consideration that would be received in such Change in Control by the holders of the securities of Mondelēz International, Inc. relating to such Grants over the exercise or purchase price (if any) for such Grants. 

 

	 	(iv)	If, and to the extent that outstanding Grants are assumed or replaced in accordance with Section 6(a)(i) above and (A) other than with respect to a Non-Management Director, a Participant’s employment
with, or performance of services for, the Mondelēz Group is terminated by the Mondelēz Group for any reasons other than Cause or, by such Participant for Good Reason, in each case, within the two-year period commencing on the Change in
Control, or (B) with respect to a Non-Management Director, such Non-Management Director’s service as a member of the Board ceases for any reason within the one-year period commencing on the Change in Control, then, as of the date of such
Participant’s termination, the Change-in-Control Treatment stated in Section 6(a)(ii) above (and Section 6(a)(vi) below, if applicable) will apply to all assumed or replaced Grants of such Participant then outstanding.

  

	 	(v)	Outstanding Stock Options or SARs that are assumed or replaced in accordance with Section 6(a)(i) may be exercised by the Participant in accordance with the applicable terms and conditions stated in the applicable
Grant agreement or elsewhere; provided, however, that Stock Options or SARs that become exercisable in accordance with Section 6(a)(iv) shall remain exercisable until the expiration of the original full term of the Stock Option or SAR
notwithstanding the other original terms and conditions of such Grant. 

  

	 	(vi)	Upon the consummation of a Change in Control, (A) any Long-Term Incentive Grants relating to Performance Cycles completed prior to the year in which the Change in Control occurs that have been earned but not paid
will be automatically converted into a right to receive a cash payment (to the extent that the Long-Term Incentive Grant is not already denominated in cash) equal to the product of the number of shares earned under the Long-Term Incentive Grant
multiplied by the closing share price of the Common Stock on the last trading day immediately preceding the closing date of the Change in Control, and (B) any Long-Term Incentive Grants relating to Performance Cycles not completed prior to the
year in which the Change in Control occurs will be automatically converted into a right to receive a cash payment equal to the Long-Term Incentive Grant Target Value for such Performance Cycle. In addition, each Participant who is eligible for or
who has received a Long-Term Incentive Grant for any then current Performance Cycle will be deemed to have earned: (x) if at least 50% or more of the Performance Cycle has elapsed on the date on which the termination occurs, an amount equal to
such Participant’s Long-Term Incentive Grant Target Value for such Performance Cycle or (y) if less than 50% of the Performance Cycle has elapsed of the date on which the termination occurs, an amount equal to the product of (A) such
Participant’s Long-Term Incentive Grant Target Value for such Performance Cycle, and (B) a fraction, the numerator of which is the number of days completed in such Performance Cycle to the date on which the termination occurs, and the
denominator of which is the total number of days in such Performance Cycle, and, in either case, such amount will become immediately payable in a lump sum within forty-five (45) days 

 

	 	(vii)	Except as otherwise specified in a Grant agreement, any of the foregoing Change in Control provisions that change the timing of payment of an Award will not apply to a Grant subject to Section 409A of the Code
unless such change is permissible under and consistent with Section 409A of the Code without the imposition of additional taxes and penalties under Section 409A of the Code. For the avoidance of doubt, the foregoing applies to all Grants
made under the Plan regardless of when made. 

  
 8 

	(b)	Definition of Change in Control. “Change in Control” means the occurrence of any of the following events: 

  

	 	(i)	Acquisition of 20% or more of the outstanding voting securities of the Company by another entity or group; excluding, however, the following: 

 

	 	(A)	any acquisition by the Company or any of its Affiliates; 

  

	 	(B)	any acquisition by an employee benefit plan or related trust sponsored or maintained by any entity within the Mondelēz Group; or 

 

	 	(C)	any acquisition pursuant to a merger or consolidation described in Section 6(b)(iii); 

  

	 	(ii)	During any consecutive 24-month period, persons who constitute the Board at the beginning of such period cease to constitute at least 50% of the Board; provided that each new Board member who is approved by a majority
of the directors who began such 24 month period will be deemed to have been a member of the Board at the beginning of such 24 month period; 

  

	 	(iii)	The consummation of a merger or consolidation of the Company with another company, and the Company is not the surviving company; or, if after such transaction, the other entity owns, directly or indirectly, 50% or more
of the outstanding voting securities of the Company; excluding, however, a transaction pursuant to which all or substantially all of the individuals or entities who are the beneficial owners of the outstanding voting securities of the Company
immediately prior to such transaction will beneficially own, directly or indirectly, more than 50% of the combined voting power of the outstanding securities entitled to vote generally in the election of directors (or similar persons) of the entity
resulting from such transaction (including, without limitation, an entity which as a result of such transaction owns the Company either directly or indirectly) in substantially the same proportions relative to each other as their ownership,
immediately prior to such transaction, of the outstanding voting securities of the Company; or 

  

	 	(iv)	The consummation of a plan of complete liquidation of the Company or the sale or disposition of all or substantially all of the Company’s assets, other than a sale or disposition pursuant to which all or
substantially all of the individuals or entities who are the beneficial owners of the outstanding voting securities of the Company immediately prior to such transaction will beneficially own, directly or indirectly, more than 50% of the combined
voting power of the outstanding securities entitled to vote generally in the election of directors (or similar persons) of the entity purchasing or acquiring the Company’s assets in substantially the same proportions relative to each other as
their ownership, immediately prior to such transaction, of the outstanding voting securities of the Company. 

 Section 7. Plan
Amendment and Termination. 
  

	(a)	The Board may at any time and from time to time amend the Plan in whole or in part; provided, however, that if an amendment to the Plan (i) would materially increase the benefits accruing to the Participants,
(ii) would materially increase the number of securities that may be issued under the Plan, (iii) would materially modify the requirements for participation in the Plan or (iv) must otherwise be approved by the shareholders of the
Company in order to comply with applicable law or the rules of the NASDAQ Global Select Market or, if the shares of Common Stock are not traded on the NASDAQ Global Select Market, the principal national securities exchange upon which the shares of
Common Stock are traded or quoted, then such amendment will be subject to shareholder approval and will not be effective unless and until such approval has been obtained. 

 

	(b)	Except in connection with a corporate transaction or event described in Section 4(b) of the Plan, at any time when the exercise price or base price of a Stock Option or SAR or other similar Grant based upon Spread
Value is above the Fair Market Value of a share, the terms of outstanding Grants may not be amended to reduce the exercise price of outstanding Stock Options or the base price of outstanding SARs (or similar Grants based upon Spread Value), or
cancel outstanding Stock Options or SARs (or similar Grants based upon Spread Value) in exchange for cash, other Grants, Awards, Stock Options or SARs (or similar Grants based upon Spread Value) with an exercise price or base price, as applicable,
that is less than the exercise price of the original Stock Option or base price of the original SAR (or similar Grant based upon Spread Value), as applicable, without shareholder approval. 

  
 9 

	(c)	Subject to Sections 5(d) and 7(b), the Board may amend the terms of any Grant under the Plan prospectively or retroactively, but subject to Section 4(b) of the Plan, no amendment may impair the rights of any
Participant without his or her consent. The Board may, in its discretion, terminate the Plan at any time. Termination of the Plan will not affect the rights of Participants or their successors under any Grants outstanding and not exercised in full
on the date of termination. 

 Section 8. Payments and Payment Deferrals. 

Awards may be paid in cash, Common Stock, Grants or combinations thereof as the Committee may determine and with such restrictions as it may impose. The
Committee, either at the time of grant or by subsequent amendment, may require or permit deferral of the payment of Awards under such rules and procedures as it may establish; provided, however, that any Stock Options, SARs, and similar Other
Stock-Based Grants based upon Spread Value that are not otherwise subject to Section 409A of the Code but would be subject to Section 409A of the Code if a deferral were permitted may not be deferred. It also may provide that deferred
settlements include the payment or crediting of interest or other earnings on the deferred amounts, or the payment or crediting of dividend equivalents where the deferred amounts are denominated in Common Stock equivalents. Any deferral and related
terms and conditions shall comply with Section 409A of the Code. 
 Section 9. Dividends and Dividend Equivalents. 

The Committee may provide that any Grants under the Plan, other than Stock Options or SARs, earn dividends or dividend equivalents. Such dividends or dividend
equivalents may be paid currently, except in the case of any Grants in which any applicable Performance Goals have not been achieved, or may be credited to a Participant’s Plan account. Any crediting of dividends or dividend equivalents may be
subject to such restrictions and conditions as the Committee may establish, including reinvestment in additional shares of Common Stock or Common Stock equivalents. 

Section 10. Transferability. 
 Except as provided in
the applicable Grant agreement or otherwise required by law, Grants and other rights to receive Awards are not be transferable or assignable other than by will or the laws of descent and distribution. In no event may any Grant or right to receive an
Award be transferred in exchange for consideration. 
 Section 11. Grant Agreements. 

Each Grant under the Plan must be evidenced by a written agreement (which may be electronic and need not be signed by the recipient unless otherwise specified
by the Committee) that, subject to Section 5(d) of the Plan, establishes the terms, conditions and limitations for each Grant. Such terms may include, but are not limited to, the term of the Grant, vesting and forfeiture provisions, and the
provisions applicable in the event the Participant’s employment terminates. Subject to Section 7 of the Plan, the Committee may amend a Grant agreement, provided that, except as stated in a Grant agreement or as necessary to comply with
applicable law or avoid adverse tax consequences to some or all Participants, no amendment may materially and adversely affect a Grant without the Participant’s consent. 

Section 12. Unfunded Status of the Plan. 
 The Plan
is unfunded. The Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver Common Stock or make payments; provided, however, that, unless the Committee otherwise determines, the
existence of such trusts or other arrangements is consistent with the “unfunded” status of the Plan. 

  
 10 

 Section 13. Compensation Recoupment Policy. 

Subject to the terms and conditions of the Plan, the Committee may provide that any Participant and/or any Grant or Award, including any shares of Common Stock
subject to a Grant, is subject to any recovery, recoupment, clawback and/or other forfeiture policy maintained by the Company from time to time. 

Section 14. General Provisions. 
  

	(a)	The Committee may require each person acquiring shares of Common Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to the
distribution of the shares. The certificates for such shares may include any legend that the Committee deems appropriate to reflect any restrictions on transfer. 

All certificates for shares of Common Stock or other securities delivered under the Plan are subject to such stock transfer orders and other
restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Commission, any stock exchange upon which the Common Stock is then listed, and any applicable Federal, state or foreign securities law, and
the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 
  

	(b)	Nothing contained in the Plan will prevent the Company, or an entity within the Mondelēz Group, from adopting other or additional compensation arrangements for their respective employees or Non-Management
Directors. 

  

	(c)	Neither the adoption of the Plan nor the making of Grants under the Plan confers upon any individual any right to continued employment or service nor will they interfere in any way with the right of the Mondelēz
Group to terminate the employment or service of any individual at any time. 

  

	(d)	The Company or another member of the Mondelēz Group as applicable has the authority to take any and all actions it deems necessary and appropriate to comply with applicable tax laws with respect to the making of
Grants, vesting or payment of Awards under the Plan. If applicable tax withholding is not timely paid by the Participant in accordance with administrative procedures established periodically and communicated to Participants, the withholding may be
satisfied by the reduction in the Grant if the taxable event occurs prior to the Award. Unless otherwise determined by the Committee, withholding obligations arising from an Award may be settled with Common Stock, including Common Stock that is part
of, or is received upon exercise or conversion of, the Award that gives rise to the withholding requirement. In no event shall the Fair Market Value of the shares of Common Stock to be withheld and delivered pursuant to this Section 14(d) to
satisfy applicable withholding taxes in connection with the benefit exceed the minimum amount of taxes required to be withheld. The obligations of the Company under the Plan are conditioned on such payment or arrangements, and the Mondelēz
Group may, to the extent permitted by law, have the right to deduct any such taxes from any payment otherwise due to the Participant. The Committee may establish such procedures as it deems appropriate, including the making of irrevocable elections,
for the settling of withholding obligations with Common Stock. 

  

	(e)	The Plan is subject to the laws of the Commonwealth of Virginia, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of the Plan to the substantive law of
another jurisdiction. Unless otherwise provided in a Grant agreement, recipients of Grants and/or Awards under the Plan are deemed to submit to the exclusive jurisdiction and venue of the Federal or state courts of the Commonwealth of Virginia, to
resolve any and all issues that may arise out of or relate to the Plan or any related Grant or Award. 

  

	(f)	All obligations of the Company under the Plan with respect to Grants and/or Awards made under the Plan are binding on any successor to the Company, whether the existence of such successor is the result of a direct or
indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. 

  

	(g)	The Plan and all Grants made under the Plan will be interpreted, construed and operated to reflect the intent of the Company that all aspects of the Plan and the Grants be interpreted either to be exempt from the
provisions of Section 409A of the Code or, to the extent subject to Section 409A of the Code, comply with Section 409A of the Code. 

  
 11 

	(h)	This Plan may be amended at any time, without the consent of any party, to avoid the application of Section 409A of the Code in a particular circumstance or that is necessary or desirable to satisfy any of the
requirements under Section 409A of the Code, but the Company is not be under any obligation to make any such amendment. Nothing in the Plan may provide a basis for any person to take action against the Company or any member of the Mondelēz
Group based on matters covered by Section 409A of the Code, including the tax treatment of any amount paid or Grant made under the Plan, and neither the Company nor any member of the Mondelēz Group will under any circumstances have any
liability to any participant or his estate for any taxes, penalties or interest due on amounts paid or payable under the Plan, including taxes, penalties or interest imposed under Section 409A of the Code. 

 

	(i)	If any provision of the Plan is held invalid or unenforceable, the invalidity or unenforceability will not affect the remaining parts of the Plan, and the Plan will be enforced and construed as if such provision had not
been included. 

  

	(j)	The Plan was approved by stockholders and became effective on May 21, 2014. No Grants may be made after May 21, 2024, provided that any Grants made prior to that date may extend beyond it. 

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00257-of-00352.parquet"}]]